var title_f17_6_17504="Fishtail deformity";
var content_f17_6_17504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fishtail deformity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 272px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An angular fishtail deformity has persisted in this 14-year-old boy who sustained a lateral condylar fracture that was treated operatively 6 years previously.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Beaty JH, Kasser JR. The elbow: Physeal fractures, apophyseal injuries of the distal humerus, avascular necrosis of the trochlea, and T-condylar fractures. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams and Wilkins 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_6_17504=[""].join("\n");
var outline_f17_6_17504=null;
var title_f17_6_17505="Dosulepin: International drug information";
var content_f17_6_17505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dosulepin: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dopin (TH);",
"     </li>",
"     <li>",
"      Dopress (NZ);",
"     </li>",
"     <li>",
"      Dothapax (GB);",
"     </li>",
"     <li>",
"      Dothep (AU, IE, MY);",
"     </li>",
"     <li>",
"      Espin (SG);",
"     </li>",
"     <li>",
"      Idom (DE);",
"     </li>",
"     <li>",
"      Prepadine (GB);",
"     </li>",
"     <li>",
"      Prothiaden (AU, BE, DK, ES, FR, GB, HK, IE, IN, MY, NL, NZ, SG, TH, ZA);",
"     </li>",
"     <li>",
"      Protiaden (CH, IT);",
"     </li>",
"     <li>",
"      Protiadene (PT);",
"     </li>",
"     <li>",
"      Thaden (ZA);",
"     </li>",
"     <li>",
"      Xerenal (AT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F2638220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Dosulepin Hydrochloride;",
"     </li>",
"     <li>",
"      Dothiapin;",
"     </li>",
"     <li>",
"      Dothiapin Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2638221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidepressant, Tricyclic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2638222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of major depressive disorders in adults and in depression associated with anxiety",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2638224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Depression:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate: 75 mg at bedtime or 25 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate-to-severe: 150 mg at bedtime or 50 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe (hospitalized): Doses up to 225 mg/day have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in elderly patients:",
"     </b>",
"     Initial dose: 50-75 mg/day; maintenance dose:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the normal dose may be adequate",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2638225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Capsule: 25 mg",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Tablet: 75 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10461 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-27.109.116.13-B2EFA6BE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_6_17505=[""].join("\n");
var outline_f17_6_17505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369744\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2638220\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2638221\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2638222\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2638224\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821176\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2638225\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10461\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10461|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_6_17506="Debrided Vibrio vulnificus infection";
var content_f17_6_17506=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vibrio vulnificus lesions following debridement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 259px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEDAYsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDlF0m4ZcYA9xUq6JclQQ5Hrg9a9Vj0WJuNn6Vat9DtwDuOPqK7XiERY8pTSb5AMSyjrg5NOOm6hkEvIT7jNeu/2LEDuZQw/wBnipDYwRqNiDJ6hhU/WQsjyBYdQj2jeMe6VK1xe5AdYn7Z2kZFepSQ2zLtmt4yfUCqNzp1jMMRx+We+e1Wq66oLHmtwJJo9ksCkenUYrjtc8DwXpM2noLOXqVAyh/Dt+Fe2vosWw7EB7cCojoILYAGMdKp1IyVmFj56k+H2rKf3clo6+u8r/Sqs3gbXY/u28Mg/wBiYf1r6Gn0YIpLKcioI9L81iqjCgZ6VPJT6BY+draDXNEu18qC7ilJ+4FLK/5da9L8LeNJo2jj1a3uLSY8B2QhT+Pb8a7saS6Odi5x0wcU2exzGVlVZI+6uMj8qEktLjRfsr62vkDbgHPO+P8AqOhq0wlgG/IePs68j8fSuX/shIyJLJ2tX67Ryh/DtWhYajd2rbblGXHHmLypqZQ7FJnR2t8cjmtW3vQ/U4rn42t7rlCIZDzlfu59x2/ChzNasPNGFPRwcqfxrBxHY65JdwJB5+tU9T0iz1SM/aIgsnaVOGH+NZNtf7Txjnk1rW16jnr+dRZoLWPP/EXha7sFeRF+0W/99OSPciuOliwxU44r39HBHHcVz+u+FLDUy0sai2uT/Go+VvqKuNXuNPueOyxgLkA4qnPCEeKVeh4JxXVa1oV5pLFbqI+WfuyDlW/GscwgwFT05xWtzRMoXcebckDp+tURF8p9R1rZePfbYx1FVVjyoPcii40zKaE7iQeKY0W4EMeSO1aUkWW5znvxUTxnsOnHNO5fMZXkkq6YOVGR60+1Hmxsr4yOorRVP3qse5qteQNBOZYx1GSPei5V7mdal7e8Y7AwB5DDqDWqgFnIl9ZgmBjh4/T2qlt3TlsYGO/StCCTyHDPzE42yL1H1pDaN64t4r6zDINyOOCDzmuL1bThC7KwJGeOOldFayNpVz5ZLtaSnj0FaGoWkd5BkYJxkEdxUy1Ji+V+R5oqtbXG1j8nY1d2KyB14q5e2Zy8cinPrUmg6TPN5kzBltUO1zUJa2NdibRhcvKPKJXGcseldfpQ2fvCyhj/ABYrPRUjjCIAYx0Iq5bMAvr9O1aIwm7m8XMoAJ+tQFdhyOc81Hby71UEDd6A1ZY/KO3NMgB/qieSBzmq1/C6KLyM/e/1gH86sKMA5HTJNWrICS2KkZ2kjnpSbAxN3mKCDn3qF4Ay9B+dWLqH7DdCP/ljJyue3tUgTJzjGOaq9xHHanA0Th1GVz82B0rHclbr1y2Qa7y7swwbotcnrNg9swlRS2DnIHSlc0jK+hb+0vDAFjXcxXgGqy6dJPIJrokuei9hVjT7hdoYgHPQ9a2YnicY4z9eaohu2xiQ2phddigZIz3qF7f/AFmOCV5J6da6F4AWAA4JHSqr26kScgUApbnIX1uFB6j6Gs7Ljjzj+ddXdWnmBgUOf5Vmtpxyc7KiSuD1Z9XgLuA/UUlxPsOMDH0rPWfaeWZR2GarPM00jbZW2njFYcupzpGg1+PujIb8qrXFxI7Y3ED0BzSRW4P3mbt3q3HaRoudh9c09EMgijd+WwB61YS2UjAAOevOatrFGijaAfaq9ze2tsCXdc4zjPJpXb2ERG1VAxU7c4warXN1FbL++27uwXkn8Kzr7V3nO23RUHdmyarW8OWVpMuzHJzWqXVjsWpL6a7BV2EaDopFKImjt9qqSxO4kelPjgUSDfnHX2pZViyRlmb3NO66AVknTftkXLDqrjH61FcNE56HI5BHP51YWJpWbjAPrzio5rF84iZcj04ppq4yg0Ss4J44+/1U/X0qGRGSP5lwPUcg/jV+SB1Ybl2OB97FRBJY0YqCynrjoa0TCxQaAJh0coT/AHelXbW+ltwVnG6I9WxlT9RUEiAvwPL9hx+VR73Q8t1PXHX2pNJjRqC0t7lN9nKInPOwnKn8e1Qt9otZNsysp7c9aqRuA+VYxOe46GtWC9yvk3aB4+OSMjmspRaKTJbLVGjID9O+TW3DeRyrlW5rnZ9NIDNauZATnY3UfQ1No32d1kimlMNwGwu7jI9KyaW4WRvyCKeJo5FV42GGVhkEVwPibwFM++48NXK28nU2k/MbfQ9RXYSJPbkH7y+op0V6GUDvUptbArrY8HutQudHuPsniLT5rGbON5BKN9DU9tLFcqXtpUkQc5U54r3DU7Kx1eza21C3juYG/hcZx9D2ryjxH8KDbyvc+Gr2WMEHMDNyPYHvWsal9C4tPcxL/ZbYlldUjHUsccVy+p+KbWIkWcZnPQuflU1W1jw9q1tK0d9HcPt/vk1zUsRaYqwKqh6YxVSlY05H0Ovg8T2YWP7TFNE5GTtG4Ul54rsThUgnf3wBXMSIJk+VWYjgAA1JbaJqF2W+z2sjhcZI4A5xUVa0IO10axw9WWqizdttd06RiZJHh9itXBqunzKFW6Tcex4rMsvBOqXJQh7JFbgMblGGQcdie/Fdx4f+Ga20QfWLdrqcnIWOdPLx7ZxmsFi43tc6Fg61ruJU0xo7u2NrKwdf4XByB7GrNlI9jIbS46A/Ix6Y9K7/AEm08MWarHOklrMMYR4D078rkH61h+OrPTpBJLoUqXRChxGrYI9QK1jWjP4Xc5p05wdpxa9TnNYshJH50OMHuKw4ri5tWLWshQlcMvZvqKv6N4gtXgdL1/JKHBEgNYep61Yfaz9laSRCcbgvFU5pdSoxa0aOi064gvUMYBimA+4TVtY2jxwwPriuPjnjuSJrST5wc4HBrodJ1pWQw3nDdN2KakTKk1qjZt5Twkgxz1xWpGw9cj19aytoIV0YFD3zV61YoBknB71aZjYsyMQG9+Kl0+YRySIxwGGetROcpgAc1GABIhbgdCaYWJ9aiNxbgrg7eTVGAjZsJAkUdD3FX93ltg4ZTVC6iaM5jxgHcp/pTQrEsYEi7Svzdhmql5ah42DKuPpUySbgJI85zyKuriUDpnGTTEcDc2zadc7kUmE/kDVuC4iIDEkD0HaukvrJZFIkA2nt61z9zo+wsYlIJ6c8ChaFXUty5byI+0AjrT1i+WQ/rVC0328qLOTkEDJ/lWvEPNSVgR9B0pozatczZoi3OTVF4p1YhcY7c1uyx4XHOTVN4xvOW5pNCTsezxQtIRuBYdsmraIFxmHG3rVYy2yplJpAQcZFRG5wrbZmOfesrNmZpfaIRncpB6dKgk1MRoxA+TPXPJrGnvniUhZCSe3WqEk00xxuxTVMDXudUmkLCJmGeMKe1VFj3ZLnax6cZJ/Om2cD8Evke3pV+K1JIyTntnmnZIYy2tVVv4snu1Xoo127Qu126EdqnQ/JtJUnqWxzU1qu9mYKBjgZrNybAjNrEFVNzbjycU37IpyInX13Px+tWmYRg4Q7+7EcVWdmYjcvmr3XNJNgNYCLBdGUAZDYypqIur9lb3BwamcI67Y3mt29N2VqvNbztyyKcf8ALRVBqkBN9pTaVePzFHbHNRItrKCYnaCQn7rDK/4iqjW7LgtGGXuykg04RkrsRif9luRT2Cw6aLyT/pEPy/8APSM5H1qrJaqWLRfvogeQOo/CrazTW5KqnBHI6iolkxL5iRiKU/gD/hTux2M+SzTJMYKnPA6iqsxmtSdjE4/hI4rWlTzcvJE8fqyjKmqcmHj2nLL2wapSKsNs9WQgpL8nv2zUF5qFpcTmC5YpKB8rjh8e3ZhUdzaq643BXPTcP0zWXe2rEbbiIOg/vfw/Q9qHFMpLU2otU1LSFDeYt3ZN0ccr9D/dNa9nqum6ptDE2s56Z6Z+tefW19dWUznSZJLsKMSQ43fQHsR9asXtpe6hrtpYQxwW00gWSWO2J2xqTjOT+HTHNcNfEUqW718jvoZdVr6pW8ztNVvo9GcC6vLZc8hd43Y7fKOay38aWu0lIZZCBnnjPOBwMnrXarofhjQLWe3uLeCXziI5Lm4AYux6ZY//AKqwrvTLa0W/R500+OWM+QsABmbI4bJ+6M9wO2a8+WOk/hVjqwuDoT+O7/C/puzktU8U3E0WBb2cbMWRVnViwIODw2OnvXF2+jyatqcs11dLIF8zciKEAUAfMSv16Cpdas9Subu4vr+W3mu53MkzKyksx6sQOBmjSdFecq2nakouGOMhSkfAyctnoPpWDxdSWj2Po45VQowvTVn33/H/AIYg17Q7GxtoY4si8kXeVZiPLXrz2GOuPesvStK/tueSRndbOLCBmPzn0AH8I/n2zzjuNM8Aanrc8siStJZOmI5ywJbJ59gOtXrnRH8FamEe3uL2OWLzIo4FDKsp+U5PbCgY+pqFPW72FJQ/gwleZm6Z4DgVEMInRmAAndyPyB4rfi8P6rZyK0WpM4VdgWZSw6Ad+/0rbs5Ip4bC5VvME64hWUkk9zx6jFdTBGotlWQKeB14/CtWlLoedUr1aLs2eX6lcavFAB9jglC8hg2RtzzxjI+lNW00/VFEburXHcFTHKnoc9xn3rt9TsUW4AgUYcEnb0rndV0mSQFIGxKBkKfvH8etZ25XdHRGsqsbMwNT8B2N7GRsNvckjc4P3u+ecis4/C2xSPM89y0m4Y8rGCPoe5rsPDepSm5Gm6nkyk7Ymbjd7Z/lXbtZApnYNwyc+tbKpN9TkqKEHaUUfPuo/D547lpNNvGihySVnVt6EHgAj7w96xLjR9atGQvbrMjEgMDjP1z0r6BvNO+0xMzgR7Bk4OMVUutJWW0U5jZCOBKoyvv+tNYiotjSNGhLdHhdhrU1pMomjkVT95SpNdfpV9aXsZNvOh/2CcEVqXPhNFfeyIRk9D1B6VQTwZbMySvsj/2TyT9MVrDHzjpJFVsmoz1pzt8i6lpLIwYM0Y7CrE1tsBSVw24YyOtQz6DewaZLcWk02+MkBDKQGNVFN9bRRz3ckscjLn94vmJj1yPzrojmMNmmcE8mqL4JJl+wt5YgyOwkiHOT1FW2VDGVOCDzWJe3NxZgm6Dn5d2+D5gF9celGi65a3ymHzkE6n7jcMfcA12Uq8KukWedXwlWhrOI3m2mZv8Alju2n2NWY5fJZecq3PFWLqJZIZEO3a3Bx/OsXT7pWeWyl5mi/UdjW6ZytaHQKyyJwRVWSME8cjriqiSSW55yR2xV6NxMpYDB96ogz5LZWYArkA+mM1TSGS3MphJCen41thB5q+mcVC6hvNPbvTQdylCxkXGMEdfaoyiZPNSqBHKRgAUyQ4cg8GmRselzXJiU7iCo75rMmujIRySBxtQVHHbNId0so+i1p29okYyAGOO/WlpEhGfFbySNkg/Vua17XT8Ll8ZwMCrNuREpLqC1XEeMqCBlz69BWcpsCBbYLjHHp/jVnycAeUwPFPG0Z9fXFQspyNuRg/Ss73GTNDnHpVtYBHEqEgdzUNucMDJkhR3oM58zgbs1LEWY1APy5x71LLbRTcOuGP8AEvH51QNxcBcCLAHXAzWVd+JdNsObzUI4mH948nHoO9Kz3Got7G7Jp0kYzFKsgx91hjFQNHcR/chwen3q5G8+JelorJb3TuSpKEQMxY+gP9apS/Fa28xUtbS6uOfmICqSMcYBPrU+0it2jZYas9os7mWWYBvOtST/AHgKrr5VwSXidZexQ8iuIf4lXVzDKltbxwTI2NjZfdz0BGF4HPJrPl8Wm+t2gnnv/MRRkRhBkHPBw2c57enpWUsVCO2p00svqz+KyPQVjbeyxzI46DcSCapXOp29lJieW2jYjvKo6da4631uGGBwLeGMR4yZ52AHGTzgbuMcA1S1DxRqWotLDoiWUUmCWkggASNWAHJbOTjPAzyaxePS6HdDJ23vf5f8E7n+3rMyBYluTK/IMETYb39MVBc3GovKpg0fzIyMvLM4QqpHBwuevvivHr7TtRguUt57+8jhgGIpTDJHlT1baTnvjNOhOuWkSwf2xcNaYDGJncLjGOOR6Y5rCeYtbNHfSyFaNp2f9eR6/LZ3BSVruaOCNT8ygE4Hoe4rnPEUmlabJCt0lxO+chiuWOM5XriuW/tfVLWWzma6ZvLQbA67kRQMLkY+Y9OoJ4Gc4qhfX1zqUr3eoPdXTu2HlaQ5Zvqcjv0GOK5KmKqVN2evhcohTldq68jpbTxRaWhhu3s4Em3NttbfkexbI7enfrU8fjuZb+C4stPigdN2ZLqXzCd3U4GAMY45PeuUjhM16yXU0FkgGWyCduAPlHq39at2OjvelWtQ0iSMUiEkgU5HV37Be2Oprnu97npPCUt5x/y/M9GuLiW8tY7vW76yiWbGxZZAMYPDCNPm+lVIra0USo1092XcM88qBEQdwozuIwOCccmsjT/h/eySbtPuYmxgN5cfmknPXOAg6evrXT2nwzeZU+0rILgtuZ7i7BH4InT86a1ep5054egre0S8kv0/4PyG37+EJdP23EoAAyd7Ffl9PrnsK5Kzn0iO/kurNV8pm8tVhiJZVHTjpk+p9K62X4bW2mXcc0uqREhizlxlFHsOcnrxS3fhuzuZni02W5EUxIcysEVunRRz07ngelN3Y6NfDxVlUlJP7jjdO8aXOmFk0izS3tTIXERlbknrgDgfgMVsReP769tZ47qzSe4dyFKA4/Dg8jNaGt/DVRpouNMhdGQZcK5Yv74PTjpXGaJaywa0yRT+SbdyI1YjL/8A1/eo1TO2EcDioupBXa+/5nR+GVnttRhuNWjdD8y2644j3dSR9BjPvXaTT6tc70tY44Y1Hyb0JJ9OSe/6VQt/Fc8tnFp95p/mGQbEcLjyyPVunX3q7ZT6tatPHczQXVqiAqYomVo+OrE8E9M4rTncVaJ5GJhKc/aTik+mt1by/wCCYerzazp9k1xcjykVgB5idQT7dO1SaDqY1NSZrfbIfu4bv7e/t15rShsNR1HQjcavdSAPJvRwpCkA/KQp/CnWnhUadbR3IuUaNgSc8HI7Z9e9OEm2Kc6Kg4ytzXtpexkeL7RYLKORpVW9VwVUMFfORyD+tb+meLIRBbw+IEuIp8EGeKAsjAL8pOOdx74GKgvoCZo7ohWVRkMQCeneqviNY7/TimnvCbmECTKn5kbg4I/HpWnM4vQw9lCtGMZff2J/7d0+7MQe/gRZGZQ3IbcoGPMTnaCScHviuY13XTbzSRSvvkZwcowZRxwCegFQSWkwvG/tCDy5pOfkwQfQism70qGRgkSBZBnbtP8AF756jionN2sj0cLh6dOV5aon0i6u9e1qC2WF1hdwGaIHcvuT0AP06V6lpvgyCO5iuA0rSx5BZvXpivP/AApdyaBPjy/PhzuHZkHcA9D6816ppfii11WyYQXMZuY1LlSNhQehB649RXPJySucuaYiqmlQVomleXUGlpvvLfzEZAxULu2KvG48cgD8q5HVxo91MLlLlYUZvkeJsKDnJBAGB+nWt/7RHq1sIZlCmQ4YemP6e3vmrKeGdPulheeCNioyB/DxkA46ZA71vGXOeFTqrDe9K6Z4t8RptC0ySzFw9xcXDh9v2aUfuE9T68np3rhvFfh21n0mLU9KP+jsm+N1BAdeh46g5r0r4qeC7SSXz7CN1kVgnDADk+/HqRmvDLxbmLChp0iBIXkgEZz+PStaKV7p6nqyrudJX1j+JQh1bUbJ/wB3dS/L/A7llP4VqHxSrXFvci38m5j+WTa2UkXv+NW7PQJ9b0rU74QSNPbsgDRkYUEHOUA56dR0rkp7dopCjDDA16lHEKfu9UeHicLUoe/vF/1qexafqlpqVmkkU8TOw+7uGc+mKt28mGxjB7ivC8EMCvB9QcGtfS/EWpaYwMc3mxg/clyw/PrXcqy6nns9o3fMv164qNiNshIOTXH6L48spWVNRie2kyPmA3r+nSuhg1vTLkSmC+t5CB0LYP61spJ7MXcnkwSM4I7VWfaGPJHtUsjAruU5HqDVSSTDkc1RJ6vBpgcHaeg7jFWYdOkTkHoeDitaC28o/u+W9zUst1FaQvJcskaR4LMxAHXH865nNmVzL+ysCcg/hQLdlGSSAehIrM1P4ieHLQOqXDXMwyAkCknp1z0xmuQ1T4rh7Yf2fp8cJMYUNcTdHzyQAORjj61k68Y7s6KeGrVPhiehb3UYyMD1GKsKpPJHIGPxrxC68f69qMcxt5La2iweQgG4f7IPOf8AGsGTXtcuwTLq14inlsOwVD3PH9KxljKaO+lk+IqeR73rmt6fpcBa+vYoQOoJyxPpgc1wl/8AE+3tn/0OxlnjJ2gynYD78ZrzEl4j5scspuA+d0nzAjjAweSc1qx6Re3T+fdlmlI3eWy8qQc8nooAx2I59awljXLSCO6OSxpK9V3H6x411nUnJku5Et3PFvEfLQc9PU8dzXPSCS8aSQld+7BXJyM9PrXVXOk+dNmdrKGIPsmkjbeSMDu35cD1rCvrSdn32sc0kVuhVnucBWReAexxzgCsHVc37zOmnh4QXuRM+zVmLNLcLAqA8lc5POAPx4/+sK7DSrS2tLdSi7pWA3ujZ9wM9u54rkI4buzs4ru3ykc6FfMjb7pz0bj5T9KgQ3UJdUjZWkBDg9SOvSs5K/U6YLS1mdvcX+m2sbWulwtcXTuMIR8q+pJzjoD61i6ndxx6gP7OWNph85mRiwyRyKyLuaCRYRBZm2CptkzIW3t689B7VNZRO+0qiFt2AcfNyPyxUSdlc0pw5paI1otJ1LUIVv7mWSZXYCOJSSznpwo/GvQdEtV0bRhFLpE18s7L9oW3lZGYBjwD/DxwTVjwdYNZaR9uaCV7tYy0UbyYXpnaM8DNTJcau9vdpbwzLcQAyqsTh4ZgRkgEgdOa55Pn1Z3e6r04JWT11t+tzHvdS1PWpoImuLi1t7UlXSVUzHg/KBnlyRgHPGfWsLV4r976Se4tijEKfkwQMjj/AD2JrPvrma8na4uJDI7HJLHA/AdhVzTtKvdVkFvbIxUJuy52Lgcd+p54rG6Z6cKEaSvol+XzFs9He6eSa7eO1hDfPLO3JP8Asgck10vh23keLzLswYgDJZqqjYpxy+0Yyx45J9a1dF8Dm+gh+3XQdLYYLeaFAI9Opxmu70fwfpNuqy3NjE0aLhJJp8q3uK0UTzcZmdKmnG935f8AB7/ked6X4etJzbwancwwrGz8HAeVm6nOSTxxWhquvaJprLaaPpouQT+8aKP5SP724gk8kc+9ekr4e0uUGaWGJlzndEz9MY+XGKW00+w0+3ZbCwt7KA/K094m4t9CTk/nSc1HRHlzzWFSV5qTt0vZf5nLWa6lfWv2i9uo7OwBKoq5yo+hrpdMsgIYvsULTrJyJZm6D1x0H41zmv6RY3UxvLjVjeXEYPkxI+yJMjGSSMflms/w1d31lD/Z0czyEZKrE+VH0J6/U1SlK+xlOk69Pmg7eVrL/NnbeJo9P0ux82aFbi7Yfu0I3c+tY2jXlqjRw2dtJeX+TJMdoC8nJyf7xOMD0q9ssrGBW1C5WW8cZcs2SPYf41Zs7/Rri5QDy0kjIwu0qVJz36Hjr9aeqZyw9yk1Zy8+n/DEYm1zeZpxbpC42Mqjcv0rOTwLZi4k1AxiC7kGA1qxwvPUA59evvW/qOpJp0cnnwu9m6NKgiTeUwOgH8QNZtj4htLkxtGEne5YEPFOEVP97Py47Z7Gh2CnPEcrlSVl5dTF1PwWbexVNJKx3SsHRmZmDHOcHORk+vHU1t6HFeXOlRLqdtcDZmKXegjGc/MOOSM9+9aN1qVgrq6tMiY2SE/MIyexxkE8HirGkXYubJgkTyWrEg9cr9D3wO1FtSauKrzpLnV9d3v95ca3aa1eC4WOVCMBZE+UegGKw/EFox0Boo4XRI3XAc/Ln610X2dZDDJG77QoO0k4PocVxnj7VbbyFs0k8+ckOAGxt554PGeKFpuc2DUp1Yxj3v6GDM+oLo7tFHujTcJG4IwuM4zwTyOnNZFzew6bLaXzQB1chJ5AQNiduP4uen413mg2cq6fbthVNxFuYZwqjJGD+GelYPjXwlfahGfsckaL5KJMkSZ5HfA6Egc/nV1IStzI9rDYyi6rpVLJXLGq6p4elnit4DNe3jDO0RBAqHPzY9jxgfhXI61p8mnslyGLiQkLCAByPbvweo9qx7PwprNrqNtLiTyC+z7THk5xyV9cciu0t9DupQjT75EVmIkB5UN1ANZc05vY7OSlhLclTmXX+uhyl5IotvMXcgH3lI2nP/6u9c++oWsUmVlRDxtOSSpOSOK7S9s4EZ4Ei8za+7PPTOcfXoOOlZCeDxdXMk94SHmIdVRhz6jpx6UpXRuqlNxfMO8MeNzZXMceopLdWzMN8oXDr9PXtkH8DXrdv4z0i5tofsE4kd/kERGHDdhivIB4XupSjELJp9vlBGg2O/clvx79xis46JLDE5t5Ua4ck4zwP9n6+9KDfY5K+XYbESupHs2utoeq7BdTs4gH3wGTDA85HfHSuR8e+G7HVNNiWMD7M8akKg+Y4Hyk+h/xrmdAl1TR4VdyAufMe3lw8b4ORlfx4x0rv7DxFpviOye32rbasmS9u7btwx95Gxz7jqPeuqmk720ZwVaDwkly3lFHI+C/D8fhtbpbRXkS42mUyHLADOBj8TXmPxJ0ZZPFFy2nWDpDIoaMwISC3RgR2OfSvXrxpreYESMynIOPpXI30n2+R0HBGGGD0JzyT29KfM6b5lubrD+1VujPC5rd45GV1KsM5BFMZCUz7V2Gu6Z5kcrLhZIs9B1GTxmuXaNtoBB46ivQpYhVY36niY3L5Yabj06FRB+8XjHIpYwu2U4/hOKfsIdeeM+tJGcCX/dIrri7nlNWFhubiEjyZ5o8dArkVY/ta/8A+fyY/wDAqpAccflTvpT5mSfRniX4sQRK8fh6BJCwwJ7gEH/gKDr65NeZ3Wq6vrE8sl3PJPJIxJLHaFJOflXp2z0rPjt4FLSSkzPkCOBMkue5OO3+NWtVu5YGiSG3jhkQ72IffhscZHT2wa4ataUz6HC4KnSV2iKOQ2c1xHcxsEI2FYiNwbIwc88/409LOWERNdRoQWb9xJzjjgt+fSrN9KyxWs1wiRTspcqGDFW9gPp1/wAKWwivL0OUB8jkElvlBI53c5yfzrhnNo92jSho39xXCYTK/vGztZnIOPp6detXLXT5rtFaNW2jgZOBnj8x61Ivli3O0qADwhXJc5+8c+gz+lT3j7PKjhd4wifdJwQT1GO1YOSPUjR0sQFobd4vKiZ5IiRI0xDJnsVA7Dn86tW+ueUhjERxvJJPJYY6Ed/bPSqaeU2Q6sQBwFOOffjpTPIV4Z2WQAoBhcctk4P0ojUaJqU4SV3qWtMurczT3c1srXoY7G3AhVxjgHjPSmvdyO2xyqhRuHmcnI6HHduTj60lppl3JZzXMVvIbeIZaQD5R+fWr+bg6JBCixwae8m1ppCD5kg5JPcAdgKbqyIhQprVLqYZjctG2OVX5gzE7jknJ9OvTpxWgvm6dPCHdXgGWWGJwvUAckc4I7E1G4CsyZztJGcYyaY07EOMli5BPOSxGcflms/aSLnSi9GUL/zDcedDHFGzEEKEGFA4AA6VBaySW9yolAcEYGwVr20MkloZNwaflmhK4Majjc2fft75pYrNopY43iKs+HUseobofoapzaVpHOqHNJSgzotG1Mf2hpcd3JL9jicJLC3KHnHT8R16Yr07V7vUZZzb6WIPPijJHmyfJCo6Ow9zXkXmx3MAsksVN+8gVZYWIL9tu3pnsDxXqsOlXUFrPaG3SG6nhVZFkcbGAGSWIzkdcgd6zg3sRjVBSjN2vro/lrueQtFJLM20iWUkuTkck8nA9a2P7WWa0sbezS4F+0imWae4CxvjouOw9ya020vSre7fTk1WaPcpaQwQNJnaOQCASF56HnvmtGwTwlBaMlhZXOr3z54MZ2KSQF3M3QdSR16dKFFnoVMVFpPlb+T/AB2VjtfDY1ddNMx0m3SZSGO8YVV9Rzz/AFrVtG1WVRLJN5T8loRCH59j6dK8+K2ul3k0lrDdLOSos4ZZC8LsOzZb5evBHTvjitjw5q2vXNs85e2tpATvUcYOegPParij5/EYdyTqRtZ91/wWda8mu6gT5V6beBOOCqM3r9Kfd6HZxxRy6lLeXZYgZUl8fh2+tYsHivV7ORXu0jurMnarrtDEg84Pf8a6rR/EsGpuVjEfmAFmiYEOoH5g/hTa03PMrQxFHWMUo/3f+GL0OgaStuYls4nQghi3JOeuTVW903SdOtZNnk2TMpIOcdutakd/D5CuMR5XcA52gj69KxPEOm2uoRtc3U0zqFykKOGQY5zgdfT8aE7LzOCjKpKpapNpfeeI+MLmS31jzYJ5Jra4AVmLdG3DJyP0zTrm9u7OKNWN1KPm3Bl+Ygng/jxXoy+FbXVrNI3jFlbkEqmMuDnjNVYPCFtaag0Es91KCm3bGT86DsR0IyAc9qmx9hDMsPyqDWsTntE8capAHWaUQRoTtjbDeUo9z37+ldZB4r8MafoMFleSSypGxYRswL5Yk5B44Jz9KyNQ8EQXMDPp88kYfcFDkFUJ4JGP5GsTXPAV9HZwypJHI8JKjaPvHg4bA6nHWn7y2MZQwGJkve5demmp0una5pL2Cz6H5c98W/1EsqsEYtgfuzjI5A3Hp1q/peqj+zQ1nDOrRljKYs+Ugzty3YkkdePxrzSXw/FObaCex+zXpG5nRx5bbjngdscV614M0u00bQILJr2WRduXeXBBPooA4H1zSjJ9THH0qNCHMm5Nv109ddO3/DkUmpy2doLy4vLp48FRFAVMjMRlQoPUZ6np71xFrLqGp67dyaghs5yEaDI++vOTnp6dK6Px1O0GnO+neS9whCoSv6cck1iWutWd1psE8lwZ7qNipCRMfL+o/Gjd3Iw1o03NR1enoX4NY1HTJopJVlktWA8+JcbwF9M/XNdhZeIEiW1V54J4ni8wTQsNzKRwG9Gz1B5Fec3niyLUreeCxjMzxEKRKmw9emfXIqpc3dtIY3him025fBlkZt8UjE8sV7H/AHfTpXVRqJaHJicC6nvONj1WHxZY/vQtsYzjPzYALdulaVvqmltag3D29vzkr2J9h3ry5b8o80d20c0Ab/W267gwx27j8qqWVxc2riWEKsYk5G8M4B6E8n245rb2jjtZnMssp1FZNxfqei6t4aguJWvoDLMRiSGKNhsbPUn6jvVC30wPaSobdsiMHLfeBPQ+x7Gqum+MWiWGKRxKnTawyPpW7pWtxSyvJN5aea5yFAOBjgVm4wlsDji6EWp6pbHK31xqFrLNZzwmNSuQqsG3Z4B2/wA6wrfTRC3mJbmIKeR6se/44r1F7jTprqCYW8DyqxV2UAdRwcd+R/Omaw1vcWF3MluEx5eZNvGVJ4/UVPsEtbm9LMZRtH2dr7/kecajZ5QsicPkLnkg9xXKXukuIfNhZhcKN6sDggjvx+HNeq31oLS1gt3wZBD5shJ5XcckH36VzN9a7Szs37xhuYD+Edgf5ms5Rsehh8SpryMnSPEUesvJDqMCLdQId+PlLj++vr746fjUU/2Wyjl+xiJ3mOR3JOO9c5rOkvE0clsXFysu9GU4KknnHbnp+NW9G1M3twYZgI9SQHquVdOfmAPf1H40+fmVnudSoRi7x2MHV7J7dyxLOZAS5HfPX+XSuM1exMb+Yn3D2Fe0nRxcRqDGrE8EAdciuT1/QdrSLFGfLUYCjoPfPfsKmLdOXMjXEKliocj3PI3UB1GMHPbvzUKZHmjJHymuj1vSmtpd6glQwwTxXPovEvP8J5r2cPUVSN0fEY/DyoVHGRAOPXJp3H+c03kGlwT2J+groOE9OtbOS6uoraJVm8QX0qpCu3Pk5PXA44A71Y+JtvpGkatbeH9BCSRW8IOoTqS5nuOcncfTnp0rF8Ma7HpPiK01bUoTdIGczRLKUcAjbnI7jJ474q9qfhdjfX+pWl7p8GnvH9rs2mmSM3CcEqgHQjPQ815knZM+lim6yvsjKVd4G1yN65ZmXnjpj/CrT3DLapDbkCONf4R945zkiptLSG48uOaUwjIwf9r+QqtNkTOkartViA5O3I7cV57bZ9GrJabmjpIjvZzEIV3HEoKtzwPu8+px+FWzBFIl20rCzO/OTICWdckr+f1PSse0Bt1a4jKFuQQy5BHXkd+cYNbOoNDc6bbztKgYHhWG1pMYB9cH6+lCsjopqbklJmbeQy2zBQQQ+djK3UA+n+PWm28Z2Sl5dhCjC4++c9Pw5NaMEwh0idIIXZnx57ysCAM4Ugeoz/npVKcNGsYwmNufkOeM9/fPFQ/It0rPmZqHXb/+xhpSyKlrtKEqmGI9D+vNZcrHyiNzEKPly2AKiLhlDZwM+uOR609xNZTQySRLvKlkjkUMD2zjuO4+maSTe4RagrxVlv6jru8sIbaCO3VpbsviaRlyFQdcDucVr+G9Rggv7CVbOEQtM3lFs7mAXBJz/CR+pPpXMa5BcLHBMqAptzE+A2fbj+R9a3vDkdnL+4spWur0ozxw/MGlbghUABG73OO9dKStoebWqSlKSk9DpdQ8NxeI/E8UWl3gtw4CN5qcI+f5Y5+nvxV3U/h1qGn6dDdrfrczbvnxHtWGEqdpOTndwflxj3rnr3xNq9tqMMFxZLazWZ2iKSLa5Un5hIT3zk5A/LrVrWNf+36PaKb27kuiQlxbPny40Q/u9jZ5yPvHrn61E3Ts77mdL60px5H7u3f+tDQ03w5pTaza202okyOiyItrOGKllJGCADkbeV6jI9a6HVdMuNQmmguNU1aCOdR/rrZcOisBiNyd2ARnAPrXNeDdSGn38ur6jp6GzlmEH24RfLDMVyEAHTI5P0rstM8daFfXax6/GbG8t98IkUGWMDdzg9snnoKxi0kaYl1oz5oJySXk9fJf0yx4d8IapoIT7Lc21zGMsFkXBUHqAR0yecVn+IEeXX/JRrCyv7jy7cz+cfNcg5XMWMNwCN3HHeuo/wCE50O3+02+iTC+u40LgorBPqHIxxXk2qS3Wu6vBqK3EupX0wX5bVdv2fH3UDf7I5zwPWm2raHPg4YivUlUrrl03at962t6nWaj4HW1ilt41F4jlipLyDy9x6AZwAMDnv3zWdYaTqE//FO6frlhGIo2kmdInIjGT8hfGC3PPpXqmgadKtrH9sczOqAPIT95sc4qaN4tPVpLeOD7NIrMdihMdj25/rVNdjheZ1dYX5mvz+Z51HofiGG2t7JprK+sYQoinBC7VxwAMdPc9a6TRrDUdFMVxLBbeYAQw87LHjqOPw61rnUoTFA06QAGX5cJt5x047f4Vfvp7byovPngB3AmNuoHbt+VG3UzrYurO0JRVn5b/cc/Jcn7YIi6bX4W2kkO059P/r1NqF5q1hCTHDpccPQGWR9ygd8Y5qKx1LQr/V3is5UknA3B1HPX19a1NcdBHA8IjnlLceZtKjnpk+vP51O+xE1acYOP3kUmqlVjito3vriQHeA2xVX1PQ9cYqto2qak0xW8tYv9YVRw/wAwHQL2FYGs+MZrXVrzy3itSlqyKs6MrBuGXGODxkD13fStzw/q8Gp6JbatqE0DzMrZWOExtkHuvT2z7U4vm0NJ4aVKlzSho/W9/wAjVm8L2Wrss92sm7oQjlckc/wkc1JNo9vpscUdvcTQKMkAsX3epOc1Hp+qSzaVPdLEscqkFR3dCcbhWtYrJNZefM7kunG4YK8k8d89M01G+p59SpWp6Tl7qdrGDqXhu3EJlW4Kh8FhKA6n3HcfhVCCK10u7FrdXrTSyj5YxCTn2AHH513KJIdu7YRjuOlLPHGV+ZFLDlTjnPbBq4xvrchZhUS5Jar5f5HE31vbtYzGWzmgt8gK8v3jzwVwePzrLutNt/8AUwQW8CICzEDA+h9/Wutu4TcWsSXrbnT5mA5Gc1mwaXJcTBBCgw2dxbpnk5/nSgueVjrp4jkjzN2ONfR1e/EFvbRpaBTN09Djr1JJ9fSibSFmUFWO0HOSMAj3r0BtKdIi+4Nvb5QgwcDoP6/zrFu7Rnt/M2tsHzAIDnnrkfWtvZ2NqeO53ozgNQsNh3M4j2dBjr6/Wqskku2LzQBg5DLwGPYHHSurudPxaK8yktuwPQVQm0uV4wPKG7GMk44rN3TPShUi1qzKWCOQ+ZbndLGMkZJJ75x/Wp7LVLixRzcbn3Hauxe3rg+lPfRbhHVkjGV54+tWZbCcgedGo7nnj8/WnGzeprKpFxte5Sh1ib7W0u5/Lx8oRucV0lr4g22ixeaQgbcQT1IPBP0rBSOEBV8sHbyysOvvWVeWss5MkZ2EMfbFU9NUJU6dfSatY9Em1BZLG2eO4QTOxYA8sx9T7DsPWuc8lZZ5BHNvOSGXnJ9q5yynmtZyZuXbjcx6H1GK2rHU4rSJyse3eMDcwG71Pr1zSvzbh9VdFPk1GXtijEmR+g7fXpXIeKrYRSR3cN0kM1uPMVxyysOh/wDrd66a61W0ZWWSYAybhEwz87Y4A4ryTxVqZn1mYwnEY+RgCDv46E9KSjd2Rbn7KN6h7P4Q1601i0RQUW9Cbti8q46Fl9Pp29xVzWrMLaFFCB2w27pg14B4cnure9E1gzpcJ86ugJ24/wAgfpXvnhvVYPE2nJKQIr2D5bmDH3Hx1A9D1H4itJLeJw3cbVVszhNc8PPc2piBAY4KZ5x6k/X2ryS9tWt7i4iY8qCOnfNfUFzZruTeAren+eteP6p4Qk1TUNYkhIjlV28sEfK3ygn6c55qsLP2c7PY5cfH6zTclujy7HPf6UAcdat3tlPZXbW9zE0U6feU9arbD616ykmtD5qUXF2Z0t0EvQwtovKMaAyEAAHkAAf5ya2NB0a3gsZdQvozJtDeVEwwScHkDrRo2mRNeILp1+zxq5kVM7zt79OecfSuhurZ5bVozG0UhjSNDuyIzgbj17DA/lXmSn0Ps6NGPNfqcpbRsIo2IIKjDbkIGe3J7/4VY8g71UJIWfgbRkk+lWliae4dcOxjTKybieecE+hI9a2xZm1tmM+5pAI2A3/eZu4Pc4zXNypu56/uxSutTAntpIw0c5WKUAn53AHHb6+1XYrm4hBvIIXjRlMKSPFvXlSrAE/LkjP5cV0cmjidES4zuwu/nG446A+4NXdYlEWiQw2Vn/ZFiZ42Z55HILKu0NgccZJHQ96lwsVDERbUYq9/69TlLy0W18P6dciNPPuZJRuV8gqmOCM99w/Kq+qQwC4imso7hLKYfIZ1OCw++FPcA4HU1MmnzXU92kTJMYD87hsh2LYGzHqf/r13GgeGoLnQXTVGdBztG8lUIyCVGcDrmotc0xFaNFc03fX8/wDI85njlMSzbspv8rDDoVA/+vTre8IOZ2c/KsYZuioM556jjGAOtb/iDaGGjadKlxEjDzJCg5b/AGD1+v5Vzk9s0fmrGxkWIZLDhRyc8H8MVUXYbXtYLp29DVgaC5uwL2VLq3hUJCS2FKgZOB3PXik8C3cVnrQtGnNtFJKxjumQ8Db6gZzxkD+hzVS0juRplxOuZLa3+9CJAM5zlsdcVFbalaqGgurdooFXdG0MhV0fGBn1ByR+NaJ6HBXineL/AK/rc6DxzbwQ+Jp/sf2hrZ0XynnXaWUcbh2OcdfXrWXZWUl3dJbQY86QgKCwXJ/Gn6V4ltYbuN7q23rGArhcBWwOnOcLnqBVvU4Yr+4X+zEhN2ZDJNJC+0IB3A9PpWU6XM2zajOCShLot/8AM6ew8F3WlapYyXj2tzGAxliWVN27b0CtjPU9QOK3fEmkf2wFk1RbiCK3jyr2yCZ3AHVgO4z0HpXGaFrlra2bySwG9ut+17pyGXy1PLeuef170DxvepqLSuUlhUkpEy7cJ2AI/rUNculjP2Nec+eL+Hrt92/4mhc+CdXt4fO0bUbae0lKybfMaPtxn8P/ANVeg+C7ePTtOha6ht4pmy0yrxkdl+mO1eZ3PjG+1OVI9Lha3mkJeSRpPlJHJx2xj1rmry/v7/zZ55pJVyA+XIyeSPlH0PTp3qrW2QquHr4qHs60kvz/ADsfTsuraabR1jvIY8rkKrjgfSsHWvEUL6Vm3+8i7ZZiudo4xgZ5OeleBGS3ktFcyS/akYJsK4G369c5rX8K3N0GubO1R5XYnJlYCKAd3x1JHYevtSjJydji/sWnQXPzXt3NzVZdT1LFnbysgkGWeU4c89NoH+cVYg0rWDbvaz6nNudf3hXqf9kE8ge1WNPZ7KNERmVgvLFtzP8A7RJycn+tXGZpiGZmO4E9f6/WtFCPU1liJr3YpJehjxaINJZJYZpIsnY8TNhJVPXOOdxqOG1t7qZIrHV7nSzuDm1uJvM8px0ADe3fNdzonh68vbaSVAkgUqGSRgTzz3/Om3fw0XVGm+0PAZoj+7QO4O3HQHGOT3NOVCUtUjNZpSjJqrPXvv8AejjNb15J7x47u6trmXBSfKmXzT/vYwPfr2qjpfiSCyjaCKN4bYDKpyQTk9Pfn6VD4u8KzaBqJSF2ubJomnWfGxUAPzR5J+ZlBGQOeelYd1az2iQNdI0RnTeiuMHGcD8+tcknKL1PWpU6FSmuTVP5fgdXH4tW5igiuWkjZSQF/giAPGD1/wAK7jSvijpkUIg1FLq2niGIndD5cwx94+nT0rznwRJpg1FIdSadJHkG1xjy+Rwp9Ca1PiAI4HSSzMYG7YQ0e4svHOeRwRjp3FWn7vNc5MThcNWqKhOD73O+8LfEKy1q9S0vWlSRCdrhSEf0JPYn0rrC99c387Ooj0tQDFxzL6n/AHRXhelz6ho2jJeT20UsMTH5VZd+0jrkZwQfUdPSvS9L1681Swt5p0hi0qBIpJrlmw3m4x5aP93b6n2NEdFqeRj8vhTlz0EuXbe9n5eZ1sk8EdoJWA9k6EmuO8U+LPIuXso5QEIDvMgywGMcflzmsnxHr0jpcXUUhaFT+7CKPKIzg57/AErg7/V0vTJAJjNcfMSQm1Rk9PetYNonC5Yn789f0/4Y9u0PxFBqk0S53DZtdSMbWzz+YxXQ35TYUi2mSUgIBjr6n2ArwjwteCNMNJmbbtK7v8811uk+IDJeSJcSExmNVBY8g5611xqtJpo4cTla5+am9F0O1n0VWAeFkySOCOM9Dj8ulYd9ZlWIdH3KemO3HNa1traLHb/aAPNLgN04z1x7f41sNbQ3XmSKyksAn9c0OHtPhOWNeph3+92OLS3KtyOnOPSklgyN43MRzgnpXWzadGFXaSXNZ19bfZoQ24cngf1qXScdzphjI1HoefeIbc+V50IdJIx8xzgmsNNQwG89U8zHGP5j9a7TWIvNEik71wFPHf0rzPxozWMkEuWJRijY6YIrF6M9zCyU4qLLOoO06ZWRA6g4Kg8D3rCvb+5ik8q4UFgDhix5U5HBHQ9KfbXAcIWdTkcYIHHqao6uN18VfacKu3b6Yz3rObsj14NQVjpdH0eTXNB1bUtSvo4CLWTyGSJlYmMfdQYx8xzuYZPHXmvNtP0+yv7LUri81KGyNnAJIoW+9cuc/KufTA9+a7jRJWn03VtIQP51/AwhZf74B+U88A15VJZTTag1rsWO4UNuWaRY9u0EkEsQAcA8dSeBk10Ya1TY8TMZSot82q6eh614C8OWs/hGbUtOlia7kUGOBp1Lyc7ZEYZyOeenG5Tk81WsdQPhzWotbFuyW0VwLG/iP3ljI6sPw4PqPevJ7SS6tZjcWpYMhA86PO0EjIG4cdO3sa1G1C8u5XmupZmmkHzszZLY6Z/z2rapScZc3Q48Pi/a03Tl+R9UG3imWKW3dJYZAHjdWyrKehB7is7RNIDJqKMoHzFgQfUCvP8A4IeK1hCeHL9tscjl7J+oRjyYz9eo98jvXqhc2k8twBmExsJAOw9ahpRdzF86Tg/keU/Ebwit7bSTwxYvIx8p/vD0rxRlIYgjBHbdivrPWGjuLVjkNGwyGB6e9fN3iiySPxBfKFI/eZ6EdRmuilVtozlr0PaLm6nQR30em38doVeWdFVJmPVVYBmBI99vA4x3ro2Z5NYf50jsbcHzPl3GUheT9M1zukLaJbXFzAvmXJ5dxgAsTgBc/Un8q2dOufMe5jZgrCI7lK43k4zn8B1rjk9dD6SlB2bKGqxLYyCKRwNscbCKHOGB67tvFdPpOmTiwtZ2ZWSeN7jYTgowXbkY4xtB4qOS2PyAIqlhG3rgL1x9R/KrMdqbS5McepF4wSsJSIKDvwHXPORtOcHpmklrc1qVW4qKeoraYslpHFBMqxzSZhAyWYgEFvr1x9TW5Dplxqnh7deOxgibyhDhS529GPZjjvnpVeYW8dxYXUUuwxhwts3VuozzjoRj6Gtmz1BLh3MCM0UmHiRfvK4HTjjHHSrscdWtNJSj0/r+mYfg3RLXT/7RjuZZEuvka1TG0kk8hs8nA5H1q14kiN9ozx2Tot3DJvyp24K9Rx69CKp67NPd3okkLNPCm5nYY4yAigE5IHHTOMVPBdxm3V0zLGoLMG4ZGPByfrWElbQ3bnOSrt3f9fmeZRBmkQwsUYNwykjaT/KmTQ+V5scrvG+MkEZHqAa9Lj0m0kkguIWcRiPLDbnc2Qc8dx61oN4fsr2G+3oUadMOxYMWweG+tZKDTO6WZU47rT/gnjDO0QZUYKrNlgFwW4wRu9Pb3qaeC2vLG1h0yOT7WCxdS3zOvJPtx278V13ifwpb2kcJsDIVCuHwMuRjIPvzXHRtJY3h82LLgAOh+U4OD17GtYytoxOUa6vH+vUwHmETgjGCcg57ehqWG8ZZlkjIUAFcRkqSCOmRU+o25vJnlkGZGPAVQAP89frWW6i2kIbHpycg1ulGWx5VV1aMtdEXre5e1ZvJYKpUqyvyrf54p97q0tyyu7t9oLFWCAAFcdv5fSsqS5QoBGdpwc5zUSsQrvn5sZAyMD8+lWqfc53i5RXLB6G1Bq1xaOVSYkOc4MYb+fSt/Q9ct1tms5mSIzOXkmd2+Uf3BxnPQjtXCxSCdyolHfr3/p/+qug1S+k1a4huLyeWa6SJYXkIC4C8KBjsBxk5P5UpQUdzSjiZT1T0O9t9WsBbqybYmR5FjuwAzOWXbhVIy3cHPHzZro7OG2060CIcRjkAnJZ++T3NeJFSG6jBPet/TdYukhTFz57RBh5cgI+X+8Ce/wDSsnpqdXO6rs9D0abUNsvBKMcDpnj0/KpLe/jB6qwzgk5P4Vw8GsPdyiR1G+PnKdcfTv8A/qrXs2ViSp5kPTOec/oO31rPmN/ZKx6PpOv3kLS/vpvmO5sNtycYGT9K6HU9bsVsBfXF20bWxRljuHMSlcgHLL165A9R6V53p8hVCCCQ3I9fyrA+IWvpFZDS4sNPMVaQnOEGQR+J7/1zWim7Hn1MFTnNPa29ux6v4vgk8UXT2EV/az6VbhbiaQAPKsuMgoR/dBGeQSfXBpnj3w9qlxpNqINRivJbVHTz7oJtWFk2lSrLkyEnIYHPpzzXH/DaRNFit1nVp477ZNAApBLqBuVkzyu443HtgjFej2N6g1C5jvdss4YyxrISQspBJXccnaM/n+dSrVL3MayqYOUY09Yw20WvR/8ABOJe0GneELWCzZJWT5Zke1bex25JDkYyGOM81yV5o+u+IJ4riZWgtUYRxqThlTjJJ/rXu9vZRXZCicDKqXttoIV/duvvio7vR3l+WKRHRuXIXbnB+6P5mj6slqiYZwotxa1fV+fyR5NaaI+j27Q2hMyoTu4+Vie2T160+1uoyltYagr3WlIuGsZGwseDxtA6YJPT3rvL/SpYwnSJB0VMDIri9f0iQ3TTxSiJCu1j5IJ2jrxUSi+p20MRGto38yxJNZ3V61ta7BanYvlMm0pgj5WFZkmgRosjxrb78FjtGOCc9PzrE3yFTLwipkCUMckepz/PtUcPiCSwl8m52m2jGfOLbQvs2Oo9CK1glYKlKrSb5XoOntZ9PupCQjwsOGDFTnOc/TnpUa3U9ndFJAxBAxxnd6H2OTWH4g8QxS2sqW1x51ywAVk5WMZ5IP0/zxXL2+ozRS+a9xMzj5d5kO7H1rSp7y0Hh1aV5vQ9z0WXU7hYpLiOTcrjYrdUXr+ZOK7+wvpYbJfM+RlHzDNeAeHvG2oaeq4dbmAA8SZ3+3zdfWut0r4irdl49Rt1iU8Bo5M5/TpWUGo9QxmXVausYpx8j1WLX/MmC7eMcDPI96j1LU0mVAcllOWGOFxnA9681j8U2sV04+fGRh8YGDwPx/wq5ba093K6RALGvLEtyPrV+0drHE8r5HzctjcuZVKFWkJYncTXB+P4Vl06QjG8NkEnGc8V0EN3m1My/vQWwOoH1rkPHVy8tnHGi5ZpQODnORwMVnKVzsoUnGZz0ul3ulpZrdquyYZjZeQpxnYfX/PpUk6ma3EycywjDpjJK54PvitjXdcl1Hw7Da3VhIiwQbUwhHyBskrnqwyTj2ri4tRktrhHjdklXowPVeuR/P8AGpSU0ejCcl7lTRmzZ3RgkSeNsPH8ynrg/wBR/wDWpdU0w+L9TvLx5oLbUHjVZHdAySdtxGOGwB05z+NR2F0JryK4jRbeRHUnylBGfUA8Z9q6CW7WeUyTr5jt1YgK3tgAcU6NOUHdOxOJUKsOSUbsztV8PaJpvhmCw0/UNYvWklEtzBnZbiYLt3YzyRzgkZxXIHT2FyIU/etnGE5DY6/hXS3/ANmDMyS3SzFxvjB3KUIwTz3rY0K2tLVPtFsrNI67U3/8swOv1P8AKtJ1JSlqc9PBQoU/dRl6Rooh017i4hMR3kwnJWQD0z1znGP6V2vgjxyL7TjDqEwF9FGVlLY/eY6P+I6++ay/E14IlSLbzuXbHnGB16+3H1zmvMNSglXzWQsrCJ+nXHpSg7y5TnxFK9N1Gj2LxD4l0yysZD5x3tkrAj8sfYA14+8EV27XFy5eaQlmYsW/U8mucFzMr5DbsDHIzSfb5F4KivTw9BU7t6nztfGKfurRHqeiW9xBbmC7SJJActgZ3rnjn1zW46WtvbojB2805Cbfcdx09q5qxuEuDKYd21iAWLE4IznFagQyhQ0zFhlVOc/gfpXmyPpoNt6sui/ZbpdwRQilgrDJZQM8epNGp+I1tbeK30yISkyeaqNkK25cMpXqPTOPxqOZd4YSbVdlUhmI65rK1aFbArdW/m28jfJM6XG0AdcYIOc+36Uos2UYSdmi+viBdU03zhE++3Byobd5Zz0B7AjH4/lXQfC2W1v5rxsExyNliR7Z49+ua4KGeO3nuZIre6SG62lpXTJjJB5ypwfXH+FR2V3eeFdZs7y0uHbTrhlJuZVOGyOT9Rn6GtVG7TRz4q6pSglY9tu9PW615rCa+lIjdGjkdQdgbq3ocHHpXOWst1D4lutO1qJnnyUN1AgMUqZwjfTjrUGm+KYZNevZ5ZlEU0cflySMNjkEj5cE8da39U1+LUbZDaOdsWNm0+bJGo6qCP4c5IFY1VZ2OXDVZr3Wrq33P+uhlajdy6F5MOlpA0DdSxxtOcsfyo0fXvMN5cm3Edz9xipOG9AO2B61izadd6xJcRSSvE8KjYrZIOTnJPXNW9Jjs7eyMeqyi1nhUoBnaCP4SPr3rnu2epKFL2dnrLrbf/gk2tTPqWm/upfIl3YLRrkr/sn2PQ4rE1TS7e7sYYhgXcafJIqEFsDufTrx1qC68SxQQ3UdnIpnZxtcr8pXvj8PXrSv4ostivGR5gjIwq87zwCSew9v6Va1LjGdOKS7nNXNpIgXeCrfwkHBP09veucuYwZ9r5GMD6e9dHqd2txdq6yLI7AbygyD/wDX46e9Y15KGYE9eOtXTUosjFxVSKYkVnFJGNwy2ODjoKjlsFjUjC7SecirljJM6PHH0I3FT36n+lF4JnRwFUbeo7+lVeaZlUoRcbpakGj6PLqeoQ2lmIBPKcJ5rBF49WPA/GlnhWCRldlyjYYqcgkHse9UCZhNjheM8daGjLNuAyc96tpt6s5FZLSJLcSK/wB3r0BpWjEcheGXfGAM7htJ9Rj/ADxUSRMUBAznAGMdas/ZblTiSGRB7jiqtZWLSk9WtRtrevG52ZA6dOCOtb9jdJFCWYF5CCOowB9fyrLtoRjgrncBgDke5qzcyJbypLZyFhycMo+VgSMEEflWM1fY6qMnTjaTudXD4kUJE2MEAcAZx/SsPUnmv4NR1Nvs0rJII2j8zEsYBXEm0dU/hz71RE1nPFBsuJvt0zYlV41WJPTBzzn8MVWKIJpVmIV1yMqdwLfUHpUqLT1G6sWvcPWPCUumamljqWjxTi8itvst5bu4Kxkk4dD1wQB/+uugvFWC5E1zcySzTDG7ZwgU8DPv+fFeOeCvEo0DVWvJInmWRliuEVgqiM/eOB/FkDB6deMkGvTNXvLe7kie11m2uLGZxOkcTq0kSFTtVgO/XIxxSceRnPzOpPV6f1p/Xod/pWoFXSWGUiOTIyR95j/n8a6TT9UilZHyUGzhOoz3/pXl2n6j5FshuXUAcCReFB6D+grehukiRPmIHGSvua3jNp3R5WJwUZ7o79mju4CsgG9l+6OcfSsbVtFFyn2dXTymHzDhdpA5OfT2qpbaj+8wsoKhex6GtaxvI2Bd8eZJwvYKK151P4jzVTqYd80DyrUvDrNviCFYpDtx2b1/D1o0zwva2tvskhM5Ax8/P1AHpXr9xZQ3XzfLuA2ggdB7Vh6larbI2APvbQQOtZzpW16Hq0c3lVXs+p4B4u8Di2eW50hSowT9nLYGfY9vpXmlzLhnBBUKTkHqPqPWvonXL6C0LGcqoAPDdxXhWqyaZPqV4JUZA8hZJ4eqn0IPBH61VBuT5WdeITVP2hTs70gYU/KPUdKv280hZi7AqeqkVQg0+NpAtvqNq2ehfcmf54qzGs9ldLFOURyMqysGUg9wR1FXWw8ormsaYDGc0lBvX7jf0+fy3UBSwYg4BAye2D25/Gu706eIwqbTymZk/e5B3Z9M+lcF9nCRNcRFSFwRgdDxVm11S7tV3RyJtPRDjDDvnv8Ayrktynv1ILERvFnpi3IaCWNDtReinHHsO1cX4ovPsVq888UcytOsikZYqBxgn6+lUz4mu3iCiKJTnk9Vx6Yq7da4s9g8UVnE5VCpZyGH4eopaPRnGsFUp7Lc1ZvE2j+JNNtQ0ptri3IZkmGMY54PfgVwN3oMlz4sGk6XLGy3jlrGR22oQcnB9Bwf0pktvDNayB1PmkDY4wAPb3/zmsKeW50q5triG5fzbWQMjjqrDnP5/hWlJXehxYqlLDxs1ov69fxNUPJo901tqUBjkRvmP3h1/wA81sw6vHKSFlK44DOcHFYN9rsutSTXd65luTw8hAG78AMYrPt2jjuULEJCx5x0U/4V3vBTdBVl80cdPMoRr+xbv5nfpBDK5YJmTIOS24jnnpW3bym2CeQTv4ZC3AjOOvuar6B9mmiVlkXDAYIIxXRQ2kQ+dWJ7Y6Zrz3Fo9GWKTVmc7Dp5m8oTIRMrlhnkLnuf9r/61ZGoaKY7K4xHmT7O+ckZP4/1r0W3jg3RqmByDWbqtqrt5KAtvRlA65B/+tWfLrdGNTEc90fPt/E0M/zAhW+ZT2Iz2qpgete2eKvCkN9pnl+XsmiXELqPunsD7V4xc2729xJDOpSWNirKexFe1RndWZ8ri6XJLmjszsNLvikbbgAiBVUhcDcP731zzWvo+oiWWRQkkyglmTd8yAnPU9QOmf0rkzHKrsy+YMkEgH+fvViG6FuXCu5dDmF1OCh78dvr3rilA9+NXQ9Ce8iaAqcJ/sueQfT61T1WcPYpcR7X2gFy/wDCO5x6j0rlbS5Rylzc73dAqrEwODz61sm/it3Ju1cSKcogGRyBkD1NZuA1Vs7oyL8sFV9/n+acpIxO7aMjGM4rOaYCLaPmABX5/mUZ/uj+H8K071FnLRxzQlww4hiwxyeFz6c1n6jCscxh85G8oAEhMKD3HuR60RjY3eI51YjtNRSz0+e1XSbC6MsnmLNOreYoxjaCCPl9q19P8Raftto2N3pqpMGV0J8qEZG7hDufoevrWCVG/EyyZPGFx1xxUTwJGEaUEn37Hpg/pWqipbo4JxlHWErHrnh/VJb25vDZ+JdO1BBGzxtcOYX4PAYdQOPQ+tYEN5pXiCa7h8U+JJNO1CKRhC8Fss1owHTDqdx6+ledmKOJ9ssfyg8EKOK2NONsRE427OPmBwB/nmhYeN7pE06843vLXyL9xpjvdxxWOoadfCVtiNHN5fPbIfBH61QuUuLXK3MEkZBKgkcNjqQehHuKs3aJKjRyRx4JysiqMjjuR2NVrq3aOMrGx2dQjHgHHb2olS8jrhiW3rIha5kLhiTuAwCOAD68dKhyc5Pr3q6Vt5botFDcWyeWCI5AJAWGAcNxx9RxV60NvGCJwko+6Mr827nj8j0pOFhutFr3g8PQyPJJKoUrGOdwzyemD2I610jQRXMnmyxBnYBScDBrMg1KK1jPlq23aO2M4z1HfHTNQXevBCHi5jPJUEDAqfZ3M54qTfulu80eHaAAsSKdysR19iB/niq02lWkUYM+FORkKSd4P8seo/GsmbxLKQRKAV7Ec4OOvsazLnWbicEmR+5/xx6VSpMzeKn1Z0mnXGmw7llaOS5AyGKYyfT8McdKpajrJYgRPhQpG0YwPeuRnvwSS0vucHnNVJtQ3jgM3HU8VrHDM5qmPhFtt3Z0sOrtbSMykZkXaQemD/X/AOvQNVVl2F1EZzgNzyep+vvXItdSMOoH0FRF2bljk+9a/VE9zleayWyOvS8YCTYxCOMMByCMg4I+oH5VUnv2t02RJuc85IyAK5wOy8KxH0NP86U/xtj3NNYVIiWZNrRWZum5LfODy3GfX2NaOkag9vd71CMVUgbhkDPeuSWVuu9s/WrUd1IGyWJqZ4e6sXSzFxkmz1e08S3V59mtnlEcW9TkdRjtz2zXoVpr8U0gtfNDFAGlDdhngk+vFcP8NPD0Xi3w1dPeQR286TJBbXEalTJhSWJ7Nj5RUvjjwvJ4a0+OZbuW6uJ8edLny9uDyQoJyCSOp7ZrzpQcZWPcWLpV0ken2N7HLtaMqY3ywPTIz1+nvW3FfAS+WT8oGSR25rzHwtq1stlYRRMx/dhFBPIx2rrYbmJ8FWwc4xnrSTJq0U2dzb6gY2UlgwHQentVnUrsTQCQgLt6Lnkn2rihdMoyWJx05q0l+5ULLKqI3BYjJHrx3q1J2scEsGuZSRwHxNRpLOdo1jMrLkuxxgA8/TjjNeHT/NMQoYpnrivonXrCHU43EufJP8Mn3mHv2ryHWPD/APZt8fNBmtQ3BjO3I9AfWqpyUT0p0ZV4RjF7HD3AMMmR908g06C+kUhXZmjGcBjnGf8AP6VpXUCSeYgBAPK7uorBlRo5GVgQwODXbTkpqzPDxEJ4WpdHbaVqUaxmOfPlkZBUd8cCpfPBbcqAHtz0HpXF2d4YGAflO3qK6C0uA+NhBUjggVy1qLie3gcz9orLc3bd1cYXmrUGI3LEHO3jkjB9ayrY4YMGxirckjADGSe1cEk09D2qeKly+8WL3ator+WyJ3LHIY+o/rXF6zdmSZY8HpnJH8q3bi+8wKsgbAGShyQT64Peuf1uY3l7GqoVCLtyRgnvXZhYWlqeJm2J56doP5HQfD+yn1H+1QunNfWUFo0t2y43WiA8TKSf4TyQM5GaxroGOFjj5W5A7f5FGlwTwyM254w42EKxG4e+Oo9jVnWYmWy3gfL1z6eterhcXGlUlTltJfiePVwc6lBVLe9H8v61N3wFfqWKbm3+h9q9MgvQAuwAyEDr/Svn6yvJtPukltnKMBng16j4a8U22pRhbwrHcAbTjjP0/wAK5MTh3B6bHThsUqys90d7a5aaNghGGBx/n/Jq3o2Z9Uck4bym/D6Vj6Lefvlidy4VgA3TI7fjir0F2lrqTSgjYqMWz2B759OOtcKdmmzrd5JryNXULY+WxI7ZzXmuraDBPqE0rxoWYjJIGegr05ruLUbBbq1dJY2GQynIPbIrk7llWdwOgPpmt79jk5eZWZ4vJLIZMq65xu3evPXn/PFESlnUgAkDdkc89vxpoYPvyVCAZPA5OajdZoi0gY7sZVjwTkcHHsK7PZNnP7exotLsQfvf3agHOc4XOMAc4qZrwOxaWeQksBz8rbsfoOtY32oR/LJIsRGM7h2HA/XPSmNqEAk8pLjAPBkAO0DHT/8AVQqDYni4o2ZdUkVZDBIEjU7VVepJ461mTXTLjzpo8u3zF2wHx3Ptmq2rXUEUQ+y3ReRwDlFH059MDjFYJJY5JyfU81qsMluctTHuLtE2LrVVDHynMzHneQVy3r7+1Z8l9O7Md4Bb73GT+dVs5FJWipxXQ4p4mrPdky3M6ggStjGMHkVattUmgICpEf73B+cehrPz1zRVcqIjVnHZnTW/iaLyts9kxHqkn+I4q6niTTZUVZluIsHhtoY49D61xfWkzRa5qsVUR3y6vpToWS+iTIyY2Ruvtn/PNZ9xq2n7MJdE8cDyyStcjk4pM1Lgn0NFjaiOiOtwjqZnXGMAY/WqMuqKxwkPy+jGsrJo9KSpRFLG1X1Lct7I/wB0Kv8AOq7yu+d7M31PFNzxTapRSOeVSUt2O7dKTNIM9aKdiRaM0gopgKKBSZo70hjwakDY+tQZpc0mhpnceCviFrPhKN4rA289qxZlgukLrGzAZZcEEE4GecHFaXiH4l3viLSY7TU7S3EocM9xFkHaDkBVzx7/ANK833GnBvesZUISd7HRTxVSGzOqs9Y8uVGilaNh05IOPrXpfhHxEb2JPNZVkQ4OOnT0614ar1raLq0unXIkjYhTwR/9auephVuj1MPmkm+Wp959IrcsR8p3d+P5+xp8kzO67pOc9Sec15xpnjCOURQSIVVk/wBduBX8e9dHFqiPA8vmNKCncgn1rz5rldme9RXOrlvU9T+y7wFkfHUqpJ696xdXsv7TRXjc5x8hkb7q9Tkdu1XXvYpIfugZH8XUDr2qB7pJZPJRTtUBnJx0/wDr/wD16i56tOPIrpanE6po/wBmnZHOTgE4bII5rD1vSy0LXMRBMQ+Zc8kZ4Negy6fda/qjxW0aQmJRvkwcADqfcegq1L/ZumrHGkkIQ5BMmD5vYk5/lVwqTi+ZHmY3DUZ3hJavt37niDcHqcVLaXbWz8cpnlcfyrT8T2UdrfNJbKRayndH/s+1YR6/jXrQlGrC/Rnx1WE8LVcdmjrLG+WQBkIYDqP8a1kkWRRgnmvP4ZnhcPGSrCun06786MMr47H2rixGG5dUe3gMw9r7ktzXkt4pAzM2HA446mqF64WVdqLHhQCVydx9Tnv9KseaQo2bWfGACahkUyzuFByOp5rCGm56VdxkvdKsTsZABng9MdK0ZQGgKPjoQc/Sls7NzIWwc98Ctmz0Ka91G0tcYWQ7nYc/IOT/AIUSkpSSQoQlGDnI85mTbOy54XjiiORopFaNmUjvnivY/HXgqO6s1nsY1S8hTC4GPMX+6ffHQ/hXjUyMhPBHUEHgivoMPUhVhaW/U+UxNKVGfNDbodP4e8W3lhdwB5CyA4w2SAM549K9D07xNperW8sV1N9nmaF0wxwygjBweleIIfnBBOQQa07S9HlyZADrG3OOtceKwcU/d2OrC5hJ3VRnr1t4ssdDtxYyXPnCMMitbxh8gD5SQCP0rDuvGFs87sBdYPpFj/2avPXuQDuQjkY44qFpyxztFc8MNpZs1q4uPMQNqEi5W2Hlpx97k1WmuriXPmzysPQscVGcc0hI9BXqNHg88n1E6GkJpT1Pb8aD7ikSNwO386MfWlPTmk5xmgBD9ePrSfXrTvXFJ60DE7UUp6GkJoATqKTr60pJpD60gDjv1pM+9KaQ/SgYdjSDrRR9aAFxxTf4qd/hTaAAfpS0maWgYnWil7UnNAB/Oij8aPegAzxS8UlH1oAX86X86bR9aQEgNODdPX1qLPNOzwOlFikzT02/a2fBJaM9R6e4967jw9rUaOgmO+3c4LdSvf8AH6V5qp6VZtrl4X3Rkj1HUGuWth1UXmelgsxlQ92WqPdmt4p7bNs6qrKPmGBkZzWb5F15zBYnSNSASDtHHAPH1rj/AAh4hkgueACirl1J7eq17Bp6w3qJL1ZhkY5B4/z0ryatNwlZn1mFzFON1qmWPD2kRIhlujOsZQrIu7YCOwwD0Pcd8dq5rxR4ZhvL+S5gdg5JLFcAAY4UL0A47dK763Ahh+RM8d6x76N3um2gqG4YjjOf6Uc9lZGXO6lRzbPJrzR5bmGW2EZcoSu5ecMK8+uImjdkcFWBwR3r6Xg0aKKABEIXJPJ7nmvG/iNo32TVZbiFSIpMOfqeuPx/mK6MHVcXyy6nmZpRVaPtILVfkcJnHWp7ScwTq+cKfvY9KicY6005Br1Wrqx85GTg7rdHV2s5STdIoZODvXqRW3DPZSAbJCHPcjP4jFcNp98YMJJ80Xb2/wDrV1Oli2mlG+TYH6FSDXmV6Liz6fA43nXuv1Oqs44YFZvtCHeN2Sv8PfJ9/wCldf4BaC9lvbiNWxGwjVjjoOePzz+NYE+g21zaIULK6LgSZzuOOp7ZqLwJqr6FrE2l6gu1Z5PkcdpDwPwIxg+v1rnpx5XdnTVre2g0j0/UkSS2YZ+UjFeBfELSFsdSM0YwshJcD19fx/nXuU85ZWGDjkdO9eQ/FG7DGGInMgJJPXArtoScaiseXiIL2Uk/U83GPMU+/anwtgSH/Z/OoxgSL0PNOjPyTEf3TXsS1ifPX1AP8wA6daN3uaYOetOAOOBmsBtkff8Ar6000rDk+hNGM1q0ZCcCkP8A+qlx6UEZH/1qmwCUnBOcUpFGOx60rANNIfenY69KTBosMTFJ6dOlOApvamAnbpSUoFJ2pAJ+FJ1+tKfb0pKQxD3o70uKSgYp6fWm07oKbQAo+tH86Sj2oAKPaikNAxaSlpKAClpKWgA7UfjSds0uaAFBpabS0AOBP50qn8qZS0rAW7S5e3mSSM/MpyK9m8FeI7ZrSBZHEaEALyAM/wB36ivEAefwrR0vUGtJRuyYj1Hce4rmxFHnV1uehgcV7KXLN6P8D6qtrwSICrKB6571YjkicEnGeleNeGPFbCIx3FyXQ8q7c59j/Q16FpF2J4wEkIXqfUA15LjZ2Z9CoK17nRwwi4nEULDazAMe9XNZ8MWV5pz208KsjDklc9sGqfhi6WO/aFz1Tcue5zjiurkmBXDHOen+FaQStc4cROcZpLY+O/HPhyXw3rk9lIGMeN8TH+JD0/EdK5luo+tfSPxt0OHUvDr3ccY+12Q82NgOSn8a/THP4V83y+telQnzR1PHxVPkldbMbntU9tdS2zfuyMd1PIP4VWzS966HFPRnPGTg7xdjrtJ8W3NoVCuVQceW3Ix9a3r7W7HV7cSFzb3iDIbdlT7f4GvNO1OBxiuWeEhLbQ9CjmlSn8SuevW3xCtksgmouROnBESbt3HUHPB9jXn/AIn1pNX1F54o3jjIA+dsk+/H8qwgSQTmlGa6aOHhT97dnPXxtSrdbIkQnepxznvUkTDZKB6EVAgJYD3qWP7svrt710SOMaD9acADzTBTiD6VlYDvr74ZalEzeRLvA/vLj+Vc/deD9btid1mzdvlYc19V/YVLHyn2t1IJ/rUT28TLsuYUJP8AFjt/jXY5we6M0j5Fn0u+g/11pOo9dlVPJc8bG59q+t5fDllcZ/dBQfyrLm8F2Ert5eEcHhT0NTamxnzLDp11OD5cEje4FWU0HUWxttnr6Tt/CNonDIAR0zV5fDFkRkKFcfkaa9mtxnzCPDepP/y7kfUil/4RnVCCVtiwHU7hX0s/heH72zIHoOKhOhQRglogwPaq/dCsfMtzot7AAZIHX61muhRyrghh1B619Q3fhq2uRlQqP2OM5rkfEHgqC5V1mg3Z5VhwfwIodOnL4dGGx4SaQjiuq1/wff6bukgzcwA9AMOv4d/wrlz3rmnTlB2Y0xlJTiPWm+tQMQ80hpetFIApo6089MU00xh+NJSg0f0oASij+VFACZopaKAE+tLSUtIYlFKRR9DQIO1LRSGgBe1A/nQO1FACjpQDz/hR6UZNIZbs7uW2cFMY7qeld34V8aNZ7Y5CWQ5+Rjgj6etede9KG49qxq0I1N9zsw2NqUFyrVdj6P07WYdTCyabOn2uHDIGbacdwR7iux0/xFDdQMoYeZGPnXnch9/evki3vbm3dWhndGXoQ3T6U+XUbyUs0lzMWb7x3kZ+p71yrByT0Z2TzKnONnF3PZ/iz41iXT5tLgJe8nUo4B4RDxk+hPYe+a8Oc5+lJnP175pDiuulS9mrHm167qyuL9KXJ9/rTR6Glx69q1MRevfinAdqQevelx+NMAFKP6UDpkdfagetNOwhyfeH1qWPhZemdppkY+Zc9jzUkf3JQf7vTNXe4hgODyRThjA6/lXSaRp13JYRS26W+yQZyRknB7099CvCxOLer9ixn1Km7axOdp9uSanJLqA4J/DpTWVCMqwywzmomBCn5uRyQai9yCzGikEjAIHApxVGhHy7GxjJHWqcchY5cDscVP5vzAEggdOagZNE3UzISOg4p80C4DKOg5ApkMhPUYPt2pHbbyvC/XikIYN3TJyf0pJY45AQoG7pkU9sMhbo3QCoto38Ejjt3p3GRiyCIzMcEdB61UuIcpl12gjj6+tbcTknnB29iOKrXUBLYiGF4LIeufahTdwOO1LR0mJbaCwPAFeceKfBFtd+ZJKjW9wfuXES53ezr3+vWva3UMSqgADnnrisy8hQbtwB46HtXRCrf3WFj5V17Qb/AEWcpewHyicJOgJjf6H19jWUR1xX05qWkxXMMkfkxyK4w8bgbW9jXk3ijwD5ZaXRgUccm0kb/wBAY/yP50pUU9YfcCfc86PJNJ+FPmjeKR45kaORThkcYKn3plYNWGKenFNyOadxim+tIBR702lFBpjEo70ZoPtSAPyo/rRSGmAtFFFACUvajv8AWigBetJQaKAFH6UtJR1pAL3ozSUv1oAPSg0UUALSnvjvTe9L+NAxf5Uc96Ttzil+lAhRR360g9+9KKAHflQO3rSA0ooAcO/60oI46U0dBSjsKAHx/wCsXtzUsf3Jf92ooj86565qWP7kvGOKuIjo/D2sT29gsQgEsMTEAg88nNag8RW+PmikB7jFYng6ZRdz28h4kXcAfUf/AFq6ZtPt2Ynywc99tdqV4ppiufQP/LTHbOamLEqpJ55P40UVxMQ24AEiAcCnQsduOw4FFFLoMndj6ntSIxKrk5+tFFQgGZIk44zUsXKZPOQaKKbAlQ4QEcEtz+dSoSVLE/MSTmiipBle/RVTcow2etZMYDyvuAOB3+tFFXEa2KE4G4nHJzWRfQxyRyK6gja3WiiumG4meb+LNNs7vRzc3FujzxodsnRhjpyK8ouI1RvlGKKK6asU6d2iE9SE03+KiivNNBaaeBRRSGGKKKKAEoFFFAwPSiiimAGlA6UUUhB6Uh6UUUDQvTFKaKKBB2FJmiihDQo5xQehoooABzTh3oop9QEHSlPSiikIPWlPFFFAxc8U4feFFFNiF6Uo64oopAxyfeX/AHh/OpU4Ew7AEfrRRVIRc0B2TWrMqcfPj8MGvRdooorqi7U0Lqf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Appearance of the hand of the immunocompromised patient with bullous Vibrio vulnificus skin infection after surgical debridement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rolando E Saenz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_6_17506=[""].join("\n");
var outline_f17_6_17506=null;
var title_f17_6_17507="mini radial probe image";
var content_f17_6_17507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Endobronchial ultrasound (EBUS) mini radial probe image",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) The radial probe endobronchial ultrasound image demonstrates six distinct layers of the bronchial wall. Layers 1 and 2 are the mucosa, submucosa, and muscle. Layers 3 and 4 are the cartilage. Layers 5 and 6 are the adventitia. Layers 1, 3, and 5 appear hyperechoic because they are interfaces. B) Cross section of a normal bronchus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_6_17507=[""].join("\n");
var outline_f17_6_17507=null;
var title_f17_6_17508="Cefadroxil: Patient drug information";
var content_f17_6_17508=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cefadroxil: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10357?source=see_link\">",
"     see \"Cefadroxil: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/32/32259?source=see_link\">",
"     see \"Cefadroxil: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F146996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cefadroxil&reg;;",
"     </li>",
"     <li>",
"      PRO-Cefadroxil;",
"     </li>",
"     <li>",
"      Teva-Cefadroxil",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701735",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cefadroxil or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699479",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) in a refrigerator. Throw away any part not used after 2 weeks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11822 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_6_17508=[""].join("\n");
var outline_f17_6_17508=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146996\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015484\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015483\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015488\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015489\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015491\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015486\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015487\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015492\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015493\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10357?source=related_link\">",
"      Cefadroxil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/32/32259?source=related_link\">",
"      Cefadroxil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_6_17509="Growth hormone metabolism in chronic kidney disease";
var content_f17_6_17509=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Growth hormone metabolism in chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/6/17509/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/6/17509/contributors\">",
"     Biff F Palmer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/6/17509/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/6/17509/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/6/17509/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/6/17509/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/6/17509/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/6/17509/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progression to end-stage renal disease is associated with a variety of abnormalities in growth hormone regulation, including changes in its plasma concentration, in the regulation of its release, and in end-organ responsiveness. As an example, the plasma growth hormone concentration is commonly elevated in chronic kidney disease due to the interplay of several factors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Decreased renal clearance appears to play a major role in the genesis of this problem, since filtered growth hormone is normally reabsorbed in and metabolized by the proximal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enhanced growth hormone secretion also may contribute to the rise in plasma levels, although it is likely to be of lesser importance. Children with end-stage renal disease have an increase in the number of secretory bursts of growth hormone when compared to children with normal renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/4\">",
"     4",
"    </a>",
"    ]. Why this occurs is not clear, but protein-calorie malnutrition and stress may play a role.",
"   </p>",
"   <p>",
"    Plasma growth hormone levels fall to low-normal values after the institution of maintenance dialysis, an effect that may be mediated in part by acetate (which has now been largely replaced by bicarbonate) in the dialysis bath [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/5\">",
"     5",
"    </a>",
"    ]. For reasons that are not well understood, the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    also leads to a reduction in the basal concentration of growth hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     REGULATION OF GROWTH HORMONE RELEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of observations suggest that the hypothalamic-pituitary regulation of growth hormone is perturbed in chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/7\">",
"     7",
"    </a>",
"    ]. As an example, normal individuals suppress growth hormone release in response to induced hyperglycemia; in contrast, glucose induces a paradoxical rise in growth hormone levels in advanced renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, insulin-induced hypoglycemia, which is a potent stimulus to growth hormone release in normal subjects, elicits a blunted response in chronic kidney disease patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The response to factors other than glucose also may be altered. Thyrotropin-releasing hormone stimulates growth hormone release in uremic patients, but has little or no effect in normals [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/10\">",
"     10",
"    </a>",
"    ]. This abnormal response can be abolished with either acute or chronic administration of erythropoietin&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/7,10\">",
"     7,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The factors responsible for the abnormal growth hormone regulation in chronic kidney disease are incompletely understood. Impaired hypothalamic control appears to be of primary importance. Uremic rats, in comparison to controls, have a normal growth hormone secretory response to growth hormone-releasing hormone (GHRH) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/11\">",
"     11",
"    </a>",
"    ]. However, hypothalamic GHRH mRNA levels are reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL IMPORTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic significance of elevated growth hormone levels in chronic kidney disease is not clear. Although early studies suggested an etiologic link to the glucose intolerance that is commonly present in this setting, abnormal carbohydrate metabolism appears to be independent of growth hormone secretion. As an example, hemodialysis improves carbohydrate handling without correcting the increased plasma growth hormone concentration.",
"   </p>",
"   <p>",
"    The relationship between altered growth hormone metabolism and growth retardation in children with chronic kidney disease has also received a great deal of interest. Since circulating growth hormone levels are elevated, it has been suggested that uremic individuals may have end-organ resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/13\">",
"     13",
"    </a>",
"    ]. This hypothesis is supported by the observations in uremic rats that the number of growth hormone receptors, hepatic growth hormone receptor mRNA, and chondrocyte responsiveness to growth hormone and insulin-like growth factor-1 (IGF-1) are reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Both decreased nutritional intake (which is common in advancing renal failure) and a circulating factor appear to contribute to the decrease in growth hormone receptor density. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9274?source=see_link\">",
"     \"Pathogenesis and treatment of malnutrition in maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The plasma concentration of growth hormone binding protein is also increased in renal failure. Growth hormone binding protein may contribute to growth hormone resistance by effectively competing with the receptor for ligand binding since it contains identical amino acid sequences to those in the receptor's extracellular binding domain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Growth hormone binding protein may in fact arise by proteolytic cleavage of the growth hormone receptor.",
"   </p>",
"   <p>",
"    In order to document that there is direct end-organ resistance to both growth hormone and IGF-1 that is independent of circulating inhibitors, one study compared the growth response of epiphyseal chondrocytes isolated from chronic kidney disease and control rats [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/15\">",
"     15",
"    </a>",
"    ]. In this study, chondrocytes from rats with chronic kidney disease that were grown in normal rat serum, fetal calf serum, or serum free conditions all demonstrated a reduced growth response. The resistance was specific for the growth",
"    <span class=\"nowrap\">",
"     hormone/IGF",
"    </span>",
"    system since other cytokines such as fibroblast growth factor and transforming growth factor beta elicited growth responses comparable to that seen in control cells.",
"   </p>",
"   <p>",
"    In animal models of renal failure, growth hormone resistance can be partially overcome by the administration of large doses of recombinant growth hormone. In this setting, there is an elevation in the plasma level of IGF-1, improved growth, and an increase in the width of the tibial epiphyseal growth plate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/16,18,19\">",
"     16,18,19",
"    </a>",
"    ]. The last effect is preferentially localized to the more mature chondrocytes in the hypertrophic zone instead of the immature chondrocytes in the proliferating zone. An increase in the abundance of IGF-I mRNA is seen in both zones [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These results are consistent with the observation that administration of recombinant IGF-1 also stimulates growth in an animal model of renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/20\">",
"     20",
"    </a>",
"    ]. The growth promoting effects of recombinant growth hormone and recombinant IGF-1 are additive when they are given together [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increasing number of studies in children with renal insufficiency suggest a similar response occurs in humans as supraphysiologic doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"     recombinant human growth hormone",
"    </a>",
"    can lead to increased growth that may allow attainment of normal adult height [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27881?source=see_link\">",
"     \"Growth hormone treatment in children with chronic kidney disease and postrenal transplantation\"",
"    </a>",
"    .) In addition, treatment of children with recombinant growth hormone appears to be safe [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/22\">",
"     22",
"    </a>",
"    ]. Studies to date have shown no evidence of increased risk of malignancy, accelerated loss of residual renal function, or worsening of metabolic bone disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Somatomedins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatomedins are thought to mediate the actions of growth hormone on skeletal tissue; as a result, a number of studies have examined their role in explaining the growth failure of chronic kidney disease. The somatomedins are a family of growth hormone-dependent, insulin-like growth factors that circulate in plasma in association with specific binding proteins. The steady state levels of IGF-1 mRNA are diminished in the uremic state and fail to rise significantly after the administration of exogenous growth hormone due a defect at the transcriptional level [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decreased caloric intake and the metabolic acidosis associated with chronic kidney disease also may contribute to the peripheral growth hormone resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/14,23,24\">",
"     14,23,24",
"    </a>",
"    ]. As an example, experimental studies have demonstrated that metabolic acidosis (without renal failure) reduces both hepatic IGF-1 gene expression and hepatic mRNA for the growth hormone receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the reduction in synthesis, plasma somatomedin levels (measured by radioimmunoassay) are usually normal or elevated in uremic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/25\">",
"     25",
"    </a>",
"    ]. In particular, IGF-2 levels may be increased by as much as fourfold due primarily to decreased renal clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/26\">",
"     26",
"    </a>",
"    ]. When measured by bioassay, however, circulating somatomedin activity has typically been low [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/27\">",
"     27",
"    </a>",
"    ]. The apparent discrepancy between this observation and the normal plasma levels by radioimmunoassay appears to reflect the accumulation of a circulating peptide inhibitor that is normally cleared by the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/28\">",
"     28",
"    </a>",
"    ]. As mentioned previously, there is also direct end-organ resistance to the effects of IGF-1 independent of circulating inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/15,29\">",
"     15,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, quantitative and qualitative abnormalities in the IGF binding proteins (IGFBPs) may contribute to the decreased bioactivity of IGF-1. Plasma levels of IGFBP-1, IGFBP-2, IGFBP-4, and IGFBP-6 are increased two to three fold in advanced renal failure while the concentration of IGFBP-3, the most abundant circulating IGFBP, is typically normal [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. However, some of the IGFBP-3 may be qualitatively abnormal due to accumulation of unsaturated low-molecular weight forms of this protein which may in turn lead to a decrease in bioactive IGF-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17509/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The extent to which abnormal somatomedin metabolism contributes to disturbed growth in uremia remains to be established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H547117529\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progression to end-stage renal disease is associated with a variety of abnormalities in growth hormone regulation, including increases in plasma concentration and decreases end-organ responsiveness. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Regulation of growth hormone release'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plasma growth hormone levels fall to low-normal values after the institution of maintenance dialysis. The administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"       recombinant human erythropoietin",
"      </a>",
"      also leads to a reduction in the basal concentration of growth hormone. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physiologic significance of elevated growth hormone levels in chronic kidney disease is not clear. Growth hormone resistance may be associated with growth retardation in children with chronic kidney disease. Supraphysiologic doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/54/12137?source=see_link\">",
"       recombinant human growth hormone",
"      </a>",
"      can lead to increased growth that may allow attainment of normal adult height in children with renal insufficiency. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical importance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors that may contribute to growth hormone resistance include decreased somatomedin activity, decreased caloric intake, metabolic acidosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Somatomedins'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/1\">",
"      Veldhuis JD, Johnson ML, Wilkowski MJ, et al. Neuroendocrine alterations in the somatotrophic axis in chronic renal failure. Acta Paediatr Scand Suppl 1991; 379:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/2\">",
"      Kaskel F. Chronic renal disease: a growing problem. Kidney Int 2003; 64:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/3\">",
"      Johnson V, Maack T. Renal extraction, filtration, absorption, and catabolism of growth hormone. Am J Physiol 1977; 233:F185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/4\">",
"      T&ouml;nshoff B, Veldhuis JD, Heinrich U, Mehls O. Deconvolution analysis of spontaneous nocturnal growth hormone secretion in prepubertal children with preterminal chronic renal failure and with end-stage renal disease. Pediatr Res 1995; 37:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/5\">",
"      Orskov H, Hansen AP, Hansen HE, et al. Acetate: inhibitor of growth hormone hypersecretion in diabetic and non-diabetic uraemic subjects. Acta Endocrinol (Copenh) 1982; 99:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/6\">",
"      Kokot F, Wiecek A, Grzeszczak W, Klin M. Influence of erythropoietin treatment on function of the pituitary-adrenal axis and somatotropin secretion in hemodialyzed patients. Clin Nephrol 1990; 33:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/7\">",
"      Ramirez, G. Abnormalities in the hypothalamic-hypophyseal axes in patients with chronic renal failure. Semin Dial 1994; 7:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/8\">",
"      Rodger RS, Dewar JH, Turner SJ, et al. Anterior pituitary dysfunction in patients with chronic renal failure treated by hemodialysis or continuous ambulatory peritoneal dialysis. Nephron 1986; 43:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/9\">",
"      Ramirez G, O'Neill WM, Bloomer HA, Jubiz W. Abnormalities in the regulation of growth hormone in chronic renal failure. Arch Intern Med 1978; 138:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/10\">",
"      D&iacute;ez JJ, Iglesias PL, Sastre J, et al. Influence of erythropoietin on paradoxical responses of growth hormone to thyrotropin-releasing hormone in uremic patients. Kidney Int 1994; 46:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/11\">",
"      Santos F, Chan JC, Krieg RJ, et al. Growth hormone secretion from pituitary cells in chronic renal insufficiency. Kidney Int 1992; 41:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/12\">",
"      Metzger DL, Kerrigan JR, Krieg RJ Jr, et al. Alterations in the neuroendocrine control of growth hormone secretion in the uremic rat. Kidney Int 1993; 43:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/13\">",
"      Blum WF. Insulin-like growth factors (IGFs) and IGF binding proteins in chronic renal failure: evidence for reduced secretion of IGFs. Acta Paediatr Scand Suppl 1991; 379:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/14\">",
"      Chan W, Valerie KC, Chan JC. Expression of insulin-like growth factor-1 in uremic rats: growth hormone resistance and nutritional intake. Kidney Int 1993; 43:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/15\">",
"      Mak RH, Pak YK. End-organ resistance to growth hormone and IGF-I in epiphyseal chondrocytes of rats with chronic renal failure. Kidney Int 1996; 50:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/16\">",
"      T&ouml;nshoff B, Ed&eacute;n S, Weiser E, et al. Reduced hepatic growth hormone (GH) receptor gene expression and increased plasma GH binding protein in experimental uremia. Kidney Int 1994; 45:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/17\">",
"      Rees L, Maxwell H. The hypothalamo-pituitary-growth hormone insulin-like growth factor 1 axis in children with chronic renal failure. Kidney Int Suppl 1996; 53:S109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/18\">",
"      Mehls O, Irzynjec T, Ritz E, et al. Effects of rhGH and rhIGF-1 on renal growth and morphology. Kidney Int 1993; 44:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/19\">",
"      Hanna JD, Santos F, Foreman JW, et al. Insulin-like growth factor-I gene expression in the tibial epiphyseal growth plate of growth hormone-treated uremic rats. Kidney Int 1995; 47:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/20\">",
"      Benfield MR, Parker KL, Waldo FB, et al. Growth hormone in the treatment of growth failure in children after renal transplantation. Kidney Int Suppl 1993; 43:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/21\">",
"      Kov&aacute;cs GT, Oh J, Kov&aacute;cs J, et al. Growth promoting effects of growth hormone and IGF-I are additive in experimental uremia. Kidney Int 1996; 49:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/22\">",
"      Fine RN. Recombinant human growth hormone in children with chronic renal insufficiency--clinical update: 1995. Kidney Int Suppl 1996; 53:S115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/23\">",
"      Challa A, Chan W, Krieg RJ Jr, et al. Effect of metabolic acidosis on the expression of insulin-like growth factor and growth hormone receptor. Kidney Int 1993; 44:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/24\">",
"      Boirie Y, Broyer M, Gagnadoux MF, et al. Alterations of protein metabolism by metabolic acidosis in children with chronic renal failure. Kidney Int 2000; 58:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/25\">",
"      Takano K, Hall K, Kastrup KW, et al. Serum somatomedin A in chronic renal failure. J Clin Endocrinol Metab 1979; 48:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/26\">",
"      Goldberg AC, Trivedi B, Delmez JA, et al. Uremia reduces serum insulin-like growth factor I, increases insulin-like growth factor II, and modifies their serum protein binding. J Clin Endocrinol Metab 1982; 55:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/27\">",
"      Phillips LS, Kopple JD. Circulating somatomedin activity and sulfate levels in adults with normal and impaired kidney function. Metabolism 1981; 30:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/28\">",
"      Phillips LS, Fusco AC, Unterman TG, del Greco F. Somatomedin inhibitor in uremia. J Clin Endocrinol Metab 1984; 59:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/29\">",
"      Fouque D. Insulin-like growth factor 1 resistance in chronic renal failure. Miner Electrolyte Metab 1996; 22:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/30\">",
"      Fouque D, Le Bouc Y, Laville M, et al. Insulin-like growth factor-1 and its binding proteins during a low-protein diet in chronic renal failure. J Am Soc Nephrol 1995; 6:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/31\">",
"      Buyan N, Cinaz P, Hasanolu E, et al. Changes in serum levels of IGF-I and IGFBP-3 in children with chronic renal failure. Endocr J 1995; 42:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17509/abstract/32\">",
"      Krieg RJ Jr, Santos F, Chan JC. Growth hormone, insulin-like growth factor and the kidney. Kidney Int 1995; 48:321.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1980 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.123.134.1-8BED796ECD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_6_17509=[""].join("\n");
var outline_f17_6_17509=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H547117529\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      REGULATION OF GROWTH HORMONE RELEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL IMPORTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Somatomedins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H547117529\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27881?source=related_link\">",
"      Growth hormone treatment in children with chronic kidney disease and postrenal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9274?source=related_link\">",
"      Pathogenesis and treatment of malnutrition in maintenance dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_6_17510="Mastectomy incisions for upper outer quadrant tumors";
var content_f17_6_17510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Mastectomy incisions for tumors of the upper outer quadrant of the breast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 599px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Design of the classic Orr oblique incision for carcinoma of the upper outer quadrants of the breast. The skin incision is placed 1 to 2 cm from the margin of the tumor in an oblique plane that is directed cephalad toward the ipsilateral axilla. This incision is a variant of the original Greenough, Kocher, and Rodman techniques for ap development.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bland KI. Modified radical mastectomy and total (simple) mastectomy. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_6_17510=[""].join("\n");
var outline_f17_6_17510=null;
var title_f17_6_17511="Endoscopic staging lower GI-GVHD";
var content_f17_6_17511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F86937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F86937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Endoscopic and histological staging of lower gastrointestinal graft-versus-host disease (GI-GVHD)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper panel: Endoscopic views of the colon with the four grades of GI-GvHD. Grade 1 = loss of vascular markings and/or focal mild erythema; grade 2 = moderate edema and/or erythema; grade 3 = edema, erythema, erosions, and/or bleeding; grade 4 = ulceration, exudates, and bleeding.",
"    <br>",
"     Lower panel: Photomicrograph of the colon corresponding to the above endoscopic images: grade 1 = increased crypt apoptosis (arrows); grade 2 = apoptosis with crypt abscess (arrow); grade 3 = individual crypt necrosis (arrow); grade 4 = total denudation of areas of mucosa (H &amp; E; x220).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Cruz-Correa M, Poonawala A, Abraham SC, et al. Endoscopic findings predict the histologic diagnosis in gastrointestinal graft-versus-host disease. Endoscopy 2002; 34:808. Copyright &copy; 2002 Thieme Publishers.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_6_17511=[""].join("\n");
var outline_f17_6_17511=null;
var title_f17_6_17512="Treatment of seizures and epilepsy in the elderly patient";
var content_f17_6_17512=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of seizures and epilepsy in the elderly patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/6/17512/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/6/17512/contributors\">",
"     Jane G Boggs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/6/17512/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/6/17512/contributors\">",
"     Timothy A Pedley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/6/17512/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/6/17512/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/6/17512/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/6/17512/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A discussion of seizures and epilepsy specific to the elderly patient is important for many reasons. A high proportion (25 percent) of new seizures occur in individuals over the age of 65 years, and nearly 25 percent of all persons with epilepsy are elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The causes and clinical manifestations of seizures and epilepsy differ in this age group and affect the diagnostic approach. Treatment issues are complicated in elderly patients. Finally, there are significant implications of a seizure diagnosis in the older person already vulnerable to loss of independence, driving restrictions, impaired self confidence, and risk of falls, which result in physical injury and other sequelae.",
"   </p>",
"   <p>",
"    Acute symptomatic seizures are provoked events that are not expected to recur in the absence of a particular trigger (eg, hypoglycemia, alcohol withdrawal). Epilepsy is a condition in which recurrent unprovoked seizures are expected in the absence of treatment.",
"   </p>",
"   <p>",
"    This topic will cover aspects of the management of seizures and epilepsy that are specific to elderly individuals. A more general discussion of the treatment of seizures and epilepsy is presented elsewhere. The etiology, clinical presentation and diagnosis of seizures and epilepsy in the elderly patient is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=see_link\">",
"     \"Initial treatment of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40841?source=see_link\">",
"     \"Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, patients with acute symptomatic seizures due to obvious metabolic derangements, medication, or medication withdrawal will not require seizure treatment. Patients with acute seizures caused by an acute intracranial event (stroke, head trauma) are often treated for a limited time (a few weeks to a few months). If seizures do not recur, withdrawal of antiepileptic drugs (AEDs) should be considered depending on the patient's other risk factors and comorbidity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Post-stroke seizures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few data regarding the risk of seizure recurrence in elderly patients with unprovoked seizures, but high rates (80 to 90 percent) are often mentioned. In part, this may be inferred from a high rate of recurrence in patients with late-onset seizures after stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/3\">",
"     3",
"    </a>",
"    ] and from studies in the general adult epileptic population in which the seizure recurrence rate in the setting of a known underlying cause is as high as 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/4\">",
"     4",
"    </a>",
"    ]. Because of this presumed high risk, elderly patients with unprovoked seizures, whether of known or cryptogenic origin, are generally treated with long-term AEDs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Antiepileptic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;AEDs are the mainstay of antiepileptic treatment. However, their use in elderly patients is complicated by several factors:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several physiologic changes may complicate the use of AEDs in an elderly patient [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The combined effect of most of these suggests that both a smaller dose and less frequent dosing of AEDs is required in older patients. These include impaired hepatic metabolism and less enzyme inducibility. Renal elimination decreases by 10 percent per decade over the age of 40 years. Decreased concentrations of plasma proteins and albumin with age lower the protein binding of medication, causing the potential for toxic symptoms when drugs appear by total serum levels to be in the therapeutic range. Highly protein bound drugs include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    . Other factors include increased ratio of fat:lean body mass, altering the volume of drug distribution, and decreased gastric motility and increased gastric pH, altering drug absorption. Despite these issues, one pharmacokinetic study found that phenytoin clearance and half-life were similar in healthy elderly adults and younger adults [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/9\">",
"     9",
"    </a>",
"    ], while another found that lamotrigine clearance was reduced by about 20 percent in older compared to younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Polypharmacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another factor complicating AED use in elderly patients is the high prevalence of comorbid medical conditions and polypharmacy. The mean number of medications reported in the VACS#428 was 6.7; one-quarter of patients took &ge;15 medications daily [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]. AEDs have a high potential for drug interactions; the risk of significant drug interactions increases significantly as the number of medications taken increases (",
"    <a class=\"graphic graphic_table graphicRef80801 graphicRef55399 graphicRef53463 \" href=\"UTD.htm?0/4/72\">",
"     table 1A-C",
"    </a>",
"    ). Particularly problematic in this regard are the enzyme-inducing AEDs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ). A combination of drugs that are both highly protein-bound may also be more problematic in older rather than younger patients.",
"   </p>",
"   <p>",
"    In addition to potential drug interactions, some medications prescribed to older individuals can lower seizure threshold (",
"    <a class=\"graphic graphic_table graphicRef54610 \" href=\"UTD.htm?28/21/29020\">",
"     table 2",
"    </a>",
"    ). In a computerized database of 294 general practices in the United Kingdom, over 10 percent of AED prescriptions were coprescribed with at least one proconvulsant drug [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of AEDs are a significant problem in elderly patients because they are frequent and have potential serious sequelae. Older patients appear to be more sensitive to side effects of AEDs, experiencing them more frequently and with lower doses (",
"    <a class=\"graphic graphic_table graphicRef59755 \" href=\"UTD.htm?3/28/3533\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78896 \" href=\"UTD.htm?29/34/30252\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/1,13,14\">",
"     1,13,14",
"    </a>",
"    ]. In the VACS#428 study less than half of patients completed a 52-week trial of medication; side effects led to early withdrawal in almost 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/1\">",
"     1",
"    </a>",
"    ]. In an observational study of 67 elderly patients treated with AEDs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ), 27 percent reported side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/15\">",
"     15",
"    </a>",
"    ]. Most had AED concentrations at the lower limit of or below the recommended therapeutic ranges. Side effects were most common with phenytoin.",
"   </p>",
"   <p>",
"    Dose-dependent side effects of AEDs that are particularly problematic in elderly patients include confusion, impaired gait, sedation, tremor, dizziness, and visual disturbance. These are potentially problematic with any AED. Adverse cognitive side effects of AEDs are common, especially in patients with underlying brain disease and in the setting of polypharmacy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/14\">",
"     14",
"    </a>",
"    ]. In one study, 26 older patients with epilepsy on AED monotherapy had lower cognitive performance on neuropsychological testing compared with healthy age-, gender-, and education-matched controls. Deficits were comparable to similarly matched patients with mild cognitive impairment (MCI) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one randomized study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    in 313 patients with mild to moderate Alzheimer disease (AD), a prespecified subset of 89 patients underwent MRI scans at baseline and 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/17\">",
"     17",
"    </a>",
"    ]. The aim of the study was to evaluate a putative benefit of valproate in the management of neuropsychiatric symptoms of AD. Valproate treatment was associated with a significantly greater decline in hippocampal and total brain volume and Mini-Mental State Examination scores compared to placebo treated patients. Other cognitive and functional ratings did not differ between the two groups. While this finding is limited to one study, it seems unlikely that further data will be forthcoming and it seems reasonable to avoid valproate in patients with seizures and AD in favor of other effective AEDs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone loss is of concern in older adults, especially women. Enzyme-inducing AEDs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ) are known to produce bone loss. A case-control study comparing 78 individuals on long-term AED treatment with age, sex-matched, drug naive patients found that AEDs were an independent risk factor for bone loss (in addition to age, sex, and weight) and that nonenzyme-inducing AEDs were equally implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/18\">",
"     18",
"    </a>",
"    ]. Some recommend that patients on chronic AED therapy be regularly screened for bone loss and receive calcium and vitamin D supplementation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36969?source=see_link\">",
"     \"Antiepileptic drugs and bone disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is somewhat reassuring to note that a case-control study involving 124,655 fracture cases found only a very limited increased fracture risk among users of AEDs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/19\">",
"     19",
"    </a>",
"    ]. Another study found that most of the increased risk of fractures in persons with epilepsy was related to seizures and not to bone biomechanical competence [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/20\">",
"     20",
"    </a>",
"    ]. Gait impairment from AED use is another potential contributor to falls and fractures in elderly persons with epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Selection of AED",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many authors suggest that the newer AEDs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/22/26982?source=see_link\">",
"     tiagabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ) should be considered early in the treatment of epilepsy in an elderly patient due to the lower potential for interactions, linear pharmacokinetics, and lower incidence of side effects compared with older agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/22-27\">",
"     22-27",
"    </a>",
"    ]. Newer AEDs, however, have a less established track record and a less completely defined side-effect profile.",
"   </p>",
"   <p>",
"    Double-blind randomized trials have compared newer versus older AED regimens in elderly populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       Lamotrigine",
"      </a>",
"      was compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      in a 24-week study in 150 older patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/25\">",
"       25",
"      </a>",
"      ]. Patients on lamotrigine had a higher completion rate (71 versus 42 percent), seizure-free rate during the last 16 weeks (39 versus 21 percent), and fewer number of side effects (N = 102 versus 48).",
"     </li>",
"     <li>",
"      Another study comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      in 185 patients over 65 years found no differences between groups in study completion, time to drug withdrawal, seizure remission, or treatment-emergent adverse events after 40 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/28\">",
"       28",
"      </a>",
"      ]. Neither drug appeared to be associated with significant changes in health-related quality of life compared to baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Three treatment groups,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      were compared in 593 elderly patients with epilepsy in the VACS#428 [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/30\">",
"       30",
"      </a>",
"      ]. Early terminations (44.2, 51, and 64.5 percent, respectively) and terminations due to adverse drug reactions (12.1, 21.6, and 31 percent) were less common in those taking lamotrigine or gabapentin compared with carbamazepine. The use of immediate-release as opposed to extended-release carbamazepine in this study may have contributed to these findings. There was no significant difference in the seizure-free rates at 12 months.",
"     </li>",
"     <li>",
"      Ninety-three patients with Alzheimer disease (AD) and seizures were randomized to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"       levetiracetam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      and compared to a control group of 68 AD patients without seizures who were not treated with AEDs [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/31\">",
"       31",
"      </a>",
"      ]. Efficacy was similar among the three AEDs; levetiracetam caused the fewest adverse effects and was associated with more favorable cognitive outcomes at 12 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A nonrandomized, retrospective study of 415 older patients (&gt;55 years) with epilepsy found that 12-month retention rates were higher for patients prescribed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    (79 and 73 percent respectively) than for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    (48 to 59 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/32\">",
"     32",
"    </a>",
"    ]. Retention rates were lowest for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    (24 percent). Twelve-month seizure freedom rates were also higher for lamotrigine and levetiracetam (54 and 43 percent) compared with other AEDs.",
"   </p>",
"   <p>",
"    It is difficult to draw firm conclusions from trials with such short follow-up times. Short-term studies emphasizing dropout as an endpoint tend to favor drugs with lower side effects, even if they are less effective [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/33\">",
"     33",
"    </a>",
"    ]. The International League Against Epilepsy treatment guidelines concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    have demonstrated efficacy for seizure control in studies of elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/34\">",
"     34",
"    </a>",
"    ]. While there are no efficacy data specific to the elderly population for other AEDs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/8/27783?source=see_link\">",
"     vigabatrin",
"    </a>",
"    all have evidence of efficacy for partial-onset seizures in adults in general.",
"   </p>",
"   <p>",
"    The choice of specific AED in an elderly patient should be individualized. Clinicians should consider side-effect profiles of individual AEDs, choosing those with least potential for harm (",
"    <a class=\"graphic graphic_table graphicRef59755 \" href=\"UTD.htm?3/28/3533\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78896 \" href=\"UTD.htm?29/34/30252\">",
"     table 4",
"    </a>",
"    ). Other considerations include the route of drug metabolism or elimination, comorbid medical conditions, and other prescribed medications. The availability of different drug formulations (liquids, crushable) may be important for patients with swallowing difficulties. In patients with impaired memory, compliance is higher with drugs that can be given once or twice a day. In other patients, however, use of several smaller doses over the day may minimize side effects. Given the observed negative impact of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    therapy in one study of patients with Alzheimer disease, discussed above, it may be reasonable to avoid this medication in this subgroup in favor of other effective medications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/17\">",
"     17",
"    </a>",
"    ]. Other factors that play a role in the selection of an AED are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=see_link\">",
"     \"Initial treatment of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medication expense for those on fixed incomes with limited supplemental coverage is another important consideration. Generic formulations of AEDs are considered potentially problematic because of the greater potential variability in the chemical content of generics compared with brand medications. Because elderly patients are subject to a narrower therapeutic window than younger patients, it is possible that use of generic AEDs can increase the risk of both side effects and breakthrough seizures. However, this has not been proven, and the benefit of affordability must be balanced with these potential risks. Studies that have examined the issue of generic formulations of AEDS are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Generic substitution'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For any medication prescribed, chances of success are improved with initiation at a low dose with titration up to a higher dose [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/35\">",
"     35",
"    </a>",
"    ]. Monotherapy is greatly preferred over polypharmacy. Therapeutic drug monitoring can be helpful in particular situations (eg, documenting compliance or identifying drug interactions) but is of limited routine benefit. Elderly patients frequently experience efficacy below the standard therapeutic range and often experience symptoms of toxicity at traditionally therapeutic levels. Drug levels are also imprecise, varying by as much as 20 percent in the general population. In an elderly patient, this may be particularly problematic; one study found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    levels varied as much as threefold in a cohort of nursing home residents who were not taking other medications known to interact with phenytoin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A detailed review of antiepileptic drugs is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Vagal nerve stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vagal nerve stimulation (VNS) is provided by a surgically implanted device programmed to deliver a brief electrical stimulation on a schedule. VNS may reduce seizure frequency. There is less experience with VNS in elderly patients compared with younger adults. One cohort followed 45 individuals over 50 years (eight were over 60 years and one was over 70 years) who received VNS for intractable epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/37\">",
"     37",
"    </a>",
"    ]. At three months, 27 percent achieved a 50 percent reduction in seizures; at one year, 67 percent had achieved a 50 percent reduction in seizures. No serious surgical complications occurred. These data compare well with the efficacy of VNS in other epileptic populations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19578?source=see_link\">",
"     \"Vagus nerve stimulation therapy for the treatment of epilepsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2890?source=see_link\">",
"     \"Evaluation and management of drug-resistant epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resection of an epilepsy focus has been successful in some older patients, but experience is limited. An observational study of 18 patients over the age of 50 found that the efficacy of temporal lobectomy was similar to younger patients; 61 percent were seizure free after a mean follow-up of 64 months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/38\">",
"     38",
"    </a>",
"    ]. The mean age of these patients was only 54 years. Another retrospective review of patients over 50 years also had a mean age of 54.2 years; the oldest was 66 years. There was a slightly less favorable outcome rate; 52 percent were seizure free in follow-up compared with 75.6 percent in the younger group. However, neuropsychological outcomes and surgical complication rates were similar in younger and older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/39\">",
"     39",
"    </a>",
"    ]. Another group of 21 patients over the age of 50 years (mean age 55 years) had an anterior temporal lobectomy with a rate of seizure remission that was comparable to that of younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/40\">",
"     40",
"    </a>",
"    ]. These patient cohorts were younger than is traditionally viewed as elderly.",
"   </p>",
"   <p>",
"    A third case series of 52 patients over the age of 50 years included 11 patients over 60 years (oldest age 71 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/41\">",
"     41",
"    </a>",
"    ]. While the outcomes regarding seizure recurrence were similar in patients over 50 years compared with younger patients, permanent neurologic complications, including declines in cognitive measures and other neurologic deficits, were slightly higher in the older patients. Finally, another center's experience with eight patients over 60 years of age reported similar efficacy and safety compared with younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the data regarding the efficacy of epilepsy surgery in elderly patients is somewhat limited, the available literature suggests that surgery is similarly effective in older and younger adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41593?source=see_link\">",
"     \"Surgical therapy of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited long-term prospective data that provide prognostic information for older patients with seizures.",
"   </p>",
"   <p>",
"    An overall high success rate (70 percent) is often quoted for treatment efficacy in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/13,15,43\">",
"     13,15,43",
"    </a>",
"    ]. This may represent an extrapolation from poststroke epilepsy in which good response rates to single antiepileptic drugs (AEDs) have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/44\">",
"     44",
"    </a>",
"    ]. However, this is also consistent with the results of a single-center study of 117 adults over the age of 65 years (median age 73 years) with a new diagnosis of epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/45\">",
"     45",
"    </a>",
"    ]. With the first AED, seizure freedom for at least one year was achieved by 62 percent; 26 percent did not respond; and 12 percent did not tolerate treatment. With treatment adjustments, 79 percent subsequently achieved seizure remission. The number of pretreatment seizures was associated with treatment failure or success.",
"   </p>",
"   <p>",
"    Patients with seizures in the setting of Alzheimer disease (AD) are often reported to be less responsive to AED therapy. However, one report noted that 79 percent of individuals with dementia and new onset seizures responded to AED therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients' underlying disease and comorbidity may be more important to their future morbidity and mortality than their epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/46\">",
"     46",
"    </a>",
"    ]. One study found that while chronic epilepsy was associated with increased mortality in the adult population in general, there was no excess in mortality in persons with epilepsy who were older than 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17512/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/56/28546?source=see_link\">",
"       \"Patient information: Seizures (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=see_link\">",
"       \"Patient information: Seizures in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures and epilepsy are common in older adults and are underdiagnosed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinicians should maintain a high level of suspicion for possible seizures in elderly patients presenting with intermittent or fluctuating confusional states. The usual clues to the possibility of underlying seizures may be absent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40841?source=see_link\">",
"       \"Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antiepileptic drug (AED) therapy is complicated by potential drug interactions and high rates of side effects. Success may be optimized by starting at low doses and titrating slowly up to higher doses. Target therapeutic doses and drug levels should be lower in elderly compared to younger populations. AED polypharmacy should be avoided. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Antiepileptic drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest calcium and vitamin D supplementation for older patients receiving AEDs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) and bone mineral density testing in patients taking AEDs on a chronic basis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36969?source=see_link\">",
"       \"Antiepileptic drugs and bone disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Driving should be restricted for patients with a new diagnosis of epilepsy, or uncontrolled seizures. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=see_link&amp;anchor=H28#H28\">",
"       \"Evaluation of the first seizure in adults\", section on 'Driving'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/1\">",
"      Ramsay RE, Rowan AJ, Pryor FM. Special considerations in treating the elderly patient with epilepsy. Neurology 2004; 62:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/2\">",
"      Sander JW, Hart YM, Johnson AL, Shorvon SD. National General Practice Study of Epilepsy: newly diagnosed epileptic seizures in a general population. Lancet 1990; 336:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/3\">",
"      Sung CY, Chu NS. Epileptic seizures in thrombotic stroke. J Neurol 1990; 237:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/4\">",
"      Hauser WA, Rich SS, Annegers JF, Anderson VE. Seizure recurrence after a 1st unprovoked seizure: an extended follow-up. Neurology 1990; 40:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/5\">",
"      Ramsay, RE, Rowan, AJ, Pryor, FM, et, al. Seizures in the older patient: demographics. Diagnosis and treatment. Epilepsia 2000; 41:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/6\">",
"      Hart YM, Sander JW, Johnson AL, Shorvon SD. National General Practice Study of Epilepsy: recurrence after a first seizure. Lancet 1990; 336:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/7\">",
"      Cloyd JC, Lackner TE, Leppik IE. Antiepileptics in the elderly. Pharmacoepidemiology and pharmacokinetics. Arch Fam Med 1994; 3:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/8\">",
"      Birnbaum AK. Pharmacokinetics of antiepileptic drugs in elderly nursing home residents. Int Rev Neurobiol 2007; 81:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/9\">",
"      Ahn JE, Cloyd JC, Brundage RC, et al. Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy. Neurology 2008; 71:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/10\">",
"      Arif H, Svoronos A, Resor SR Jr, et al. The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy. Epilepsia 2011; 52:1905.",
"     </a>",
"    </li>",
"    <li>",
"     Ramsay, RE. Challenges in the diagnosis and treatment of the elderly patient with epilepsy. Paper presented at the Annual Meeting of the Southern Clinical Neurological Society, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/12\">",
"      Shorvon SD, Tallis RC, Wallace HK. Antiepileptic drugs: coprescription of proconvulsant drugs and oral contraceptives: a national study of antiepileptic drug prescribing practice. J Neurol Neurosurg Psychiatry 2002; 72:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/13\">",
"      Rao SC, Dove G, Cascino GD, Petersen RC. Recurrent seizures in patients with dementia: frequency, seizure types, and treatment outcome. Epilepsy Behav 2009; 14:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/14\">",
"      Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992; 327:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/15\">",
"      Cameron H, Macphee GJ. Anticonvulsant therapy in the elderly--a need for placebo controlled trials. Epilepsy Res 1995; 21:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/16\">",
"      Griffith HR, Martin RC, Bambara JK, et al. Older adults with epilepsy demonstrate cognitive impairments compared with patients with amnestic mild cognitive impairment. Epilepsy Behav 2006; 8:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/17\">",
"      Fleisher AS, Truran D, Mai JT, et al. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology 2011; 77:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/18\">",
"      Stephen LJ, McLellan AR, Harrison JH, et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure 1999; 8:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/19\">",
"      Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004; 45:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/20\">",
"      Vestergaard P, Tigaran S, Rejnmark L, et al. Fracture risk is increased in epilepsy. Acta Neurol Scand 1999; 99:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/21\">",
"      Koppel BS, Harden CL, Nikolov BG, Labar DR. An analysis of lifetime fractures in women with epilepsy. Acta Neurol Scand 2005; 111:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/22\">",
"      Ramsay RE, Pryor F. Epilepsy in the elderly. Neurology 2000; 55:S9.",
"     </a>",
"    </li>",
"    <li>",
"     Pryor, FM, Ramsay, RE, Rowan, AJ, et al. Epilepsy in older adults: update from VA Cooperative Study #428. Epilepsia 2002; 43 Suppl 7:165 [abstract].",
"    </li>",
"    <li>",
"     Mehta, S, Pryor, FM, Kraut, L, et al. Efficacy and tolerability of Topiramate in the elderly population. Epilepsia; 43 Suppl 7:165 [abstract].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/25\">",
"      Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999; 37:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/26\">",
"      Ferrendelli JA, French J, Leppik I, et al. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. Epilepsy Behav 2003; 4:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/27\">",
"      Kutlu G, Gomceli YB, Unal Y, Inan LE. Levetiracetam monotherapy for late poststroke seizures in the elderly. Epilepsy Behav 2008; 13:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/28\">",
"      Saetre E, Perucca E, Isoj&auml;rvi J, et al. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 2007; 48:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/29\">",
"      Saetre E, Abdelnoor M, Perucca E, et al. Antiepileptic drugs and quality of life in the elderly: results from a randomized double-blind trial of carbamazepine and lamotrigine in patients with onset of epilepsy in old age. Epilepsy Behav 2010; 17:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/30\">",
"      Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005; 64:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/31\">",
"      Cumbo E, Ligori LD. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease. Epilepsy Behav 2010; 17:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/32\">",
"      Arif H, Buchsbaum R, Pierro J, et al. Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Arch Neurol 2010; 67:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/33\">",
"      French JA, Chadwick DW. Antiepileptic drugs for the elderly: using the old to focus on the new. Neurology 2005; 64:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/34\">",
"      Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/35\">",
"      Ramsay RE, Uthman B, Pryor FM, et al. Topiramate in older patients with partial-onset seizures: a pilot double-blind, dose-comparison study. Epilepsia 2008; 49:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/36\">",
"      Birnbaum A, Hardie NA, Leppik IE, et al. Variability of total phenytoin serum concentrations within elderly nursing home residents. Neurology 2003; 60:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/37\">",
"      Sirven JI, Sperling M, Naritoku D, et al. Vagus nerve stimulation therapy for epilepsy in older adults. Neurology 2000; 54:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/38\">",
"      Boling W, Andermann F, Reutens D, et al. Surgery for temporal lobe epilepsy in older patients. J Neurosurg 2001; 95:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/39\">",
"      Sirven JI, Malamut BL, O'Connor MJ, Sperling MR. Temporal lobectomy outcome in older versus younger adults. Neurology 2000; 54:2166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/40\">",
"      Murphy M, Smith PD, Wood M, et al. Surgery for temporal lobe epilepsy associated with mesial temporal sclerosis in the older patient: a long-term follow-up. Epilepsia 2010; 51:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/41\">",
"      Grivas A, Schramm J, Kral T, et al. Surgical treatment for refractory temporal lobe epilepsy in the elderly: seizure outcome and neuropsychological sequels compared with a younger cohort. Epilepsia 2006; 47:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/42\">",
"      Acosta I, Vale F, Tatum WO 4th, Benbadis SR. Epilepsy surgery after age 60. Epilepsy Behav 2008; 12:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/43\">",
"      Holt-Seitz A, Wirrell EC, Sundaram MB. Seizures in the elderly: etiology and prognosis. Can J Neurol Sci 1999; 26:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/44\">",
"      Gupta SR, Naheedy MH, Elias D, Rubino FA. Postinfarction seizures. A clinical study. Stroke 1988; 19:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/45\">",
"      Stephen LJ, Kelly K, Mohanraj R, Brodie MJ. Pharmacological outcomes in older people with newly diagnosed epilepsy. Epilepsy Behav 2006; 8:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/46\">",
"      Pugh MJ, Copeland LA, Zeber JE, et al. The impact of epilepsy on health status among younger and older adults. Epilepsia 2005; 46:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17512/abstract/47\">",
"      Mohanraj R, Norrie J, Stephen LJ, et al. Mortality in adults with newly diagnosed and chronic epilepsy: a retrospective comparative study. Lancet Neurol 2006; 5:481.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2225 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_6_17512=[""].join("\n");
var outline_f17_6_17512=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Polypharmacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Selection of AED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Vagal nerve stimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/2225\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2225|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/29/6621\" title=\"table 1A\">",
"      Carbamazepine interactions with other AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/26/9645\" title=\"table 1B\">",
"      Phenytoin interactions with other AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/36/39500\" title=\"table 1C\">",
"      Valproate interactions with other AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/21/29020\" title=\"table 2\">",
"      Drugs that cause seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/28/3533\" title=\"table 3\">",
"      Common side effects of AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/34/30252\" title=\"table 4\">",
"      Rare serious side effects AEDs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36969?source=related_link\">",
"      Antiepileptic drugs and bone disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2890?source=related_link\">",
"      Evaluation and management of drug-resistant epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=related_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=related_link\">",
"      Initial treatment of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/56/28546?source=related_link\">",
"      Patient information: Seizures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/27/34229?source=related_link\">",
"      Patient information: Seizures in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40841?source=related_link\">",
"      Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41593?source=related_link\">",
"      Surgical therapy of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19578?source=related_link\">",
"      Vagus nerve stimulation therapy for the treatment of epilepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_6_17513="Overview of cyanosis in the newborn";
var content_f17_6_17513=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of cyanosis in the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/6/17513/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/6/17513/contributors\">",
"     Eric C Eichenwald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/6/17513/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/6/17513/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/6/17513/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/6/17513/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/6/17513/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12812737\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanosis is a bluish discoloration of the tissues that results when the absolute level of reduced hemoglobin in the capillary bed exceeds 3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17513/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The appearance of cyanosis depends upon the total amount of reduced hemoglobin rather than the ratio of reduced to oxygenated hemoglobin. Cyanosis is a common clinical finding in newborn infants. Neonatal cyanosis, particularly central cyanosis, can be associated with significant and potentially life-threatening diseases due to cardiac, metabolic, neurological, infectious, and parenchymal and non-parenchymal pulmonary disorders (",
"    <a class=\"graphic graphic_table graphicRef50161 \" href=\"UTD.htm?18/6/18540\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The etiology, evaluation, and initial management of the newborn with cyanosis will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95089272\">",
"    <span class=\"h1\">",
"     CENTRAL VERSUS PERIPHERAL CYANOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two mechanisms result in cyanosis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral cyanosis due to increased oxygen extraction by the tissues",
"     </li>",
"     <li>",
"      Central cyanosis caused by systemic arterial oxygen desaturation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95089554\">",
"    <span class=\"h2\">",
"     Peripheral cyanosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with peripheral cyanosis have normal systemic arterial oxygen saturation and increased tissue oxygen extraction that leads to a widened systemic arteriovenous oxygen difference of 60 percent (from the normal 40 percent) resulting in an increased concentration of reduced hemoglobin on the venous side of the capillary bed. Peripheral cyanosis typically affects the distal extremities and sometimes the circumoral or periorbital areas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17513/abstract/1\">",
"     1",
"    </a>",
"    ]. The extremities may be cool or clammy. Peripheral cyanosis may be associated with peripheral vasoconstriction or many causes associated with central cyanosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95089610\">",
"    <span class=\"h3\">",
"     Acrocyanosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acrocyanosis is often seen in healthy newborns and refers to the peripheral cyanosis around the mouth and the extremities (hands and feet). It is caused by benign vasomotor changes that result in peripheral vasoconstriction and increased tissue oxygen extraction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17513/abstract/4\">",
"     4",
"    </a>",
"    ]. This presentation of peripheral cyanosis in the newborn is differentiated from central cyanosis as the mucus membrane of the neonate remains pink. It is very common in newborns after birth and may persist for 24 to 48 hours. It is usually not a sign of pathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95089279\">",
"    <span class=\"h2\">",
"     Central cyanosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central cyanosis is caused by reduced arterial oxygen saturation. Newborn infants normally have central cyanosis until up to 5 to 10 minutes after birth, as the oxygen saturation rises to 85 to 95 percent by 10 minutes of age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17513/abstract/5\">",
"     5",
"    </a>",
"    ]. Persistent central cyanosis is always abnormal and should be evaluated and treated promptly. The etiology of persistent central cyanosis varies from a wide range of disorders, including cardiac, metabolic, neurological, infectious, and parenchymal and non-parenchymal pulmonary disorders (",
"    <a class=\"graphic graphic_table graphicRef50161 \" href=\"UTD.htm?18/6/18540\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87792679\">",
"    <span class=\"h1\">",
"     FACTORS THAT AFFECT CYANOSIS DETECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following factors can affect the detection of cyanosis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemoglobin concentration",
"     </li>",
"     <li>",
"      Fetal hemoglobin",
"     </li>",
"     <li>",
"      Skin pigmentation",
"     </li>",
"     <li>",
"      Physiological conditions that affect oxygen dissociation curve",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95089307\">",
"    <span class=\"h2\">",
"     Hemoglobin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total hemoglobin concentration affects the level of oxygen saturation at which cyanosis can be detected because the appearance of cyanosis is dependent on the absolute concentration of reduced hemoglobin, not the ratio of reduced to oxyhemoglobin. Cyanosis is visually perceptible when reduced hemoglobin exceeds 3",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    which generally corresponds to an oxygen saturation level below 85 percent in a neonate with a hemoglobin concentration of 15",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef70325 \" href=\"UTD.htm?6/21/6494\">",
"     figure 1",
"    </a>",
"    ). However, cyanosis is detected at higher levels of oxygen saturation in polycythemic patients, whereas significant oxygen desaturation can be present in an anemic patient without clinically detectable cyanosis. As examples, cyanosis (3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    of reduced hemoglobin) is detected when the oxygen saturation is 86 percent in a patient with hemoglobin of 20",
"    <span class=\"nowrap\">",
"     g/L",
"    </span>",
"    and 67 percent in a patient with a hemoglobin concentration of 9",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95089314\">",
"    <span class=\"h2\">",
"     Fetal hemoglobin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal",
"    hemoglobin, the predominant form of hemoglobin in newborn erythrocytes, binds oxygen more avidly than adult hemoglobin, which aids in fetal uptake of oxygen from the placenta but results in less oxygen delivery to the tissues. The oxygen dissociation curve for fetal versus adult hemoglobin is shifted to the left, so that for a given level of arterial oxygen tension (PaO2), the arterial oxygen saturation (SaO2) is higher in newborns than older infants or adults (",
"    <a class=\"graphic graphic_figure graphicRef59739 \" href=\"UTD.htm?30/36/31310\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17513/abstract/6\">",
"     6",
"    </a>",
"    ]. So for a given level of SaO2, there is a lower PaO2 value in newborns compared with older patients. As examples, when SaO2 is 50 percent, PaO2 is 20 mmHg in newborns and 27 mmHg in older patients; at SaO2 of 80 percent, PaO2 is 35 mmHg in newborns and 45 mmHg in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17513/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, cyanosis is detected at a lower PaO2 in newborns who have predominantly fetal hemoglobin compared with older patients. This observation should prompt the measurement of PaO2 (eg, arterial blood gas) when evaluating a cyanotic newborn as the PaO2 provides more complete data than SaO2. (See",
"    <a class=\"local\" href=\"#H12812864\">",
"     'Arterial blood gas'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95089764\">",
"    <span class=\"h2\">",
"     Skin pigmentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanosis is often less apparent in patients with darker skin pigmentation. For this reason, examination should include the nail beds, tongue, and mucous membranes, which are less affected by pigmentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95089321\">",
"    <span class=\"h2\">",
"     Other physiologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other physiologic factors common in sick newborns affect the oxygen dissociation curve (",
"    <a class=\"graphic graphic_figure graphicRef59739 \" href=\"UTD.htm?30/36/31310\">",
"     figure 2",
"    </a>",
"    ) .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Factors that increase the affinity of hemoglobin for oxygen include alkalosis, hyperventilation (low PCO2), cold temperature, and low levels of 2,3 diphosphoglycerate [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17513/abstract/6\">",
"       6",
"      </a>",
"      ]. In these conditions, the oxygen dissociation curve is shifted to the left, which decreases the concentration of reduced hemoglobin at a given PaO2 and lowers the PaO2 at which cyanosis first appears.",
"     </li>",
"     <li>",
"      In contrast, acidosis, fever, or increased concentration of adult hemoglobin shifts the curve to the right, thereby lowering oxygen affinity. As a result, at a given PaO2, these conditions increase oxygen delivery to the tissues resulting in a greater concentration of reduced hemoglobin, and promote the appearance of cyanosis at a higher PaO2.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12812744\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, cyanosis is divided into peripheral and central cyanosis.",
"   </p>",
"   <p>",
"    Peripheral cyanosis is due to increased oxygen extraction that generally results from sluggish movement of blood through the capillary circulation. Causes include vasomotor instability, vasoconstriction caused by exposure to cold, venous obstruction, elevated venous pressure, polycythemia, and low cardiac output. In neonates, although peripheral cyanosis (acrocyanosis) is generally a benign transient finding, sepsis may be accompanied by peripheral cyanosis due to poor cardiac output and vasomotor instability.",
"   </p>",
"   <p>",
"    The causes of central cyanosis due to reduced arterial oxygen saturation are generally the result of one of the following pathologic mechanisms (",
"    <a class=\"graphic graphic_table graphicRef50161 \" href=\"UTD.htm?18/6/18540\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alveolar hypoventilation",
"      <strong>",
"      </strong>",
"      &ndash; Although the primary effect of alveolar hypoventilation is hypercarbia (eg, recurrent apnea), decreased ventilation of the lung can cause hypoxemia resulting in reduced oxygen saturation and cyanosis.",
"     </li>",
"     <li>",
"      Ventilation-perfusion mismatch",
"      <strong>",
"      </strong>",
"      &ndash; Normally, areas of decreased ventilation are matched with decreased blood flow. Alterations of this relationship can cause hypoxemia (eg, neonatal pneumonia, pneumothorax) resulting in reduced oxygen saturation and cyanosis.",
"     </li>",
"     <li>",
"      Right to left shunt",
"      <strong>",
"      </strong>",
"      &ndash; In right to left shunting, systemic venous blood bypasses ventilated alveoli and returns to the left side of the heart without being oxygenated resulting in reduced oxygen saturation and cyanosis. The site of shunting can be intracardiac (eg, Tetralogy of Fallot), through the ductus arteriosus (eg, persistent pulmonary hypertension), or intrapulmonary (eg, perfusion of non-ventilated areas of the lung). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20359?source=see_link\">",
"       \"Cardiac causes of cyanosis in the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link\">",
"       \"Persistent pulmonary hypertension of the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diffusion impairment",
"      <strong>",
"      </strong>",
"      &ndash; Oxygen molecules must diffuse from the alveoli to the pulmonary capillaries to oxygenate hemoglobin. Interference with alveolar-arterial diffusion (eg, pulmonary edema) results in reduced oxygen saturation.",
"     </li>",
"     <li>",
"      Abnormal hemoglobin with decreased oxygen affinity (eg, methemoglobinemia).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Causes of central cyanosis in the newborn can be categorized based on the above pathophysiology as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypoventilatory disorders (eg, airway abnormalities and neurologic disorders)",
"     </li>",
"     <li>",
"      Pulmonary disease with",
"      <span class=\"nowrap\">",
"       ventilation/perfusion",
"      </span>",
"      mismatch (eg, respiratory distress syndrome) and diffusion impairment (eg, pulmonary edema)",
"     </li>",
"     <li>",
"      Disorders with right to left shunting (eg, cyanotic congenital heart disease)",
"     </li>",
"     <li>",
"      Hematologic disease (eg, hemoglobinopathy with inadequate oxygen transport)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12812751\">",
"    <span class=\"h2\">",
"     Hypoventilatory disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoventilation resulting in hypoxemia may be due to airway abnormalities, and neurologic or metabolic disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95092090\">",
"    <span class=\"h3\">",
"     Airway abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most airway abnormalities will present shortly after birth; cyanosis due to the following conditions is generally due to alveolar hypoventilation secondary to airway obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17513/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Choanal atresia",
"      <strong>",
"      </strong>",
"      &ndash; While choanal atresia is usually unilateral, bilateral atresia will present immediately after birth (",
"      <a class=\"graphic graphic_picture graphicRef50816 graphicRef79734 \" href=\"UTD.htm?42/48/43782\">",
"       picture 1A-B",
"      </a>",
"      ) and should be suspected in an infant who develops respiratory distress and cyanosis while in a quiet state but becomes pink while crying. The diagnosis is suspected by the inability to pass a suction catheter through the nose into the oropharynx, and computed tomography will confirm the diagnosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef82266 \" href=\"UTD.htm?2/30/2543\">",
"       image 1",
"      </a>",
"      ). Placement of an oral airway should relieve the obstruction until definitive surgical therapy can be performed. Severe choanal stenosis also may present with respiratory distress and cyanosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17513/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35575?source=see_link&amp;anchor=H10#H10\">",
"       \"Congenital anomalies of the nose\", section on 'Choanal atresia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Micrognathia or retrognathia",
"      <strong>",
"      </strong>",
"      &ndash; Micrognathia or retrognathia that is severe enough to be symptomatic is readily apparent on physical examination. Airway obstruction is caused by the posterior tongue obstructing the retropharyngeal airway while the infant is supine. Generally, obstruction is relieved by placing the infant prone, but an oral airway may be necessary. Although some infants may require tracheotomy, surgical mandibular distraction may be performed in the newborn period and avoid the need for a tracheotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17513/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1977?source=see_link&amp;anchor=H4#H4\">",
"       \"Congenital anomalies of the jaw, mouth, oral cavity, and pharynx\", section on 'Micrognathia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/15/250?source=see_link&amp;anchor=H9#H9\">",
"       \"Syndromes with craniofacial abnormalities\", section on 'Robin sequence'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Laryngeal and tracheal abnormalities",
"      <strong>",
"      </strong>",
"      &ndash; Laryngeal and tracheal abnormalities include congenital laryngomalacia, vocal cord paralysis, tracheal stenosis, and vascular rings that cause external compression of the trachea. These conditions may all present soon after birth with airway obstruction, stridor, and cyanosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17513/abstract/11\">",
"       11",
"      </a>",
"      ]. Stridor and cyanosis is especially evident while the neonate is crying because the increased negative thoracic pressure causes greater airway obstruction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37543?source=see_link&amp;anchor=H3#H3\">",
"       \"Congenital anomalies of the larynx\", section on 'Laryngomalacia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link&amp;anchor=H6#H6\">",
"       \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\", section on 'Tracheal stenosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=see_link\">",
"       \"Vascular rings\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95092292\">",
"    <span class=\"h3\">",
"     Neurologic or metabolic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic dysfunction, such as hypoxic ischemic encephalopathy, intracranial hemorrhage, or seizures may cause hypoventilation and apnea resulting in hypoxemia and cyanosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Metabolic disorders such as severe hypoglycemia may also be complicated by apnea leading to intermittent episodes of hypoxemia and cyanosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=see_link&amp;anchor=H15#H15\">",
"     \"Neonatal hypoglycemia\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12812783\">",
"    <span class=\"h2\">",
"     Pulmonary disorders and ventilation-perfusion mismatch",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary disease resulting in ventilation-perfusion mismatch is the most common cause of neonatal cyanosis. Newborn infants who present with cyanosis from lung disease will almost always have some degree of respiratory distress. Specific causes, which are discussed in detail separately, include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Respiratory distress syndrome (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19656?source=see_link\">",
"       \"Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Transient tachypnea of the newborn (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32804?source=see_link\">",
"       \"Transient tachypnea of the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Meconium aspiration syndrome (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=see_link\">",
"       \"Clinical features and diagnosis of meconium aspiration syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neonatal pneumonia (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=see_link\">",
"       \"Neonatal pneumonia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Air leak syndromes (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4631?source=see_link\">",
"       \"Pulmonary air leak in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital abnormalities of the lung and diaphragm including congenital diaphragmatic hernia and cystic adenomatoid malformation (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28026?source=see_link\">",
"       \"Congenital diaphragmatic hernia in the neonate\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/50/810?source=see_link\">",
"       \"Congenital pulmonary airway (cystic adenomatoid) malformation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95092508\">",
"    <span class=\"h2\">",
"     Disorders with right to left shunting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions that result in right to left shunting of deoxygenated blood to the systemic circulation include intracardiac lesions and persistent pulmonary hypertension. Intrapulmonary lesions resulting in impaired",
"    <span class=\"nowrap\">",
"     ventilation/perfusion",
"    </span>",
"    of affected alveoli also causes right to left shunting. (See",
"    <a class=\"local\" href=\"#H12812783\">",
"     'Pulmonary disorders and ventilation-perfusion mismatch'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12812790\">",
"    <span class=\"h3\">",
"     Cyanotic congenital heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever a newborn presents with cyanosis, especially if respiratory distress is not present, cyanotic congenital heart disease (CHD) should always be considered as a potential etiology. The causes, evaluation, and initial management of cyanotic CHD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20359?source=see_link\">",
"     \"Cardiac causes of cyanosis in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=see_link\">",
"     \"Diagnosis and initial management of cyanotic heart disease in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12812812\">",
"    <span class=\"h3\">",
"     Persistent pulmonary hypertension of the newborn",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent pulmonary hypertension of the newborn (PPHN) is a condition in which the normal circulatory transition from the fetal to newborn circulation fails to occur. In newborns with PPHN, the pulmonary vascular resistance remains abnormally elevated after birth, and right to left shunting of blood persists through the fetal circulatory channels (ductus arteriosus and foramen ovale). This shunting leads to severe hypoxemia and cyanosis. PPHN is most frequently associated with parenchymal lung disease, including meconium aspiration syndrome, neonatal pneumonia, and respiratory distress syndrome. As a result, the majority of infants with PPHN will present with respiratory distress and cyanosis. However, idiopathic PPHN may also occur unaccompanied by underlying parenchymal lung disease. PPHN including its pathophysiology, clinical features, diagnosis, and management is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link\">",
"     \"Persistent pulmonary hypertension of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H278376757\">",
"    <span class=\"h2\">",
"     Impaired alveolar-arterial diffusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary edema is the major cause of impaired alveolar-arterial diffusion that results in neonatal cyanosis. Pulmonary edema may be associated with both pulmonary and nonpulmonary disease. Examples of nonpulmonary causes of pulmonary edema include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sepsis",
"      <strong>",
"      </strong>",
"      &ndash; In the early stages of sepsis, tachypnea is often a finding due to increased respiratory drive resulting in respiratory alkalosis in response to sepsis-related metabolic acidosis. In the later stages of sepsis, capillary leak may result in pulmonary edema with impaired alveolar-arterial diffusion and ventilation-perfusion mismatch. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6410?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical features and diagnosis of sepsis in term and late preterm infants\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      AV or venous malformations",
"      <strong>",
"      </strong>",
"      &ndash; Very large arteriovenous or venous malformations (eg, Vein of Galen malformation) may cause high output cardiac failure and pulmonary edema resulting in respiratory distress and cyanosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=see_link&amp;anchor=H5#H5\">",
"       \"High-output heart failure\", section on 'Systemic arteriovenous fistulas'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Heart failure in patients with cyanotic congenital heart disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20359?source=see_link&amp;anchor=H22#H22\">",
"       \"Cardiac causes of cyanosis in the newborn\", section on 'Heart failure'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12812827\">",
"    <span class=\"h2\">",
"     Hematologic causes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172573399\">",
"    <span class=\"h3\">",
"     Hemoglobinopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobinopathies that inadequately transport oxygen can result in cyanosis. These disorders include methemoglobinemia (a genetic disorder in which the iron of heme is oxidized to the ferric state, which is unable to bind oxygen) and other rare variants of hemoglobin with low oxygen affinity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4841?source=see_link\">",
"     \"Genetics and pathogenesis of methemoglobinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=see_link\">",
"     \"Genetic disorders of hemoglobin oxygen affinity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=see_link&amp;anchor=H18#H18\">",
"     \"Genetic disorders of hemoglobin oxygen affinity\", section on 'Low oxygen affinity hemoglobin mutants: Cyanosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172573314\">",
"    <span class=\"h3\">",
"     Polycythemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal polycythemia, usually defined as a hematocrit &gt;65 percent or a hemoglobin concentration &gt;22, occurs in approximately 1 to 5 percent of births. It is observed more frequently in infants of diabetic mothers, with delayed clamping or stripping of the umbilical cord, chronic fetal hypoxia, and fetal growth restriction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36968?source=see_link\">",
"     \"Neonatal polycythemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Polycythemia can cause cyanosis by one of the two following mechanisms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polycythemic infants may appear cyanotic with a normal oxygen saturation and PO2 because of their elevated hemoglobin concentration. However, cyanosis is unlikely to occur in infants with arterial oxygen saturation above 90 percent (",
"      <a class=\"graphic graphic_figure graphicRef70325 \" href=\"UTD.htm?6/21/6494\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Polycythemia with associated hyperviscosity may interfere with pulmonary perfusion and result in persistent pulmonary hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17513/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12812812\">",
"       'Persistent pulmonary hypertension of the newborn'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12812835\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of evaluation are to identify and provide supportive care to the critically or potentially critically ill infant, and determine the underlying cause of neonatal cyanosis so that intervention can be focused on correcting or addressing the consequences of the specific disorder. Evaluation of the cyanotic infant should systematically assess the infant for airway, pulmonary, cardiovascular, or other causes.",
"   </p>",
"   <p>",
"    For patients who are critically ill, immediate intervention should be given to maintain adequate cardiorespiratory support to ensure sufficient",
"    <span class=\"nowrap\">",
"     organ/tissue",
"    </span>",
"    perfusion and oxygenation. (See",
"    <a class=\"local\" href=\"#H12812900\">",
"     'Initial management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the stable cyanotic neonate or after stabilizing the critically ill infant, the evaluation is focused on differentiating amongst the possible causes of cyanosis. One approach is to determine is to whether the infant is in respiratory distress [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17513/abstract/4\">",
"     4",
"    </a>",
"    ]. In general, an infant with signs and symptoms of respiratory distress (tachypnea, costal and sub-costal retractions, nasal flaring, and audible grunting) strongly suggests the cyanosis is due to pulmonary disease. In contrast, cyanotic infants who appear comfortable are more likely to be suffering from a right to left shunt because of a cyanotic cardiac lesion. This differentiation can help determine the most appropriate evaluation including testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12812842\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history may provide clues to the underlying etiology of neonatal cyanosis and should include a complete assessment of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy and labor &ndash; Maternal diabetes may be associated with cyanotic heart disease, neonatal polycythemia, and hypoglycemia. Other important pregnancy and labor historical factors include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Polyhydramnios is associated with fetal airway, esophageal, and neurological conditions.",
"     </li>",
"     <li>",
"      Oligohydramnios is associated with renal defects and pulmonary hypoplasia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32231?source=see_link&amp;anchor=H4#H4\">",
"       \"Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)\", section on 'Amniotic fluid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prolonged rupture of the fetal membranes and peripartum maternal fever may be associated with neonatal sepsis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6410?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical features and diagnosis of sepsis in term and late preterm infants\", section on 'Maternal and neonatal risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Meconium staining of the amniotic fluid is associated with meconium aspiration syndrome and persistent pulmonary hypertension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=see_link&amp;anchor=H94133577#H94133577\">",
"       \"Clinical features and diagnosis of meconium aspiration syndrome\", section on 'Pulmonary findings'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link&amp;anchor=H8#H8\">",
"       \"Persistent pulmonary hypertension of the newborn\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Family risk factors including a history of cyanotic heart disease or underlying hemoglobinopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=see_link\">",
"       \"Diagnosis and initial management of cyanotic heart disease in the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=see_link&amp;anchor=H2707632#H2707632\">",
"       \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\", section on 'Family history'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12812849\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination is central to determining the cause of cyanosis. As noted above, the presence and degree of respiratory distress are important factors in delineating between a pulmonary disorder (in which respiratory distress will almost always be present) and a cardiac disorder (in which respiratory distress may not be present). However, some cardiac lesions may have a prominent component of respiratory distress (eg, obstructed total anomalous pulmonary venous return and left sided obstructive disease), thus its presence does not rule out congenital heart disease.",
"   </p>",
"   <p>",
"    Respiratory assessment includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory rate &ndash; The respiratory rate should be counted for a full minute to account for variations in rate and rhythm. A normal early rate in the newborn period is 40 to 60 breaths per minute. Cyanosis due to neurologic or metabolic causes is usually due to alveolar hypoventilation, discernible on physical examination by slow or irregular respirations or intermittent apnea, whereas pulmonary and cardiac disorders are associated with tachypnea.",
"     </li>",
"     <li>",
"      Chest wall movement &ndash; In neonates with respiratory disorders or airway obstruction, poor lung compliance or obstructed air flow causes high intrathoracic pressures resulting in intercostal, subcostal, or subxiphoid retractions in the highly compliant newborn chest wall.",
"     </li>",
"     <li>",
"      Other signs of neonatal respiratory disease include grunting, which prevents end-expiratory alveolar collapse, and nasal flaring, which reduces nasal resistance and increased use of accessory respiratory muscles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cardiac examination should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of heart rate, pulses, and perfusion.",
"     </li>",
"     <li>",
"      Cardiac auscultation to detect any abnormality in the second heart sound or the presence of a heart murmur.",
"     </li>",
"     <li>",
"      Four extremity blood pressure to assist in detection of interrupted aortic arch lesions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cardiac findings suggestive of critical congenital heart disease are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=see_link&amp;anchor=H2707639#H2707639\">",
"     \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\", section on 'Cardiovascular examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As part of the physical exam, measuring oxygen saturation by pulse oximeter will confirm the presence of clinical cyanosis. It is useful to obtain both preductal (right hand) and post-ductal (foot) to determine if there is right to left shunting at the level of the ductus arteriosus. Differential saturations are frequently seen in infants with PPHN, as well as in some cardiac lesions (eg, severe coarctation of the aorta). However, in infants with PPHN, if right to left shunting is predominantly through the foramen ovale rather than the ductus, pre- and post-ductal saturations may not be different. These cases are difficult to differentiate from cyanotic heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=see_link&amp;anchor=H2707728#H2707728\">",
"     \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\", section on 'Pulse oximetry screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In any infant who presents with respiratory distress, cyanosis, poor perfusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shock, both neonatal sepsis and congenital heart disease should be considered. Left sided obstructive lesions in which ductal closure has severely affected systemic blood flow may be indistinguishable from severe sepsis on physical exam and usually requires echocardiographic confirmation of the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12812856\">",
"    <span class=\"h2\">",
"     Initial laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial laboratory testing includes measurement of arterial oxygenation, complete blood count, blood glucose, blood culture and a chest radiograph. In some cases, these studies may be sufficient to determine the underlying cause of neonatal cyanosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12812864\">",
"    <span class=\"h3\">",
"     Arterial blood gas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of an arterial blood gas is standard in the evaluation of cyanosis. However, the pain associated with an arterial puncture may cause agitation in the newborn, and a resultant decrease in the PO2. In cases of methemoglobinemia, oxygen saturation will be low, but the measured PO2 will be normal, which would not be the case in other causes of cyanosis.",
"   </p>",
"   <p>",
"    An elevated arterial PCO2 suggests pulmonary disease. A metabolic acidosis on a blood gas indicates poor perfusion, which may be due to inadequate cardiac output or oxygen delivery, or shock. Many blood gas analyzers can also measure a lactate level, which provides additional information about perfusion and oxygen delivery to the tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12812872\">",
"    <span class=\"h3\">",
"     Other blood tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other laboratory studies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count and differential will reveal a high hematocrit and hemoglobin in cases of polycythemia. Many infants with sepsis will have a low rather than high white blood cell count, and a low absolute neutrophil count or an elevated immature to total neutrophil ratio [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17513/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6410?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical features and diagnosis of sepsis in term and late preterm infants\", section on 'Other blood tests'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Blood glucose as cyanosis due to apnea and poor blood perfusion can be seen in neonates with significant hypoglycemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=see_link&amp;anchor=H15#H15\">",
"       \"Neonatal hypoglycemia\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Blood culture as cyanosis may be observed in neonatal sepsis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6410?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical features and diagnosis of sepsis in term and late preterm infants\", section on 'Other findings'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12812879\">",
"    <span class=\"h3\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the chest radiograph is central to assessment of the cyanotic newborn because there may be findings that help differentiate between cardiac and pulmonary etiologies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Findings suggestive of cardiac disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=see_link\">",
"       \"Diagnosis and initial management of cyanotic heart disease in the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=see_link&amp;anchor=H14#H14\">",
"       \"Diagnosis and initial management of cyanotic heart disease in the newborn\", section on 'Chest radiograph'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The situs of the heart, stomach, and liver should be examined because abnormal locations of these organs (eg, dextrocardia, situs inversus) strongly suggest cardiac disease.",
"     </li>",
"     <li>",
"      Cardiac size and shape may also be abnormal in specific congenital heart lesions, such as Tetralogy of Fallot (\"boot shaped\" heart) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef78997 \" href=\"UTD.htm?18/50/19232\">",
"       image 2",
"      </a>",
"      ) and transposition of the great arteries (\"egg on a string\" shaped heart).",
"     </li>",
"     <li>",
"      Decreased pulmonary vascular markings may be seen in both cyanotic cardiac lesions as well as idiopathic pulmonary hypertension of the newborn.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most cases of pulmonary disorders, the lung fields will be abnormal. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31511?source=see_link\">",
"       \"Overview of neonatal respiratory distress: Disorders of transition\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The chest radiograph in transient tachypnea of the newborn (TTN) usually exhibits characteristic bilateral perihilar linear streaking secondary to engorged lymphatic or blood vessels. Patchy infiltrates that clear within 24 to 48 hours may also reflect the fluid retention of TTN but make initial differentiation from pneumonia problematic. Lung ultrasound has been proposed as an imaging technique for reliable early diagnosis and differentiation of TTN (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64045 \" href=\"UTD.htm?30/36/31298\">",
"       image 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17513/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In respiratory distress syndrome, atelectasis results in the classical radiographic findings of a diffuse, reticulogranular, ground glass appearance with air bronchograms, and low lung volume (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52323 \" href=\"UTD.htm?36/11/37040\">",
"       image 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Most congenital lesions of the lung and diaphragm (eg, lobar emphysema (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54447 \" href=\"UTD.htm?36/10/37039\">",
"       image 5",
"      </a>",
"      ), congenital pulmonary airway malformation [also referred to as cystic adenomatous malformation] (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62424 \" href=\"UTD.htm?29/61/30673\">",
"       image 6",
"      </a>",
"      ), and congenital diaphragmatic hernia (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52913 \" href=\"UTD.htm?14/37/14928\">",
"       image 7",
"      </a>",
"      )) will be evident on an initial chest radiograph, and may evolve in appearance over time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87793356\">",
"    <span class=\"h2\">",
"     Further testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the initial evaluation, the underlying etiology of neonatal cyanosis may still be unclear. Although the hyperoxia test may be helpful in distinguishing cyanotic heart disease from etiologies, echocardiography is generally the definite test in separating between cardiac and non-cardiac causes of neonatal cyanosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12812886\">",
"    <span class=\"h3\">",
"     Hyperoxia test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hyperoxia test is useful in distinguishing cyanotic congenital heart disease with right to left shunting from pulmonary and other causes of cyanosis (",
"    <a class=\"graphic graphic_table graphicRef54070 \" href=\"UTD.htm?16/41/17053\">",
"     table 2",
"    </a>",
"    ). In this test, arterial oxygen tension is measured in the right radial artery (preductal) while the patient breathes 100 percent oxygen concentration for 10 minutes. Oxygen can be administered via a hood or endotracheal tube if the patient is already intubated. A transcutaneous oxygen monitor can be used to assess whether arterial oxygen tension rises in response to the increased inspired oxygen concentration, thereby avoiding arterial puncture for blood sampling. However, an abnormal or equivocal response must be verified by measurement of an arterial blood gas.",
"   </p>",
"   <p>",
"    The preductal oxygen tension while breathing 100 percent oxygen will rarely exceed 150 mm Hg in cyanotic heart disease but will frequently exceed this value in pulmonary disorders. However, there are many limitations to this test. Infants with severe pulmonary disease may have only minimal improvement of their oxygen tension in 100 percent oxygen. In addition, it may be impossible to differentiate cyanotic heart disease from PPHN using this test, since both are characterized by a right to left shunt. In preterm infants, given the known toxicity of high oxygen concentrations, this test should only be used if reliable echocardiography is not immediately available. The hyperoxia test and its interpretation are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=see_link&amp;anchor=H21#H21\">",
"     \"Diagnosis and initial management of cyanotic heart disease in the newborn\", section on 'Hyperoxia test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our center, we usually prefer to directly perform an echocardiography if there is suspicion of cardiac disease and forgo the hyperoxia test because of the potential harmful effects of 100 percent oxygen especially in preterm infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12812893\">",
"    <span class=\"h3\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography generally differentiates between cardiac and non-cardiac causes of neonatal cyanosis. It should be performed in infants whose degree of cyanosis is more severe than the pulmonary pathology would suggest, remain cyanotic despite provision of supplemental oxygen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    positive pressure ventilation, have a physical exam or radiographic evidence consistent with heart disease, or present with abnormal perfusion or shock.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12812900\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborns with persistent central cyanosis after birth should be promptly evaluated, and empirical treatment should be initiated until the underlying cause is determined.",
"   </p>",
"   <p>",
"    Initial management begins with general care that includes cardiorespiratory support and monitoring to ensure sufficient",
"    <span class=\"nowrap\">",
"     organ/tissue",
"    </span>",
"    perfusion and oxygenation. Vital signs should be monitored and vascular access established for sampling of blood and administration of medications. Placement of secure intravenous and intraarterial catheters is most easily accomplished via the umbilical vessels. This will enable efficient correction and monitoring of acid-base balance, metabolic derangements (eg, hypoglycemia, hypocalcemia), and blood pressure. Other initial therapeutic measures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If there is respiratory compromise, an adequate airway should be established immediately and supportive therapy (eg, supplemental oxygen",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mechanical ventilation) instituted as needed. Supplemental oxygen (initially via head box) is provided to bring the oxygen saturation up to 85 to 95 percent, if possible. If infants have evidence for airway obstruction, prone positioning or an oral airway may be adequate to relieve the cyanosis. For infants with respiratory distress and carbon dioxide retention, continuous positive airway pressure (CPAP) or intubation for positive pressure ventilation should be considered.",
"     </li>",
"     <li>",
"      In infants who are cyanotic but do not have respiratory distress, intubation is generally not necessary while the evaluation proceeds.",
"     </li>",
"     <li>",
"      Patients with hypotension or poor perfusion require cardiopulmonary resuscitation. Prompt treatment with administration of fluids is initiated in any infant with impaired circulation, and inotropic therapy may be necessary to correct hypotension.",
"     </li>",
"     <li>",
"      Cyanosis may be an initial finding of sepsis. As a result, unless another specific etiology is promptly identified, broad spectrum antibiotics should be initiated (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      ) after obtaining blood cultures.",
"     </li>",
"     <li>",
"      Monitoring and maintaining adequate blood glucose levels of &gt;45 to 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in the first 24 hours after delivery and &gt;50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      thereafter [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17513/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If cyanotic heart disease is suspected, a pediatric cardiology consultation and echocardiogram should be promptly performed. Until a definitive diagnosis is made, prostaglandin E1 (alprostadil) should be initiated as a continuous intravenous infusion at 0.01 to 0.05",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per min, which is increased as need to a maximum dose of 0.1",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per min. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=see_link&amp;anchor=H27#H27\">",
"       \"Diagnosis and initial management of cyanotic heart disease in the newborn\", section on 'Prostaglandin E1'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent therapy is directed towards correcting or managing the consequences of the underlying etiology. (See appropriate topics for specific diseases).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12812907\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyanosis is a bluish discoloration of the tissues that results when the absolute level of reduced hemoglobin in the capillary bed exceeds 3",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    It is a common clinical finding in newborn infants.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonatal cyanosis, particularly central cyanosis, can be associated with significant and sometimes life-threatening diseases due to cardiac, metabolic, neurological, infectious, and parenchymal and non-parenchymal pulmonary disorders (",
"      <a class=\"graphic graphic_table graphicRef50161 \" href=\"UTD.htm?18/6/18540\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H95089272\">",
"       'Central versus peripheral cyanosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors that affect the detection of neonatal cyanosis include hemoglobin concentration, the presence of fetal hemoglobin, skin pigmentation, and other physiologic factors that affect the oxygen dissociation curve (eg, acid-base balance, temperature of the infant, low pCO2 level, and levels of 2,3 diphosphoglycerate) (",
"      <a class=\"graphic graphic_figure graphicRef59739 \" href=\"UTD.htm?30/36/31310\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Central cyanotic lesions can be classified based on their pathophysiology as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Alveolar hypoventilation",
"      <strong>",
"      </strong>",
"      &ndash; Hypoventilation resulting in hypoxemia may be due to airway obstructive lesions, or neurologic or metabolic disorders. (See",
"      <a class=\"local\" href=\"#H12812751\">",
"       'Hypoventilatory disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventilation-perfusion mismatch &ndash; Pulmonary disease (such as respiratory distress syndrome, neonatal pneumonia, meconium aspiration syndrome, and air leak syndromes) resulting in ventilation-perfusion mismatch is the most common cause of neonatal cyanosis. (See",
"      <a class=\"local\" href=\"#H12812783\">",
"       'Pulmonary disorders and ventilation-perfusion mismatch'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Right to left shunt &ndash; Disorders with right to left shunting include intracardiac lesions, persistent pulmonary hypertension through a patent ductus arteriosus, or intrapulmonary disease (eg, perfusion of non-ventilated areas of the lung). (See",
"      <a class=\"local\" href=\"#H95092508\">",
"       'Disorders with right to left shunting'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20359?source=see_link\">",
"       \"Cardiac causes of cyanosis in the newborn\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link\">",
"       \"Persistent pulmonary hypertension of the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inadequate transport of oxygen by hemoglobin &ndash; Hemoglobinopathies that inadequately transport oxygen include methemoglobinemia and rare variants of hemoglobin with low oxygen affinity. (See",
"      <a class=\"local\" href=\"#H172573399\">",
"       'Hemoglobinopathies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diffusion impairment",
"      <strong>",
"      </strong>",
"      &ndash; Pulmonary edema is the most common cause of impaired diffusion of oxygen from the alveoli to the pulmonary capillaries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants with persistent central cyanosis after birth should be promptly evaluated and treated as they are at-risk for significant and potentially life-threatening disease. The goals of evaluation are to identify and treat critically ill patients, and to determine the underlying cause of cyanosis so that treatment can focus on correcting or managing the specific disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The history may identify maternal or perinatal conditions, or family history that provides clues to the underlying cause. (See",
"      <a class=\"local\" href=\"#H12812842\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical examination may provide information that helps determine the underlying cause of neonatal cyanosis. In particular, signs of respiratory distress (tachypnea, costal and sub-costal retractions, nasal flaring and audible grunting) are suggestive of pulmonary disease, whereas abnormal cardiac findings (eg abnormal heart rate and sounds, and pathologic murmurs) indicate a cardiac etiology. (See",
"      <a class=\"local\" href=\"#H12812849\">",
"       'Physical examination'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=see_link&amp;anchor=H6#H6\">",
"       \"Diagnosis and initial management of cyanotic heart disease in the newborn\", section on 'Physical examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Laboratory studies that may be helpful in differentiating among the variety of underlying causes of neonatal cyanosis include complete blood count, blood culture, blood glucose, chest radiograph, hyperoxia test, and cardiac echocardiography. (See",
"      <a class=\"local\" href=\"#H12812856\">",
"       'Initial laboratory studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial management of newborns with cyanosis includes general supportive care to ensure adequate tissue perfusion and oxygenation. (See",
"      <a class=\"local\" href=\"#H12812900\">",
"       'Initial management'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Other therapeutic interventions include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Because the differential diagnosis for neonatal cyanosis includes sepsis, we recommend administering empiric antibiotic therapy after obtaining blood cultures in neonates with cyanosis in whom no underlying cause has been identified (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6410?source=see_link&amp;anchor=H22#H22\">",
"       \"Clinical features and diagnosis of sepsis in term and late preterm infants\", section on 'Differential diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26200?source=see_link&amp;anchor=H4#H4\">",
"       \"Treatment and outcome of sepsis in term and late preterm infants\", section on 'Empiric antibiotic therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When cyanotic heart disease is suspected, a pediatric cardiology consultation and echocardiogram should be promptly performed. Until a definitive diagnosis is made in an infant suspected of having cyanotic heart disease, we recommend administering prostaglandin E1 (alprostadil) as an initial continuous intravenous infusion at 0.01",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per min (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=see_link&amp;anchor=H27#H27\">",
"       \"Diagnosis and initial management of cyanotic heart disease in the newborn\", section on 'Prostaglandin E1'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17513/abstract/1\">",
"      Lees MH. Cyanosis of the newborn infant. Recognition and clinical evaluation. J Pediatr 1970; 77:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17513/abstract/2\">",
"      Marino BS, Bird GL, Wernovsky G. Diagnosis and management of the newborn with suspected congenital heart disease. Clin Perinatol 2001; 28:91.",
"     </a>",
"    </li>",
"    <li>",
"     Nadas AS, Fyler DC. Hypoxemia. In: Nadas' Pediatric Cardiology, 2nd ed, Keane JF, Lock JE, and Fyler DC (Eds), Saunders Elsevier, Philadelphia 2006. p.97.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17513/abstract/4\">",
"      Sasidharan P. An approach to diagnosis and management of cyanosis and tachypnea in term infants. Pediatr Clin North Am 2004; 51:999.",
"     </a>",
"    </li>",
"    <li>",
"     Textbook of Neonatal Resuscitation, 6th ed, American Academy of Pediatrics, 2011.",
"    </li>",
"    <li>",
"     Rudolph AM. Oxygen uptake and delivery. In: Congenital diseases of the heart, Rudolph AM (Ed), Futura, Armonk 2001. p.85.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17513/abstract/7\">",
"      Yabek SM. Neonatal cyanosis. Reappraisal of response to 100% oxygen breathing. Am J Dis Child 1984; 138:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17513/abstract/8\">",
"      Daniel SJ. The upper airway: congenital malformations. Paediatr Respir Rev 2006; 7 Suppl 1:S260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17513/abstract/9\">",
"      Ramsden JD, Campisi P, Forte V. Choanal atresia and choanal stenosis. Otolaryngol Clin North Am 2009; 42:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17513/abstract/10\">",
"      Cheng AT, Corke M, Loughran-Fowlds A, et al. Distraction osteogenesis and glossopexy for Robin sequence with airway obstruction. ANZ J Surg 2011; 81:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17513/abstract/11\">",
"      Thompson DM. Laryngomalacia: factors that influence disease severity and outcomes of management. Curr Opin Otolaryngol Head Neck Surg 2010; 18:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17513/abstract/12\">",
"      Sarkar S, Rosenkrantz TS. Neonatal polycythemia and hyperviscosity. Semin Fetal Neonatal Med 2008; 13:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17513/abstract/13\">",
"      Newman TB, Puopolo KM, Wi S, et al. Interpreting complete blood counts soon after birth in newborns at risk for sepsis. Pediatrics 2010; 126:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17513/abstract/14\">",
"      Copetti R, Cattarossi L. The 'double lung point': an ultrasound sign diagnostic of transient tachypnea of the newborn. Neonatology 2007; 91:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17513/abstract/15\">",
"      Committee on Fetus and Newborn, Adamkin DH. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics 2011; 127:575.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14305 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-15E18CE5C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_6_17513=[""].join("\n");
var outline_f17_6_17513=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12812907\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12812737\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95089272\">",
"      CENTRAL VERSUS PERIPHERAL CYANOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95089554\">",
"      Peripheral cyanosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95089610\">",
"      - Acrocyanosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95089279\">",
"      Central cyanosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87792679\">",
"      FACTORS THAT AFFECT CYANOSIS DETECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95089307\">",
"      Hemoglobin concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95089314\">",
"      Fetal hemoglobin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95089764\">",
"      Skin pigmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95089321\">",
"      Other physiologic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12812744\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12812751\">",
"      Hypoventilatory disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95092090\">",
"      - Airway abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H95092292\">",
"      - Neurologic or metabolic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12812783\">",
"      Pulmonary disorders and ventilation-perfusion mismatch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95092508\">",
"      Disorders with right to left shunting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12812790\">",
"      - Cyanotic congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12812812\">",
"      - Persistent pulmonary hypertension of the newborn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H278376757\">",
"      Impaired alveolar-arterial diffusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12812827\">",
"      Hematologic causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172573399\">",
"      - Hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172573314\">",
"      - Polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12812835\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12812842\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12812849\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12812856\">",
"      Initial laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12812864\">",
"      - Arterial blood gas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12812872\">",
"      - Other blood tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12812879\">",
"      - Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87793356\">",
"      Further testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12812886\">",
"      - Hyperoxia test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12812893\">",
"      - Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12812900\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12812907\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/14305\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14305|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/30/2543\" title=\"diagnostic image 1\">",
"      CT choanal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/50/19232\" title=\"diagnostic image 2\">",
"      Chest xray tetralogy Fallot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/36/31298\" title=\"diagnostic image 3\">",
"      Chest radiograph TTN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/11/37040\" title=\"diagnostic image 4\">",
"      Chest radiograph RDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?36/10/37039\" title=\"diagnostic image 5\">",
"      Congenital lobar emphysema chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/61/30673\" title=\"diagnostic image 6\">",
"      CPAM newborn chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/37/14928\" title=\"diagnostic image 7\">",
"      Congenital diaphragmatic hernia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14305|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/21/6494\" title=\"figure 1\">",
"      Cyanosis and Hgb concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/36/31310\" title=\"figure 2\">",
"      Factors affecting neonatal oxygen dissociation curve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14305|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/32/4611\" title=\"picture 1A\">",
"      Anatomy choanal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/11/13488\" title=\"picture 1B\">",
"      Endoscopy choanal atresia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/14305|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/6/18540\" title=\"table 1\">",
"      Causes central cyanosis newborn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/41/17053\" title=\"table 2\">",
"      Interpretation neonatal hyperoxia test",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20359?source=related_link\">",
"      Cardiac causes of cyanosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=related_link\">",
"      Clinical features and diagnosis of meconium aspiration syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/16/6410?source=related_link\">",
"      Clinical features and diagnosis of sepsis in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=related_link\">",
"      Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42697?source=related_link\">",
"      Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1977?source=related_link\">",
"      Congenital anomalies of the jaw, mouth, oral cavity, and pharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37543?source=related_link\">",
"      Congenital anomalies of the larynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35575?source=related_link\">",
"      Congenital anomalies of the nose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28026?source=related_link\">",
"      Congenital diaphragmatic hernia in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=related_link\">",
"      Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/50/810?source=related_link\">",
"      Congenital pulmonary airway (cystic adenomatoid) malformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/2/43048?source=related_link\">",
"      Diagnosis and initial management of cyanotic heart disease in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32231?source=related_link\">",
"      Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=related_link\">",
"      Genetic disorders of hemoglobin oxygen affinity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4841?source=related_link\">",
"      Genetics and pathogenesis of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=related_link\">",
"      High-output heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=related_link\">",
"      Neonatal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36968?source=related_link\">",
"      Neonatal polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31511?source=related_link\">",
"      Overview of neonatal respiratory distress: Disorders of transition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19656?source=related_link\">",
"      Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=related_link\">",
"      Persistent pulmonary hypertension of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4631?source=related_link\">",
"      Pulmonary air leak in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/15/250?source=related_link\">",
"      Syndromes with craniofacial abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32804?source=related_link\">",
"      Transient tachypnea of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26200?source=related_link\">",
"      Treatment and outcome of sepsis in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27735?source=related_link\">",
"      Vascular rings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_6_17514="Total knee arthroplasty";
var content_f17_6_17514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Total knee arthroplasty",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/6/17514/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/6/17514/contributors\">",
"     Gregory M Martin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/6/17514/contributors\">",
"     Thomas S Thornhill, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/6/17514/contributors\">",
"     Jeffrey N Katz, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/6/17514/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/6/17514/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/6/17514/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/6/17514/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/6/17514/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total knee arthroplasty, also known as total knee replacement, is one of the most commonly performed orthopedic procedures. As of 2010, about 600,000 total knee replacements were being performed annually in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/1\">",
"     1",
"    </a>",
"    ]. A variety of pathologic conditions affecting the knee can be treated in this way, leading to pain relief, to restoration of function, and to mobility.",
"   </p>",
"   <p>",
"    The normal knee joint functions as a complex hinge primarily allowing flexion and extension but also allowing rotation and gliding. The knee joint is made up of three compartments: lateral, medial, and patellofemoral. Damage to the cartilage of one or more compartments may be the result of osteoarthritis (idiopathic or post-traumatic), inflammatory arthritis (rheumatoid, psoriatic, etc), avascular necrosis, tumors, or congenital deformities. Over 95 percent of total knee replacements in the US are performed for osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The introduction of the &ldquo;total condylar prosthesis&rdquo; by Insall and colleagues in 1972 is generally agreed to mark the era of &ldquo;modern&rdquo; knee replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/3\">",
"     3",
"    </a>",
"    ]. This prosthesis was the first to replace all three compartments of the knee. There are variations of the original design, and there is increasing interest in partial (unicompartmental) knee replacements. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Choice of prosthesis and fixation technique'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22\">",
"     'Alternatives to total knee arthroplasty'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Modern total knee arthroplasty consists of resection of the diseased articular surfaces of the knee, followed by resurfacing with metal and polyethylene prosthetic components. For the properly selected patient, the procedure results in significant pain relief, as well as improved function and quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the potential benefits of total knee arthroplasty, it is an elective procedure and should only be considered after extensive discussion of the risks, benefits, and alternatives. This topic reviews aspects of total knee arthroplasty including preoperative, operative, and postoperative considerations.",
"   </p>",
"   <p>",
"    As with any major surgical procedure, complications may result during or after total knee arthroplasty. Complications of this procedure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16902?source=see_link\">",
"     \"Complications of total knee arthroplasty\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main indication for total knee arthroplasty is for the relief of pain associated with arthritis of the knee in patients who have failed nonoperative treatments. As an example, nonoperative therapies for the patient with osteoarthritis include activity modification, weight loss, use of a cane, analgesics,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nonsteroidal antiinflammatory agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=see_link\">",
"     \"Nonpharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Total knee arthroplasty may be necessary in some patients with osteonecrosis. However, the outcomes for such patients may be poorer than for those with osteoarthritis or inflammatory arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link&amp;anchor=H43#H43\">",
"     \"Osteonecrosis (avascular necrosis of bone)\", section on 'Total joint replacement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should have radiographs documenting advanced arthritic changes. If knee pain appears to be out of proportion to the radiographic appearance, other causes should be excluded before arthroplasty is pursued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link&amp;anchor=H29#H29\">",
"     \"Evaluation of the active adult patient with knee pain\", section on 'Referred pain syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Correction of deformity and restoration of function should be considered secondary outcomes of the surgery and should not be considered the primary indication. Total knee arthroplasty is performed in patients of all ages (except the skeletally immature).",
"   </p>",
"   <p>",
"    The prosthetic joint has a finite lifetime, and the durability of the prosthesis depends upon factors related to the patient and to the arthroplasty. Among the considerations are [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient age &mdash; Ten-year survival of the prosthesis of 11,606 primary (not revision) total knee arthroplasties done between 1978 and 2000 for patients 55 years of age or younger versus those over age 70 were significantly different (83 versus 90 percent, respectively).",
"     </li>",
"     <li>",
"      Underlying disease &mdash; Durability of the prosthesis was shorter in patients with osteoarthritis than in those with rheumatoid arthritis (10-year prosthesis survival of 90 versus 95 percent, respectively).",
"     </li>",
"     <li>",
"      Obesity &mdash; Obesity has a negative effect on outcome after total knee replacement. In a 2012 meta-analysis, patients who were obese (body mass index &ge;30) demonstrated increased rates of infection (odds ratio [OR] 1.90, 95% CI 1.47-2.47) and revision for any reason (OR 1.30, 95% CI 1.02-1.67), compared with patients who were not obese [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3230182\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total knee replacement should not be performed in the following clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Active infection in the knee or anywhere in the body",
"     </li>",
"     <li>",
"      A non-functioning extensor mechanism",
"     </li>",
"     <li>",
"      Poor extremity circulation or vascularity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neurologic disease affecting the extremity is a relative contraindication to total knee replacement, depending upon the impact of the neurologic disorder on the potential for successful rehabilitation and for improvements in pain and function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall mortality rates of total knee and total hip arthroplasty are similar, approximating 0.5 to 1 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful preoperative evaluation must be performed to determine the correct diagnosis, to identify the need for surgery, to assist with surgical planning, and to prevent complications in the perioperative period. General issues relating to preoperative evaluation are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=see_link\">",
"     \"Evaluation of preoperative pulmonary risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A thorough preoperative evaluation includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History (see",
"      <a class=\"local\" href=\"#H6\">",
"       'History'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Physical examination (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Physical examination'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Imaging studies (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Imaging studies'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Laboratory studies (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Laboratory studies'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Review of treatment alternatives (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Review of treatment alternatives'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Discussion of risks and benefits of the procedure, its timing, and the alternatives (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Discussion of risks and benefits'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Consideration of autologous blood donation (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Autologous blood donation'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient&rsquo;s symptoms should be documented. It is critical to document and investigate any history of concomitant back pain (often described as hip pain by the patient), of hip pain (often described as groin pain by the patient), or of numbness, paresthesia, or pain in the leg. The presence of back or hip symptoms may indicate that knee pain is referred from these sites, while neurologic complaints may arise from peripheral nerve, root, or central nervous system disorders. The interviewer must also inquire about calf pain or claudication which could indicate peripheral vascular disease or spinal stenosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Onset &mdash; If the patient is having knee pain, it is important to document the date of onset. It should be noted if the pain was gradual in onset or if there was a specific traumatic event.",
"     </li>",
"     <li>",
"      Location &mdash; The location of the pain should be described (eg, medial, lateral, or patellofemoral). Often, the patient will describe these locations as inside the knee, outside the knee, or behind the knee cap, respectively. It should be noted whether the pain is unilateral or bilateral and, if bilateral, which side is worse.",
"     </li>",
"     <li>",
"      Severity and functional effects &mdash; The severity of the pain and the effect of the pain on the patient&rsquo;s activities of daily living and quality of life should be documented. Activities which bring on the pain should be elicited (eg, stair climbing, especially down stairs, is often indicative of patellofemoral pain).",
"     </li>",
"     <li>",
"      Locking, catching, popping &mdash; Other symptoms, such as locking or catching, should be noted as they could indicate pain arising from meniscal pathology. Instability or a history of the patient hearing a pop could indicate ligament injury or rupture.",
"     </li>",
"     <li>",
"      Previous treatments &mdash; Note any previous treatments the patient has had for the knee pain and their efficacy (eg, nonsteroidal antiinflammatory drugs [NSAIDS], glucocorticoid injections, hyaluronan injections, physical therapy, alternative treatments, surgical procedures).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Comorbid medical problems/review of systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient undergoing total knee arthroplasty must be able to tolerate anesthesia, operative stress including introduction of marrow elements into the circulation, and perioperative blood loss. Since most patients presenting as candidates for total knee replacement are older, specific attention should be paid to the patient&rsquo;s comorbid medical problems and review of symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical problems &mdash; Communication between the patient&rsquo;s medical clinician and the surgeon or anesthesiologist is paramount. Any history of cardiovascular disease (eg, angina, myocardial infarction, hypertension, congestive heart failure, arrhythmia) or pulmonary disease (chronic obstructive pulmonary disease, restrictive lung disease, respiratory infection, pulmonary embolus, sleep apnea, asthma) should be investigated thoroughly.",
"     </li>",
"     <li>",
"      Review of systems &mdash; Other particularly important components of the review of systems include those indicating the possible presence of cerebrovascular disease (transient ischemic attacks, stroke, carotid stenosis), peripheral vascular disease (claudication, rest pain, non-healing ulcers, deep venous thrombosis), hematologic disorders (anemia, coagulopathies, blood dyscrasias), endocrine disorders (diabetes mellitus, thyroid disorders, steroid or glucocorticoid use), urologic disorders (benign prostatic hypertrophy, obstructive uropathy, prostate cancer, urinary tract infections), and infectious disease (HIV, hepatitis, osteomyelitis). Appropriate medical and surgical consults should be obtained preoperatively as needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient&rsquo;s current medications, including all doses, should be noted. In patients undergoing total knee or total hip arthroplasty, special attention should be paid to the following medications (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10106?source=see_link\">",
"     \"Total hip arthroplasty\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      and NSAIDS &mdash; Given an association with perioperative bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/9,10\">",
"       9,10",
"      </a>",
"      ] it is recommended to discontinue these medications at least one week prior to surgery.",
"     </li>",
"     <li>",
"      Coxibs &mdash; The literature is conflicting whether or not cyclooxygenase-2 (COX-2)-selective inhibitors (coxibs) have a clinically significant effect on the coagulation system. One prospective study of 100 patients undergoing total knee arthroplasty with random assignment to receive rofecoxib or placebo revealed no significant difference in perioperative bleeding or in international normalized ratio (INR) between the two groups. Rofecoxib was subsequently withdrawn from the worldwide market because of an increased risk of serious adverse cardiovascular events. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link&amp;anchor=H2#H2\">",
"       \"COX-2 selective inhibitors: Adverse cardiovascular effects\", section on 'Ischemic cardiovascular disease'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Other studies have demonstrated and interaction between coxibs and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , though in varying degrees and with different agents [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/11-14\">",
"       11-14",
"      </a>",
"      ]. The ultimate decision should lie with the operating surgeon. Some surgeons are prescribing preoperative coxibs to assist with postoperative pain management, so more information should become available concerning this topic.",
"     </li>",
"     <li>",
"      Anticoagulants &mdash; Prior to undergoing total knee arthroplasty, patients should have a normal prothrombin time (PT) and international normalized ratio (INR). This usually requires discontinuing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      a minimum of three to five days prior to surgery. High risk patients (eg, patients with mechanical heart valves) either should be bridged with a low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or should be admitted preoperatively and heparinized. Heparin should be stopped six hours prior to surgery, and a partial thromboplastin time should be checked. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link\">",
"       \"Management of anticoagulation before and after elective surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antibiotics &mdash; As previously noted, active septic arthritis is a contraindication to total joint arthroplasty. Patients with resolved infections should be off antibiotics at least 48 hours prior to surgery.",
"     </li>",
"     <li>",
"      Insulin or oral hypoglycemics &mdash; Insulin should be reduced or should be given in a decreased dose depending upon the scheduled time for surgery. Oral hypoglycemic agents should be held the day of surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29688?source=see_link\">",
"       \"Perioperative management of diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glucocorticoids &mdash; Glucocorticoids should ideally be tapered to the lowest possible dose to decrease suppression of the immune system and to minimize the risk of interfering with wound healing. Depending upon the patient&rsquo;s normal dose, patients are sometimes given &ldquo;stress-dose&rdquo; glucocorticoids in the perioperative period to avoid possible effects of adrenal insufficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"       \"Treatment of adrenal insufficiency in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      &mdash; We continue methotrexate (MTX) perioperatively in patients with normal renal function and with absence of active infection whose disease is controlled by the drug. The use of MTX and other disease-modifying antirheumatic drugs (DMARDs) in the perioperative setting is reviewed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=see_link&amp;anchor=H42#H42\">",
"       \"Perioperative medication management\", section on 'Rheumatologic agents'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/35/15929?source=see_link&amp;anchor=H9#H9\">",
"       \"Preoperative evaluation and perioperative management of patients with rheumatic diseases\", section on 'Methotrexate and other nonbiologic DMARDs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Biologics &mdash; The use of tumor necrosis factor (TNF)-alpha inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      ) and other biologic therapies used to treat rheumatoid arthritis (RA) and other inflammatory rheumatic disorders has been associated with an increase risk of both typical and atypical infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link\">",
"       \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"       \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      As a result, anti-TNF agents and other biologic DMARDs are generally avoided in the perioperative period. The use of these agents in the perioperative setting is reviewed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=see_link&amp;anchor=H42#H42\">",
"       \"Perioperative medication management\", section on 'Rheumatologic agents'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/35/15929?source=see_link&amp;anchor=H10#H10\">",
"       \"Preoperative evaluation and perioperative management of patients with rheumatic diseases\", section on 'Biological agents'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Allergies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previous allergies to antibiotics and the type of reaction (eg, rash, shortness of breath, anaphylaxis) should be clearly documented. Also, the patient&rsquo;s use and tolerance (or intolerance) of opioid analgesics should be investigated. Proper and prominent documentation will prevent errors in the perioperative period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who may be candidates for total knee replacement need to undergo a thorough musculoskeletal examination. Proper examination of the arthritic knee includes observation, palpation, and assessment with special manual tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observing the patient&rsquo;s gait pattern and skin are important part of the physical examination.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gait &mdash; Among the abnormal gaits that may be observed in patients with knee pain are the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Antalgic gait &mdash; Patients with knee arthritis will often have an antalgic gait. The patient with an antalgic gait spends a shorter time bearing weight on the affected side because of pain.",
"     </li>",
"     <li>",
"      Knee thrust &mdash; An abnormal medial or lateral movement of the knee while walking (thrust) may indicate ligament instability.",
"     </li>",
"     <li>",
"      Trendelenburg gait &mdash; With a Trendelenburg gait, the patient shifts the torso over the affected hip, thereby reducing the load on the hip that is imposed by stabilizing the pelvis and thereby decreasing pain. This suggests the presence of hip joint disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      weakness of the gluteus medius muscle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin &mdash; The skin over both of the entire lower extremities should be thoroughly inspected for any abrasions, ulcerations, swelling, redness, vascular changes, or infections. Surgical implantation of a prosthesis is contraindicated in the presence of an active infection. Any previous scars over the knee should be noted. Wound healing problems are common around the knee, and previous incisions need to be taken into account at the time of surgery. Any gross deformities (eg, varus, valgus, recurvatum, flexion contracture) should be noted. Deformities will be definitively assessed with radiographs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The knee should be palpated for an effusion. Keeping a hand on the patella while passively taking the knee through a range of motion will allow the clinician to detect patellofemoral crepitus. Medial and lateral joint line tenderness on palpation is often observed in arthritis but also may indicate meniscal pathology. Distal pulses, including the dorsalis pedis and posterior tibialis, should also be assessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Assessment with other manual tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous maneuvers are performed to aid the preoperative assessment as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Range of motion &mdash; In order to assess the extensor mechanism and to document preoperative range of motion, maximal active and passive knee flexion and extension are recorded. Joint contracture is noted.",
"     </li>",
"     <li>",
"      Muscle testing &mdash; Motor strength and tone should be tested in the entire lower extremity with special attention devoted to the quadriceps or extensor mechanism.",
"     </li>",
"     <li>",
"      Nerve testing &mdash; In addition to checking motor strength, sensory and deep tendon reflex assessments (patella and ankle jerks) should be performed.",
"     </li>",
"     <li>",
"      Ligament examination &mdash; The lateral collateral ligament (LCL) and, especially, the medial collateral ligament (MCL) are highly important structures to preserve during a total knee replacement. Preoperative assessment of the stability or degree of contracture of these ligaments is indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Collateral ligaments &mdash; The LCL and MCL are tested with the knee in 30 degrees of flexion with varus and valgus stresses, respectively. In a varus knee, the LCL is usually lax while the MCL is contracted. In a valgus knee, the LCL is usually contracted, and the MCL is lax. Evidence of MCL incompetence may indicate the need for a more constrained prosthesis.",
"     </li>",
"     <li>",
"      Cruciate ligaments &mdash; The anterior cruciate ligament (ACL) is sacrificed in the majority of total knee replacement designs, and, therefore, its assessment is not crucial. The posterior cruciate ligament (PCL) may be retained or sacrificed at the time of surgery. It may be assessed by the posterior drawer test with the knee flexed to 90 degrees and with application of a posterior directed force on the tibia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Meniscal examination &mdash; If the patient is having predominantly mechanical symptoms, such as locking or catching of the knee, there may be a meniscal tear. Such patients may benefit from a less invasive arthroscopy, although arthroscopic partial meniscectomy in the presence of moderate to severe osteoarthritis does not appear to be any more efficacious than nonoperative therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Review of treatment alternatives'",
"      </a>",
"      below.) Meniscal examination is performed with a McMurray test and with the Apley Compression test. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=see_link&amp;anchor=H44#H44\">",
"       \"Evaluation of the active adult patient with knee pain\", section on 'Tests for meniscal tear'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/15/16632?source=see_link\">",
"       \"Meniscal injury of the knee\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Spine and hip examination &mdash; It is important to exclude referred pain to the knee originating in the spine or hip. Elicitation of the knee pain with straight leg raising or with hip motion (especially internal rotation) should raise suspicion and warrants further study including imaging of the lumbar spine, the hip, or both.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous imaging modalities are available to assist with the management of a painful knee including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plain radiographs &mdash; Plain radiographs are the mainstay of diagnosis, preoperative planning, and postoperative assessment of arthritis and total knee arthroplasty. A minimum of three views (standing anteroposterior view, lateral view, and a tangential patella view) should be obtained. Other views are sometimes utilized. A standing 45 degree posteroanterior radiograph may be ordered to more accurately determine joint space narrowing of the medial and lateral sides. A long-length, three-joint, standing film is obtained to determine the anatomic and mechanical alignment of the limb (eg, varus, valgus), which is helpful for preoperative planning.",
"      <br/>",
"      <br/>",
"      The three basic views that should be obtained in all patients are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Standing anteroposterior view &mdash; The anteroposterior view should be obtained with the patient standing in order to normally load the joint. The medial and lateral joint spaces should both be assessed for narrowing.",
"     </li>",
"     <li>",
"      Lateral view &mdash; The lateral view is used to assess the patellofemoral joint and the position of the patella (eg, patella baja, patella alta).",
"     </li>",
"     <li>",
"      Tangential patellar view &mdash; The patellofemoral joint space should be assessed on a tangential patellar view (&ldquo;sunrise,&rdquo; &ldquo;skyline,&rdquo; or Merchant view).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Magnetic resonance imaging (MRI) &mdash; MRI is not indicated in the majority of patients being assessed for a total joint replacement. While MRI is more sensitive than plain radiographs in detecting early osteoarthritis changes, total knee replacement (TKR) candidates, as a rule, have more advanced, radiographically apparent disease. MRI visualizes meniscal tears which are nearly ubiquitous in patients with advanced osteoarthritis (OA) and which may not be responsible for symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/16\">",
"       16",
"      </a>",
"      ]. In the patient with knee pain and mild osteoarthritic change on plain radiographs, MRI may be helpful in identifying an alternative source of discomfort, such as a meniscal tear or osteonecrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative laboratory requirements vary depending upon the patient&rsquo;s health and institutional policy, but they typically include a complete blood count, basic chemistry panel, and coagulation studies (prothrombin time, INR, and partial thromboplastin time). An electrocardiogram and a chest radiograph are usually required depending upon patient age and anesthesia policy. Urinalysis and urine culture are obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Review of treatment alternatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to take into account the history, physical examination, and radiographs to determine if the patient could benefit from less invasive alternative treatment. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Alternatives to total knee arthroplasty'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Discussion of risks and benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient must thoroughly understand all the risks and outcomes associated with the surgery. The patient must be aware of the rigors of the rehabilitation following TKR. A summary of this information is presented separately for patients considering this procedure. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=see_link\">",
"     \"Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of total knee arthroplasty are presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16902?source=see_link\">",
"     \"Complications of total knee arthroplasty\"",
"    </a>",
"    .) The following is a brief summary of potential risks, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anesthetic and intraoperative events &mdash; As with any major operation, there are risks associated with the administration of anesthetics and with intraoperative misadventures.",
"     </li>",
"     <li>",
"      Thromboembolism &mdash; Deep venous thrombosis and venous thromboembolism are potential and, sometimes, lethal complications. The risk of proximal venous thrombosis following knee surgery is reduced by the use of anticoagulation, but it may still occur during use of prophylactic adjusted-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or of unfractionated or low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      . Symptomatic proximal deep vein thrombosis has been documented following knee replacement surgery in up to 3 percent of patients despite pharmacologic prophylaxis. The risk of pulmonary embolism is approximately 1 percent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infection &mdash; Infectious complications are uncommon but potentially serious. Prosthetic joint infection may result in prolonged hospitalization, in the need for removal of the infected prosthesis, and in an extended course of antibiotic treatment, followed by reimplantation. Up to 1 percent of TKR recipients experience an infected prosthesis over the course of the first postoperative year. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=see_link\">",
"       \"Prevention of prosthetic joint infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42680?source=see_link\">",
"       \"Clinical manifestations and diagnosis of prosthetic joint infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=see_link\">",
"       \"Treatment of prosthetic joint infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patellofemoral disorders &mdash; Various disorders of the prosthetic patellofemoral joint and of the extensor mechanism may occur, including patellar subluxation, dislocation, component loosening, fracture, impeded patellar mobility (&ldquo;clunk&rdquo; phenomenon), and rupture of the extensor mechanism (quadriceps or patellar tendon ruptures).",
"     </li>",
"     <li>",
"      Nerve injuries &mdash; Intraoperative or postoperative injuries to the peroneal nerve may occur leading to tibialis anterior muscle weakness (drop foot) and sensory loss.",
"     </li>",
"     <li>",
"      Arterial injuries &mdash; Popliteal or other arterial injuries may lead to increased blood loss and to the need for arterial repair. Arterial thrombosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      peripheral embolization may occur.",
"     </li>",
"     <li>",
"      Periprosthetic fractures &mdash; Fracture proximal to the femoral component (supracondylar fracture) or distal to the tibial implant may occur.",
"     </li>",
"     <li>",
"      Wound problems &mdash; Wound dehiscence increases the risk of prosthetic joint infection and may require additional plastic surgical procedures to achieve adequate coverage of the incision and a functional range of knee motion.",
"     </li>",
"     <li>",
"      Prosthetic wear and failure &mdash; Polyethylene wear can provoke an inflammatory response that sometimes leads to loosening of the prosthesis. If this leads to failure of the prosthetic knee, revision arthroplasty may be necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bilateral simultaneous knee arthroplasty has been associated with increased risks of complications, and patients should be counseled as such. A 2007 meta-analysis demonstrated that simultaneous bilateral knee replacement carries an increased risk of serious cardiac and pulmonary complications, as well as increased mortality, compared with staged bilateral or unilateral surgery. The period of time to stage bilateral procedures has not been well-established [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the introduction, the expected benefits of total knee arthroplasty are pain relief, restoration of function, and mobility. Modest improvement in varus or valgus deformities may be achieved. Flexion contractures are more difficult to overcome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain relief &mdash; A systematic review documented that about 20 percent of recipients of TKR and 10 percent of recipients of total hip replacement (THR) report persistent or recurrent pain in the year or so following surgery. Some of these patients are nonetheless satisfied, but it is important for patients to bear in mind that the risk of less than complete pain relief is not trivial. Research is ongoing to identify risk factors for suboptimal outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Functional improvement &mdash; Patients generally experience dramatic improvements in the capacity to perform daily and community activities. Patients with worse functional status preoperatively tend to gain the most function following surgery, while patients with the best preoperative function preoperatively tend to achieve the highest level of postoperative functional status [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/19\">",
"       19",
"      </a>",
"      ]. While activities of daily living are generally easier to perform due to decreased knee pain following total knee arthroplasty, objective measures of knee function (eg, range of motion) typically improve less. Only 23 percent of knees were rated as having excellent function when followed up a mean of 17 years following initial surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/20\">",
"       20",
"      </a>",
"      ]. The postoperative motion that can be expected is highly dependent on the preoperative motion [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Correction of deformities &mdash; Surgical technique allows a normal or near-normal amount of knee valgus to be restored. Knee flexion contractures can be reduced in most cases by appropriate component selection and by soft tissue release. As an example, in one retrospective study of 542 knee arthroplasties in knees with flexion contractures, 95 percent had residual flexion deformities of three degrees or less [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/22\">",
"       22",
"      </a>",
"      ]. Severe deformities may not be amenable to correction during total knee arthroplasty.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Autologous blood donation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing total knee arthroplasty may benefit from autologous blood donation. Patients should be informed about this option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=see_link\">",
"     \"Preoperative autologous blood donation\"",
"    </a>",
"    .) Most data on autologous blood donation in orthopedics have been from studies on total hip arthroplasty. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10106?source=see_link&amp;anchor=H25#H25\">",
"     \"Total hip arthroplasty\", section on 'Autologous blood donation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ALTERNATIVES TO TOTAL KNEE ARTHROPLASTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed earlier, nonsurgical treatment should be tried before resorting to surgery for osteoarthritis or inflammatory arthritis.",
"   </p>",
"   <p>",
"    The suitability of surgical approaches other than total joint arthroplasty depends upon several factors, including the severity of the disease (eg, early chondral changes with minimal loss of joint space); the extent and location of disease, including whether it is unicompartmental (lateral, medial, or patellofemoral) versus bi- or tricompartmental; the disease process causing joint pathology (eg, osteoarthritis, rheumatoid arthritis, psoriatic arthritis, etc); and the patient&rsquo;s preferences for the risks and advantages associated with each option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Nonsurgical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before proceeding to total knee arthroplasty for an indication of osteoarthritis, a multifaceted regimen of nonoperative treatment should be attempted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=see_link\">",
"     \"Nonpharmacologic therapy of osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"     \"Pharmacologic therapy of osteoarthritis\"",
"    </a>",
"    .) Guidelines from the American Academy of Orthopedic Surgeons, the American College of Rheumatology, and the Osteoarthritis Research Society all suggest that patients be offered nonpharmacologic therapy including strengthening, stretching, and conditioning exercises; weight loss for those who are overweight; pharmacologic therapy, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and nonsteroidal antiinflammatory agents for patients who do not have contraindications; a trial of glucocorticoid injections; and use of wedge insoles or bracing [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/23-26\">",
"     23-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with rheumatoid arthritis or other forms of inflammatory arthritis should have failed medical management before proceeding with total knee arthroplasty. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37861?source=see_link\">",
"     \"Evaluation and medical management of end-stage rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Arthroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthroscopy may be considered as an alternative in the following scenarios:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with diseased rheumatoid synovium with preservation of cartilage may undergo arthroscopic synovectomy. In one series of 41 patients, 83 percent had good results at three years, but those with good results decreased to 46 percent at eight years.",
"     </li>",
"     <li>",
"      The use of arthroscopic lavage and debridement for osteoarthritis in the absence of mechanical symptoms is controversial. In one study of 180 patients with knee osteoarthritis, who were randomly assigned to arthroscopic debridement, arthroscopic lavage, or placebo surgery, the patients in the debridement and lavage groups did not have significantly greater improvement in pain or function compared with patients in the placebo group, in whom sham incisions were made [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/27\">",
"       27",
"      </a>",
"      ]. A second trial showed no benefit of arthroscopy for osteoarthritis compared with a physical therapy-based nonoperative regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/28\">",
"       28",
"      </a>",
"      ]. Another randomized trial also failed to support the efficacy of arthroscopic partial meniscectomy in patients with meniscal tear and concomitant osteoarthritis.",
"     </li>",
"     <li>",
"      Younger patients with isolated or multiple chondral defects may be candidates for cartilage preserving or restoring techniques including subchondral drilling, microfracture, osteochondral allograft transfer (OATS), or autologous chondrocyte implantation. An in depth discussion of these techniques is beyond the scope of this topic review, but several excellent reviews of these evolving techniques are available [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Osteotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteotomy, popularized by Coventry [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], continues to be an option in younger patients with predominantly unicompartmental disease, either lateral or medial, which is noninflammatory in nature. The basic premise of an osteotomy about the knee is to unload the diseased compartment by realigning the mechanical axis of the lower extremity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Varus knee",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the varus knee (more common), this is accomplished with a proximal tibial osteotomy, also known as a high tibial osteotomy, which can be opening-wedge, closing-wedge, or dome. Established indications and contraindications include [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Indications for osteotomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age less than 60 years",
"     </li>",
"     <li>",
"      Unicompartmental arthritis",
"     </li>",
"     <li>",
"      Ten to 15 degrees of varus deformity on weightbearing radiographs",
"     </li>",
"     <li>",
"      Preoperative motion arc of at least 90 degrees",
"     </li>",
"     <li>",
"      Flexion contracture of less than 15 degrees",
"     </li>",
"     <li>",
"      Ability and motivation to effectively and safely perform rehabilitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contraindications to osteotomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lateral compartment loss of joint space",
"     </li>",
"     <li>",
"      Lateral tibial subluxation greater than 1 cm",
"     </li>",
"     <li>",
"      Medial bone loss greater than 2 to 3 mm",
"     </li>",
"     <li>",
"      Ligamentous instability",
"     </li>",
"     <li>",
"      Inflammatory arthritis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2005 systematic review of 11 studies, of which six were considered to be high quality, found that patients who received a valgus high tibial osteotomy improved following the procedure, as indicated by deceased pain and by better function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/34\">",
"     34",
"    </a>",
"    ]. Limited data were available comparing high tibial osteotomy with other surgical procedures for OA of the knee, such as unicompartmental arthroplasty (see",
"    <a class=\"local\" href=\"#H28\">",
"     'Unicompartmental knee replacement'",
"    </a>",
"    below) or other types of osteotomies for varus knee OA.",
"   </p>",
"   <p>",
"    The outcomes that can be expected are illustrated by one long-term (15-year average follow-up) retrospective study of 102 high tibial osteotomies for varus knees [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/35\">",
"     35",
"    </a>",
"    ]. Excellent or good results were noted in 55 percent of patients, and fair or poor results were noted in 45 percent. Clinical results tend to deteriorate 10 to 15 years postoperatively.",
"   </p>",
"   <p>",
"    High tibial osteotomy can be converted to total knee replacement. However, there is controversy regarding whether the results are equivalent to or inferior to a primary total knee arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Valgus knee",
"    </span>",
"    &nbsp;&mdash;&nbsp;For valgus knees, osteotomy is usually performed at the supracondylar region of the distal femur. Indications include [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Valgus deformity less than 15 degrees",
"     </li>",
"     <li>",
"      Preoperative motion arc of at least 90 degrees",
"     </li>",
"     <li>",
"      Less than 10 degree flexion contracture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Outcomes of osteotomy of 21 valgus knees were 90 percent good or excellent at an average follow-up of five years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/38\">",
"     38",
"    </a>",
"    ]. Another study of 49 knees revealed that 87 percent of valgus knees had not been converted to total knee arthroplasty at an average of seven years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteotomies may have serious complications including non-union, failure of hardware, incomplete pain relief requiring conversion to total knee arthroplasty, neurovascular injuries, and compartment syndrome. Nevertheless, in an appropriately selected patient, osteotomy remains an excellent alternative to total knee arthroplasty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Unicompartmental knee replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unicompartmental knee replacement began in the 1950s with the introduction of a prosthesis by McKeever [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Since that time, there have been numerous design variations and varying results. As a result, the role for unicompartmental knee replacement in the treatment of the arthritic knee is the subject of controversy.",
"   </p>",
"   <p>",
"    Detractors claim that only resurfacing one compartment often results in incomplete pain relief and in earlier prosthetic failure and makes for a more difficult revision. Proponents claim that the procedure allows sparing of the normal anatomic ligament structure, resulting in more natural kinematics of the knee and in the preservation of the patellofemoral joint and other compartment (leaving more bone stock for subsequent revision surgery). Proponents attribute poorer survival compared with total knee arthroplasty to flaws in earlier designs of unicompartmental prostheses.",
"   </p>",
"   <p>",
"    There has been a resurgence of interest in unicompartmental knee replacement as an alternative both to total knee replacement and to osteotomy in the treatment of patients with unicompartmental, noninflammatory arthritis. Widely accepted contraindications to unicompartmental knee replacement include inflammatory arthritis, less than 90 degrees of flexion, greater than 15 degree flexion contracture, or a large deformity not amenable to correction with available unicompartmental designs.",
"   </p>",
"   <p>",
"    Unicompartmental knee replacement may be successful in the appropriately selected patient, as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 28 unicompartmental knee replacements in patients with an average age of 52 years found early results (two to six years) to be superior to results of osteotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A five-year retrospective study of 102 patients compared unicompartmental knee replacement with total knee replacement [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/43\">",
"       43",
"      </a>",
"      ]. Those who had the unicompartmental surgery had an increased range of motion, less pain, and a faster recovery than those who had a total knee arthroplasty.",
"     </li>",
"     <li>",
"      A retrospective study of the results of using a Lubinus patellofemoral prosthesis for patients with isolated disease of this compartment noted good to excellent results in 64 percent of 45 arthroplasties in 34 patients and noted unsatisfactory outcomes in 17 percent of the procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/44\">",
"       44",
"      </a>",
"      ]. A subsequently developed prosthesis may have better outcomes. Among 15 patients followed for a mean of 3.75 years, 14 (93 percent) had good or excellent results [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The durability of unicompartmental knee arthroplasty may be similar to that of total knee replacement. As an example, a retrospective study of 60 patients who underwent unicompartmental knee replacement found 93 percent survivorship at a mean follow-up of 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/46\">",
"     46",
"    </a>",
"    ]. Another long-term follow-up study of 63 unicompartmental knee replacements revealed 84 percent survival at 10 years and 79 percent survival at 15 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are conflicting reports of whether the results after conversion to a total knee replacement are more similar to a primary knee replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/48\">",
"     48",
"    </a>",
"    ] or to a revision [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications after unicondylar knee replacement are similar to total knee replacement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16902?source=see_link\">",
"     \"Complications of total knee arthroplasty\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Knee arthrodesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knee arthrodesis, or fusion, is not typically considered a primary operation for knee arthritis. It remains a viable salvage option in cases of multiple prosthetic infections, of failed extensor mechanism, and of other complex situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SURGICAL TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are positioned supine on the operating table. General, spinal, or epidural anesthesia may be used. Prophylactic antibiotics are given prior to skin incision. Most often, a tourniquet is used (although not always).",
"   </p>",
"   <p>",
"    The knee is typically approached via a midline skin incision. If previous scars exist, all possible attempts are made to incorporate previous skin incisions. With multiple scars, the most lateral is usually used because of blood supply to the flap. Occasionally, preoperative plastic surgery consult is needed in knees with multiple scars. The majority of surgeons use a medial parapatellar approach to enter the knee. With this approach, an incision is made in the quadriceps tendon above, down along the medial side of the patella, down to the medial aspect of the tibial tubercle. Occasionally, the lateral parapatellar approach is used. Subvastus and midvastus approaches are experiencing a resurgence in use in combination with &ldquo;minimally invasive&rdquo; techniques.",
"   </p>",
"   <p>",
"    Soft tissue balancing is a critical component of total knee arthroplasty. Varus knees are usually tight medially and lax laterally. Valgus knees are usually tight laterally and lax medially. Soft tissue balance is typically achieved by performing releases on the collateral ligament on the tight side. Capsular releases are usually performed first. In the majority of total knee replacements, every effort is made to preserve the integrity of the lateral collateral ligament and, especially, the medial collateral ligament. The anterior cruciate ligament is almost always sacrificed. As discussed below, the posterior cruciate ligament may be retained or sacrificed.",
"   </p>",
"   <p>",
"    Implant selection is surgeon-dependent. The role of techniques such as minimally invasive knee replacement and surgical computer-assisted navigation remains to be defined [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     CHOICE OF PROSTHESIS AND FIXATION TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Implant selection is surgeon-dependent. All total knee arthroplasties consist of a femoral component, a tibial component, and a patella component. There are a large number of manufacturers and designs of knee prostheses. Most available systems are modular with a metal tibia tray with polyethylene inserts. Designs either can retain the posterior cruciate ligament (PCL) or may sacrifice the PCL. Fixation techniques include cemented (both femur and tibia are cemented), uncemented, or hybrid (usually femur is uncemented and tibia is cemented).",
"   </p>",
"   <p>",
"    There is no consensus on prosthesis choice, and there is wide variance among nations, states, cities, and individual surgeons. This variance in design and technique makes it difficult to analyze and generalize reported results. Approximately 90 to 95 percent survivorship of total knee arthroplasties is expected at 10-years follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Posterior cruciate retaining versus sacrificing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both posterior cruciate retention and sacrificing (also called substitution, because the tibial component requires the addition of a post to provide the stability normally provided by the PCL) designs have compelling reasons for their existence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Theoretical advantages of PCL retention include greater range of motion due to reproduction of femoral rollback, decreased stress on the implant leading to lower rates of failure, improved proprioception in stair climbing, and preservation of bone stock [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Theoretical advantages of PCL sacrificing include more reliable correction of deformity; easier balancing of the knee; and elimination of excessive femoral rollback, which may compromise implant fixation and which may increase conformity of the prosthesis, thus leading to decreased contact stresses and to decreased polyethylene wear [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of these theoretical advantages for either approach have not been observed in clinical studies, and excellent results may be obtained with either design [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/52\">",
"     52",
"    </a>",
"    ]. Numerous long-term follow-up studies of both cruciate retaining [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/53-55\">",
"     53-55",
"    </a>",
"    ] and cruciate sacrificing [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/56-58\">",
"     56-58",
"    </a>",
"    ] designs demonstrate a greater than 90 percent survivorship at 10 years with minimal differences in functional outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Fixation technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of total knee arthroplasties have been performed with cemented components, and the long-term follow-up studies available have been with cemented implantation. Generally, cementless implantation in total knee arthroplasty is considered to be less desirable due to higher incidence of tibial loosening, polyethylene wear, and osteolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/51\">",
"     51",
"    </a>",
"    ]. However, some surgeons have obtained excellent results (&gt;90 percent survival of the primary arthroplasty) at 10 or more years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Patella resurfacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patella resurfacing, typically with a polyethylene button, remains a controversial topic in total knee arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/52\">",
"     52",
"    </a>",
"    ]. The primary reason to resurface the patella is the belief that it lessens anterior knee pain and, therefore reduces, the need for a second operation to resurface the patella. This is offset by advantages of not resurfacing, which include preservation of bone stock and reduction of patellofemoral complications such as fractures and loosening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16902?source=see_link&amp;anchor=H10#H10\">",
"     \"Complications of total knee arthroplasty\", section on 'Patellofemoral disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Other designs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous other prosthetic designs are available, including meniscal-bearing prostheses and rotating platform prostheses which were developed to decrease polyethylene wear and to decrease prosthetic loosening. More constrained designs are also available (eg, hinged implants) for situations including severe instability and revision surgery. In general, a more constrained implant shifts more force onto the components leading to higher failure rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative management includes prophylaxis against infection and venous thromboembolism, as well as appropriate physical therapy to achieve the best possible knee motion and safe rehabilitation that is practicable.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prophylactic antibiotics are given preoperatively and are continued for a brief period of time postoperatively. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=see_link&amp;anchor=H2#H2\">",
"       \"Prevention of prosthetic joint infections\", section on 'Before and after joint replacement surgery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend the routine use of pharmacologic prophylaxis for venous thromboembolism postoperatively. Reasonable choices include low molecular weight (LMW)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      , or a vitamin K antagonist (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ). The use of intermittent pneumatic compression (IPC) is an alternative option to anticoagulant prophylaxis for patients with a high bleeding risk, or it can be employed in combination with other thromboprophylactic options. The optimal approach is uncertain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H39#H39\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Special groups'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increasingly, patients are managed with femoral nerve blocks in order to reduce the complications and the delay in rehabilitation associated with general anesthesia and with indwelling epidural catheters. Patient controlled analgesia (PCA) can be useful in the post-arthroplasty setting. Subsequently, oral opioid analgesics may be used. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link\">",
"       \"Management of postoperative pain\"",
"      </a>",
"      .) Pain control after total knee replacement has improved considerably with increasing use of multimodal pain management strategies. This typically includes &ldquo;preemptive&rdquo; management with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      , COX-2 selective NSAIDs, femoral nerve blocks, regional anesthetics, and periarticular injections [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/61\">",
"       61",
"      </a>",
"      ]. Increasingly,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      is being used to help manage perioperative pain [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/62\">",
"       62",
"      </a>",
"      ]. Antinausea agents are often given preemptively, and the use of parenteral narcotics and PCA pumps is diminishing.",
"     </li>",
"     <li>",
"      Cooperation by the patient in a postoperative rehabilitation program is required for a successful outcome following total knee arthroplasty. Interventions that attempt to preserve knee motion include the use of a knee immobilizer and pillows under the operative foot while in bed to maintain extension and to avoid flexion contracture. Range of motion exercises, supervised by a physical therapist, should be started as soon as possible.",
"      <br/>",
"      <br/>",
"      A well-structured physical therapy (PT) program including range of motion, gait training, quadriceps strengthening, and training in activities of daily living is an important component of the rehabilitation process. A 2007 meta-analysis of five randomized trials concluded that participation after discharge from the hospital in a functional exercise program supervised by a physical therapist improves knee function and range of motion in the short term when compared with routine care [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of continuous passive motion (CPM) devices to improve knee range of motion is common in postoperative rehabilitative care in many institutions, but there is uncertainty regarding whether the clinical benefits justify the inconvenience and expense of CPM [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/64\">",
"       64",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A 2010 systematic review and meta-analysis of 20 randomized trials, which compared CPM, combined with routine postoperative care and PT, with similar postoperative care and PT alone, found that the combination of CPM and PT resulted in a small increase in passive and active knee flexion range of motion (two and three degrees, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/64\">",
"       64",
"      </a>",
"      ]. More limited data suggested that CPM did not affect length of hospital stay but did reduce the need for manipulation under anesthesia (relative risk 0.15, 95% CI 0.03-0.70). Given an observed baseline risk of 12 percent, one manipulation was prevented for every 56 patients treated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rehabilitation goals should be realistic. Although the flexion deformities may be partially or completely corrected by total knee arthroplasty, the maximal knee range of motion may not be much improved, and the postoperative motion is determined largely by the preoperative arc [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the long term, patients may be encouraged to pursue low to moderate intensity, low impact exercises, as patients who are more active do not appear to increase their risk of needing revision arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?17/6/17514/abstract/65\">",
"     65",
"    </a>",
"    ]. The limited evidence available suggests that remaining active may actually be associated with a reduced risk of requiring subsequent replacement of the operated knee.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/50/29474?source=see_link\">",
"       \"Patient information: Knee replacement (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=see_link\">",
"       \"Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H191081796\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Modern total knee arthroplasty consists of resection of the diseased articular surfaces of the knee, followed by resurfacing with metal and polyethylene prosthetic components. For the properly selected patient, the procedure results in significant pain relief, as well as improved function and quality of life. Despite the potential benefits of total knee arthroplasty, it is an elective procedure and should only be considered after extensive discussion of the risks, benefits, and alternatives. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main indication for total knee arthroplasty is for the relief of pain associated with arthritis of the knee in patients who have failed nonoperative treatments. Correction of deformity and restoration of function should be considered secondary outcomes of the surgery and should not be considered the primary indication. The prosthetic joint has a finite lifetime, and factors upon which the durability of the prosthesis depends include patient age, underlying disease, and presence of obesity, as well as prosthesis and surgical factors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Contraindications to total knee replacement include active infection in the knee or anywhere in the body, a nonfunctioning extensor mechanism, and poor extremity circulation or vascularity. Neurologic disease affecting the extremity is a relative contraindication. Overall 30-day mortally rates of total knee and total hip arthroplasty are similar. (See",
"      <a class=\"local\" href=\"#H3230182\">",
"       'Contraindications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A careful preoperative evaluation must be performed to determine the correct diagnosis, to identify the need for surgery, to assist with surgical planning, and to prevent complications in the perioperative period. A thorough evaluation includes particular elements of the history, a physical examination, imaging and laboratory studies, a review of treatment alternatives, and discussions of the benefits and risks of the procedure and of autologous blood donation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Preoperative evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"       \"Preoperative medical evaluation of the healthy patient\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"       \"Estimation of cardiac risk prior to noncardiac surgery\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=see_link\">",
"       \"Evaluation of preoperative pulmonary risk\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The suitability of surgical approaches other than total joint arthroplasty depends upon several factors, including the severity of the disease, the number of compartments involved, and the disease process causing joint pathology. Alternatives include nonsurgical treatment, arthroscopy, osteotomy, unicompartmental knee replacement, and knee arthrodesis. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Alternatives to total knee arthroplasty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients are positioned supine on the operating table, and regional, general, spinal, or epidural anesthesia may be used. Prophylactic antibiotics are given prior to skin incision. A tourniquet is often used. Implant selection is surgeon-dependent. The roles of minimally invasive knee replacement and surgical computer-assisted navigation, for which long-term follow-up is lacking, are poorly defined. All total knee arthroplasties consist of a femoral component, a tibial component, and a patella component. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Surgical technique'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31\">",
"       'Choice of prosthesis and fixation technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postoperative management includes prophylaxis against infection and venous thromboembolism, as well as appropriate physical therapy to achieve the best possible knee motion and safe rehabilitation that is practicable. Multimodal pain control techniques have improved upon the patient experience following total knee arthroplasty. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Postoperative management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     HCPUnet, Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality. file://hcupnet.ahrq.gov (Accessed on December 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/2\">",
"      Mahomed NN, Barrett J, Katz JN, et al. Epidemiology of total knee replacement in the United States Medicare population. J Bone Joint Surg Am 2005; 87:1222.",
"     </a>",
"    </li>",
"    <li>",
"     Insall JN. Historical development, classification, and characteristics of knee prostheses. In: Surgery of the Knee, 2nd, Insall JN (Ed), Churchill Livingstone, New York 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/4\">",
"      Lavernia CJ, Guzman JF, Gachupin-Garcia A. Cost effectiveness and quality of life in knee arthroplasty. Clin Orthop Relat Res 1997; :134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/5\">",
"      Rand JA, Trousdale RT, Ilstrup DM, Harmsen WS. Factors affecting the durability of primary total knee prostheses. J Bone Joint Surg Am 2003; 85-A:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/6\">",
"      Kerkhoffs GM, Servien E, Dunn W, et al. The influence of obesity on the complication rate and outcome of total knee arthroplasty: a meta-analysis and systematic literature review. J Bone Joint Surg Am 2012; 94:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/7\">",
"      Ibrahim SA, Stone RA, Han X, et al. Racial/ethnic differences in surgical outcomes in veterans following knee or hip arthroplasty. Arthritis Rheum 2005; 52:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/8\">",
"      Mahomed NN, Barrett JA, Katz JN, et al. Rates and outcomes of primary and revision total hip replacement in the United States medicare population. J Bone Joint Surg Am 2003; 85-A:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/9\">",
"      Robinson CM, Christie J, Malcolm-Smith N. Nonsteroidal antiinflammatory drugs, perioperative blood loss, and transfusion requirements in elective hip arthroplasty. J Arthroplasty 1993; 8:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/10\">",
"      Connelly CS, Panush RS. Should nonsteroidal anti-inflammatory drugs be stopped before elective surgery? Arch Intern Med 1991; 151:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/11\">",
"      Stoner SC, Lea JW, Dubisar BM, Farrar C. Possible international normalized ratio elevation associated with celecoxib and warfarin in an elderly psychiatric patient. J Am Geriatr Soc 2003; 51:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/12\">",
"      Stading JA, Skrabal MZ, Faulkner MA. Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors. Am J Health Syst Pharm 2001; 58:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/13\">",
"      Mersfelder TL, Stewart LR. Warfarin and celecoxib interaction. Ann Pharmacother 2000; 34:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/14\">",
"      Schwartz JI, Bugianesi KJ, Ebel DL, et al. The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin. Clin Pharmacol Ther 2000; 68:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/15\">",
"      Herrlin S, H&aring;llander M, Wange P, et al. Arthroscopic or conservative treatment of degenerative medial meniscal tears: a prospective randomised trial. Knee Surg Sports Traumatol Arthrosc 2007; 15:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/16\">",
"      Bhattacharyya T, Gale D, Dewire P, et al. The clinical importance of meniscal tears demonstrated by magnetic resonance imaging in osteoarthritis of the knee. J Bone Joint Surg Am 2003; 85-A:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/17\">",
"      Restrepo C, Parvizi J, Dietrich T, Einhorn TA. Safety of simultaneous bilateral total knee arthroplasty. A meta-analysis. J Bone Joint Surg Am 2007; 89:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/18\">",
"      Wylde V, Hewlett S, Learmonth ID, Dieppe P. Persistent pain after joint replacement: prevalence, sensory qualities, and postoperative determinants. Pain 2011; 152:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/19\">",
"      Lingard EA, Katz JN, Wright EA, et al. Predicting the outcome of total knee arthroplasty. J Bone Joint Surg Am 2004; 86-A:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/20\">",
"      Gill GS, Joshi AB. Long-term results of cemented, posterior cruciate ligament-retaining total knee arthroplasty in osteoarthritis. Am J Knee Surg 2001; 14:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/21\">",
"      Ritter MA, Stringer EA. Predictive range of motion after total knee replacement. Clin Orthop Relat Res 1979; :115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/22\">",
"      Whiteside LA, Mihalko WM. Surgical procedure for flexion contracture and recurvatum in total knee arthroplasty. Clin Orthop Relat Res 2002; :189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/23\">",
"      Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/24\">",
"      Zhang W, Nuki G, Moskowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010; 18:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/25\">",
"      Richmond J, Hunter D, Irrgang J, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on the treatment of osteoarthritis (OA) of the knee. J Bone Joint Surg Am 2010; 92:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/26\">",
"      Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/27\">",
"      Moseley JB, O'Malley K, Petersen NJ, et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2002; 347:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/28\">",
"      Kirkley A, Birmingham TB, Litchfield RB, et al. A randomized trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2008; 359:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/29\">",
"      Bentley G, Minas T. Treating joint damage in young people. BMJ 2000; 320:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/30\">",
"      Minas T, Nehrer S. Current concepts in the treatment of articular cartilage defects. Orthopedics 1997; 20:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/31\">",
"      Coventry MB. Osteotomy of the upper portion of the tibia for degenerative arthritis of the knee. A preliminary report. 1965. Clin Orthop Relat Res 1989; :4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/32\">",
"      Coventry MB. Osteotomy about the knee for degenerative and rheumatoid arthritis. J Bone Joint Surg Am 1973; 55:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/33\">",
"      Phillips MJ, Krackow KA. High tibial osteotomy and distal femoral osteotomy for valgus or varus deformity around the knee. Instr Course Lect 1998; 47:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/34\">",
"      Brouwer RW, Jakma TS, Bierma-Zeinstra SM, et al. Osteotomy for treating knee osteoarthritis. Cochrane Database Syst Rev 2005; :CD004019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/35\">",
"      Rinonapoli E, Mancini GB, Corvaglia A, Musiello S. Tibial osteotomy for varus gonarthrosis. A 10- to 21-year followup study. Clin Orthop Relat Res 1998; :185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/36\">",
"      Takai S, Yoshino N, Hirasawa Y. Revision total knee arthroplasty after failed high tibial osteotomy. Bull Hosp Jt Dis 1997; 56:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/37\">",
"      Meding JB, Keating EM, Ritter MA, Faris PM. Total knee arthroplasty after high tibial osteotomy. A comparison study in patients who had bilateral total knee replacement. J Bone Joint Surg Am 2000; 82:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/38\">",
"      St&auml;helin T, Hardegger F, Ward JC. Supracondylar osteotomy of the femur with use of compression. Osteosynthesis with a malleable implant. J Bone Joint Surg Am 2000; 82:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/39\">",
"      Cameron HU, Botsford DJ, Park YS. Prognostic factors in the outcome of supracondylar femoral osteotomy for lateral compartment osteoarthritis of the knee. Can J Surg 1997; 40:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/40\">",
"      McKeever DC. The classic: Patellar prosthesis.1955. Clin Orthop Relat Res 2005; 440:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/41\">",
"      McKeever DC. The classic: Tibial plateau prosthesis.1960. Clin Orthop Relat Res 2005; 440:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/42\">",
"      Schai PA, Suh JT, Thornhill TS, Scott RD. Unicompartmental knee arthroplasty in middle-aged patients: a 2- to 6-year follow-up evaluation. J Arthroplasty 1998; 13:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/43\">",
"      Newman JH, Ackroyd CE, Shah NA. Unicompartmental or total knee replacement? Five-year results of a prospective, randomised trial of 102 osteoarthritic knees with unicompartmental arthritis. J Bone Joint Surg Br 1998; 80:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/44\">",
"      Smith AM, Peckett WR, Butler-Manuel PA, et al. Treatment of patello-femoral arthritis using the Lubinus patello-femoral arthroplasty: a retrospective review. Knee 2002; 9:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/45\">",
"      Merchant AC. Early results with a total patellofemoral joint replacement arthroplasty prosthesis. J Arthroplasty 2004; 19:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/46\">",
"      Cartier P, Sanouiller JL, Grelsamer RP. Unicompartmental knee arthroplasty surgery. 10-year minimum follow-up period. J Arthroplasty 1996; 11:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/47\">",
"      Tabor OB Jr, Tabor OB. Unicompartmental arthroplasty: a long-term follow-up study. J Arthroplasty 1998; 13:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/48\">",
"      Levine WN, Ozuna RM, Scott RD, Thornhill TS. Conversion of failed modern unicompartmental arthroplasty to total knee arthroplasty. J Arthroplasty 1996; 11:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/49\">",
"      Chakrabarty G, Newman JH, Ackroyd CE. Revision of unicompartmental arthroplasty of the knee. Clinical and technical considerations. J Arthroplasty 1998; 13:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/50\">",
"      Leopold SS. Minimally invasive total knee arthroplasty for osteoarthritis. N Engl J Med 2009; 360:1749.",
"     </a>",
"    </li>",
"    <li>",
"     Campbell's Operative Orthopaedics, 9th, Mosby, 1999.",
"    </li>",
"    <li>",
"     Archibeck MJ, Berger RA, Garvin KL, et al. Orthopaedic Knowledge Update 7, Koval KJ (Ed), AAOS, 2002. p.517.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/53\">",
"      Ansari S, Ackroyd CE, Newman JH. Kinematic posterior cruciate ligament-retaining total knee replacements. A 10-year survivorship study of 445 arthroplasties. Am J Knee Surg 1998; 11:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/54\">",
"      Hanyu T, Murasawa A, Tojo T. Survivorship analysis of total knee arthroplasty with the kinematic prosthesis in patients who have rheumatoid arthritis. J Arthroplasty 1997; 12:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/55\">",
"      Malkani AL, Rand JA, Bryan RS, Wallrichs SL. Total knee arthroplasty with the kinematic condylar prosthesis. A ten-year follow-up study. J Bone Joint Surg Am 1995; 77:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/56\">",
"      Emmerson KP, Moran CG, Pinder IM. Survivorship analysis of the Kinematic Stabilizer total knee replacement: a 10- to 14-year follow-up. J Bone Joint Surg Br 1996; 78:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/57\">",
"      Font-Rodriguez DE, Scuderi GR, Insall JN. Survivorship of cemented total knee arthroplasty. Clin Orthop Relat Res 1997; :79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/58\">",
"      Colizza WA, Insall JN, Scuderi GR. The posterior stabilized total knee prosthesis. Assessment of polyethylene damage and osteolysis after a ten-year-minimum follow-up. J Bone Joint Surg Am 1995; 77:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/59\">",
"      Buechel FF. Cementless meniscal bearing knee arthroplasty: 7- to 12-year outcome analysis. Orthopedics 1994; 17:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/60\">",
"      Armstrong RA, Whiteside LA. Results of cementless total knee arthroplasty in an older rheumatoid arthritis population. J Arthroplasty 1991; 6:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/61\">",
"      Maheshwari AV, Blum YC, Shekhar L, et al. Multimodal pain management after total hip and knee arthroplasty at the Ranawat Orthopaedic Center. Clin Orthop Relat Res 2009; 467:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/62\">",
"      Dietrich C, Pulido J, et al. Preoperative gabapentin in patients undergoing primary total knee arthroplasty. Acute Pain 2009; 11:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/63\">",
"      Minns Lowe CJ, Barker KL, Dewey M, Sackley CM. Effectiveness of physiotherapy exercise after knee arthroplasty for osteoarthritis: systematic review and meta-analysis of randomised controlled trials. BMJ 2007; 335:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/64\">",
"      Harvey LA, Brosseau L, Herbert RD. Continuous passive motion following total knee arthroplasty in people with arthritis. Cochrane Database Syst Rev 2010; :CD004260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/6/17514/abstract/65\">",
"      Jones DL, Cauley JA, Kriska AM, et al. Physical activity and risk of revision total knee arthroplasty in individuals with knee osteoarthritis: a matched case-control study. J Rheumatol 2004; 31:1384.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7967 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-78FC411DA4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_6_17514=[""].join("\n");
var outline_f17_6_17514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H191081796\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3230182\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Comorbid medical problems/review of systems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Allergies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Observation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Palpation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Assessment with other manual tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Review of treatment alternatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Discussion of risks and benefits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Risks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Benefits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ALTERNATIVES TO TOTAL KNEE ARTHROPLASTY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Nonsurgical treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Arthroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Osteotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Varus knee",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Valgus knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Unicompartmental knee replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Knee arthrodesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SURGICAL TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      CHOICE OF PROSTHESIS AND FIXATION TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Posterior cruciate retaining versus sacrificing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Fixation technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Patella resurfacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Other designs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H191081796\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42680?source=related_link\">",
"      Clinical manifestations and diagnosis of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/32/16902?source=related_link\">",
"      Complications of total knee arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37861?source=related_link\">",
"      Evaluation and medical management of end-stage rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=related_link\">",
"      Evaluation of preoperative pulmonary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6618?source=related_link\">",
"      Evaluation of the active adult patient with knee pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/15/16632?source=related_link\">",
"      Meniscal injury of the knee",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=related_link\">",
"      Nonpharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/50/29474?source=related_link\">",
"      Patient information: Knee replacement (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/13/21717?source=related_link\">",
"      Patient information: Total knee replacement (arthroplasty) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29688?source=related_link\">",
"      Perioperative management of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=related_link\">",
"      Pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12134?source=related_link\">",
"      Preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/35/15929?source=related_link\">",
"      Preoperative evaluation and perioperative management of patients with rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/34/28198?source=related_link\">",
"      Prevention of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10106?source=related_link\">",
"      Total hip arthroplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=related_link\">",
"      Treatment of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_6_17515="Indications for SCIT";
var content_f17_6_17515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical indications for allergen immunotherapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Symptoms of allergic rhinitis, allergic conjunctivitis, allergic asthma, or any combination of these disorders after natural exposure to aeroallergens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"        <strong>",
"         AND",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demonstrable evidence of clinically relevant specific IgE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"        <strong>",
"         AND",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        At least one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Poor response to pharmacotherapy, allergen avoidance, or both",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Unacceptable adverse effects of medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Wish to reduce or avoid long-term pharmacotherapy and the cost of medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Coexisting allergic rhinitis and asthma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Possible prevention of asthma in patients with allergic rhinitis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_6_17515=[""].join("\n");
var outline_f17_6_17515=null;
var title_f17_6_17516="Causes eosinophilic meningitis";
var content_f17_6_17516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of eosinophilic meningitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Infectious, parasitic causes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Roundworm (nematode) infections - commonly present as eosinophilic meningitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Angiostrongylus cantonensis - migrating larvae inherently neurotropic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gnathostoma spinigerum - migrating larvae in visceral and/or neural tissues",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Baylisascaris procyonis - migrating larvae inherently neurotropic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Tapeworm (cestode) infections - may present as eosinophilic meningitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cysticercosis - cysts develop in CNS and/or visceral tissues",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Fluke (trematode) infections - occasionally cause eosinophilic meningitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Paragonimus westermani - ectopic spinal or cerebral localization",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Schistosomiasis - ectopic spinal or cerebral localization",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Fascioliasis - ectopic CNS localization",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Other roundworm infections which occasionally cause eosinophilic meningitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Toxocariasis - migrating larvae",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Nonparasitic, infectious causes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Coccidioidomycosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cryptococcosis - CSF eosinophilia rare",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Myiasis - with CNS penetration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Virus and bacteria - are of uncertain causality",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Noninfectious causes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Idiopathic hypereosinophilic syndromes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ventriculoperitoneal shunts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Leukemia or lymphoma with CNS involvement (Hodgkin's)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nonsteroidal antiinflammatory drugs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Antibiotics - ciprofloxacin, trimethoprim-sulfamethoxazole, intraventricular gentamicin or vancomycin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Myelography contrast agents",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Weller, PF, Liu, LX, Semin Neurol 1993; 13:161.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_6_17516=[""].join("\n");
var outline_f17_6_17516=null;
var title_f17_6_17517="WHO clinical staging HIV criteria";
var content_f17_6_17517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    WHO clinical staging for adults and adolescents: HIV/AIDS-related clinical events",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical stage 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asymptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistent generalized lymphadenopathy (PGL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical stage 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate unexplained weight loss (&lt;10 percent of presumed or measured body weight)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent presumed bacterial&nbsp;respiratory tract infection&nbsp;(two or more in any six-month period)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpes zoster",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angular cheilitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent oral ulcerations occurring twice or more in six months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Papular pruritic eruptions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seborrhoeic dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fungal nail infections of fingers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical stage 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe unexplained weight loss (more than 10 percent of presumed or measured body weight)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unexplained chronic diarrhea for longer than one month",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unexplained persistent fever (intermittent or constant and for longer than one month)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral candidiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral hairy leukoplakia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary TB (current or in last two years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe presumed bacterial infection (eg, pneumonia, meningitis, empyema, pyomyositis, bone or joint infection, bacteraemia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute necrotizing ulcerative gingivitis or necrotizing ulcerative periodontitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unexplained anaemia (&lt;8 g/dl), neutropenia (&lt;1000/mm",
"        <sup>",
"         3",
"        </sup>",
"        ) or thrombocytopenia(&lt;50000/mm",
"        <sup>",
"         3",
"        </sup>",
"        ) for more than one month",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical stage 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV wasting syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumocystis pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent severe or radiological bacterial pneumonia (two or more episodes within one year)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic herpes simplex virus (HSV) infection (orolabial, genital or anorectal of more than one month, or visceral of any duration)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oesophageal candidiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extrapulmonary/disseminated TB",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kaposi's sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CMV (retinitis or CMV infection of an organ other than liver, spleen or lymph nodes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CNS toxoplasmosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryptococcal meningitis or other extrapulmonary",
"        <em>",
"         Cryptococcus",
"        </em>",
"        infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disseminated non-tuberculous mycobacteria infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PML",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Candidiasis of trachea, bronchi, lungs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryptosporidiosis (with diarrhoea lasting more than one month)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isosporiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any disseminated mycosis (eg, coccidiomycosis, histoplasmosis, penicilliosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent non-typhoidal salmonella septicaemia (two or more episodes in last year)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma (cerebral or B cell non-Hodgkin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Invasive cervical carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visceral leishmaniasis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance: African Region, 2005. Copyright &copy; 2005 World Health Organization.",
"     <a href=\"file://www.who.int/hiv/pub/guidelines/clinicalstaging.pdf\" target=\"_blank\">",
"      www.who.int/hiv/pub/guidelines/clinicalstaging.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_6_17517=[""].join("\n");
var outline_f17_6_17517=null;
var title_f17_6_17518="P ANCA";
var content_f17_6_17518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    P-ANCA pattern on indirect immunofluorescence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Demonstration of perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) by indirect immunofluorescence with normal neutrophils. Staining is limited to the perinuclear region, and the cytoplasm is nonreactive. Among patients with vasculitis, the antibodies are usually directed against myeloperoxidase. However, a P-ANCA pattern can also be seen with autoantibodies against a number of other antigens including lactoferrin and elastase. Non-MPO P-ANCA can be seen in a variety of nonvasculitic disorders.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_6_17518=[""].join("\n");
var outline_f17_6_17518=null;
var title_f17_6_17519="Gram stain abscess 1B answer";
var content_f17_6_17519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Streptococcus pyogenes on blood agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Culture of Streptococcus pyogenes on blood agar showing large zones of clear beta-hemolysis around the small colonies. The susceptibility of this organism to bacitracin is demonstrated by the zone of inhibition around the bacitracin-containing disc (A) on the left side of the plate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_6_17519=[""].join("\n");
var outline_f17_6_17519=null;
